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General Introduction
The enzyme phosphofructokinase (ATP-D-fructose-6-phosphate-1-
phosphotransferase, E.C. 2.7.1.11) catalyzes the transfer of the gamma
phosphate of adenosine triphosphate (ATP) to fructose-6-phosphate,
forming fructose-1,6-bisphosphate and adenosine diphosphate (ADP).
In yeast and in mammals, this nearly irreversible reaction is a major
rate-limiting step of glycolysis.Glycolysis is the anaerobic catabolic
pathway in which glucose is converted to lactate, yielding production of 2
moles of ATP per mole of glucose consumed.Glycolysis occurs
ubiquitouslythroughoutnature.Pyruvatekinase and glycogen
phosphorylase also catalyze critical steps in carbohydrate metabolism.
Regulation of these enzymes is therefore important in the control of energy
metabolism.
The mammalian enzyme is inhibited at millimolar concentrations of
the substrate ATP. The reaction rate increases in a sigmoidal manner with
increasing concentration of the substrate fructose-6-phosphate.Positive
allosteric effectors decrease the ATP inhibition while moving the sigmoidal
fructose-6-phosphate rate dependence to lower concentrations; negative2
effectors increase the sensitivity to ATP and increase the concentration of
fructose-6-phosphate necessary to activate the enzyme (Uyeda, 1979). The
interplay of various allosteric effectors is a major controlling factor in the
regulation of mammalian phosphofructokinase.
Thelistofpositiveandnegativeallostericeffectorsof
phosphofructokinase is extensive.Citrate (Denton and Randle, 1966;
Pogson and Randle, 1966), long chain fatty acids (Ramadoss et al, 1976b),
transfer RNA (Rabinovitz, 1995), and creatine phosphate (Krzanowski and
Matschinsky, 1969) are allosteric inhibitors.Fructose-2,6-bisphosphate
(Ogush et al., 1990; Pilkis et al., 1981), fructose -1,6- bisphosphate, glucose -
1,6-bisphosphate, AMP, ADP, inositol phosphate (Mayr, 1989), ribose-1,5-
bisphosphate (Ogush et al, 1990), inorganic phosphate (Kuhn et al, 1974),
and NH4+ (Kuhn et al., 1974) allosterically activate phosphofructokinase.
VariationsinpHalsomayregulatetheactivityof
phosphofructokinase. The pH optimum of the rabbit muscle enzyme is
near pH 8.0, with catalytic activity decreasing sharply below pH6.9 (Hill
and Hammes, 1975). This may be an important control mechanism for the
enzyme, as the intracellular skeletal muscle pH decreases to 6.4-6.6during
intenseperiodsofcontraction(Spriet,1991). Thelossin
phosphofructokinase activity as the pH is lowered is amplified in the
presence of ATP. Fructose-2,6-bisphosphate abolishes the effectof ATP,3
making enzyme activity at pH 6.8 behave as if it were at pH 7.2 (Dobson et
al, 1986).
Fructose-2,6-bisphosphate is the most potent allosteric activator of
phosphofructokinase discovered to date. It is able to activate rat liver
phosphofructokinase 1000 and 2500 times more effectively and has a S-
and 90-fold greater affinity for the enzyme than fructose-1,6-bisphosphate
and glucose-6-bisphosphate, respectively (Foe et al., 1983; Van Schaftingen
et al, 1981).The concentration of fructose-2,6-bisphosphate varies by
tissue, with liver containing the highest concentrations, followed by brain,
kidney, testis, and skeletal muscle (Kuwajima and Uyeda, 1982).
The enzyme 6-phosphofructo-2-kinase catalyzes the formation of
fructose-2,6-bisphosphate and ADP through the coupled phosphorylation
of fructose-6-phosphate and de-phosphorylation of ATP.The reverse
reaction,a de-phosphorylationoffructose-2,6-bisphosphate forming
fructose-6-phosphate, is catalyzed by fructose-2,6-bisphosphatase activity
found on the same polypeptide chain as 6-phosphofructo-2-kinase (Pilkis
et al, 1984). The kinase activity of 6-phosphofructo-2-kinase is stimulated
by low concentrations of fructose-6-phospate, amplifying the activating
effects of fructose-6-phosphate toward phosphofructokinase.
Phosphofructokinase is ubiquitous to all living species. There are
two general classes of enzyme: a form found in propionibacteria, some
plant species, and amitochondriate protists, which use pyrophosphate as a4
substrate, and a form which employs ATP as a substrate that is found in
most other organisms (Siebers et al, 1998).Within mammals, three
immunologically distinct forms of the enzyme exist, generally classified as
types M (muscle), L (liver), and C (erythrocytes). The proportions of these
three types vary with tissue and age. In developed skeletal muscle, the M-
form predominates (Dunaway et al, 1986). Rat heart contains a proportion
of 0.5/4.5/0.4 of L/M/C isotypes (Dunaway and Kasten, 1985), rat lung a
proportion of 0.65/0.25/0.10 (Heesbeen et al, 1989), and brain contains
predominantly M and C forms (Dunaway and Kasten, 1988).The
sensitivity of phosphofructokinase toallosteric regulation varies by
isotype.In rabbits, the relative sensitivity to ATP inhibition is L>C>M,
while to citrate inhibition is M>C>L. The C-isozyme is less sensitive than
either M or L to activation by fructose-2,6-bisphosphate, AMP, and
inorganic phosphate (Foe and Kemp, 1985).Shortly following conception,
all three isoforms are active across all tissues in fetal rat. During prenatal
development, the levels of mRNA change significantly (Mhaskar and
Dunaway, 1991). A steady increase of expression of rat C-isozyme in brain
occurs during the first 30 days following birth.It is hypothesized that the
altered level of transcription is due to age-dependent methylation of the
gene promoters of the genes coding for the various isotypes(Mhaskar and
Dunaway, 1995).5
The gene encoding L-type human phosphofructokinase has been
characterized. It contains 2340 nucleotides, coding for a protein 780 amino
acids in length. 90% amino acid homology exists between the human and
mouse liver enzyme, while there is only 68% homology betweenthe
human M- and L-forms (Levanonet al.,1989). The gene is at least 28 Kb in
length and contains 22 introns (Elsonet al.,1990). The promoter sequence
contains four binding sites for the transcription factor SP1 (Levanonet al.,
1995). The L-phosphofructokinase gene is located at human chromosome
21 (Levanonet al.,1986). It is overexpressed in Down's syndrome patients
(Elsonet al.,1994). Overexpression of transfected phosphofructokinase-L
gene in PC12 cells causes increased expression of protein kinase C(PKC);
such an increase in PKC may disrupt gene expression, leading to many
symptoms of the disease (Elson et a!, 1994).
The gene encoding phosphofructokinase-C is located on human
chromosome 10 (Schwartzet al,1984; Simpson and Fothergill-Gilmore,
1991). The human C-type isoform shows 71% amino acid homology to
human M-phosphofructokinase and 63% homology to the L-type (Simpson
and Fothergill-Gilmore, 1991). The cDNA of C-isotype from rabbit brain
has been cloned and expressed in E. Coli (Liet al.,1994).
M-phosphofructokinase cDNAs from rabbit (Kaoet al,1990; Liet
al.,1993), human (Nakajimaet al.,1987), and dog (Smithet al.,1996) have
been cloned. The gene encoding human M-phosphofructokinase is located6
on chromosome 1 (Voraet al,1982), and contains 35 Kb with 22 exons and
two transcriptional promoters (Vaisanenet al,1992). The rabbit muscle
phosphofructokinase gene is similar in structure to the L-type gene, 17 Kb
in length with 22 exons (Leeetal., 1987), coding for 779 amino acids, and
contains multiple transcription start sites (Liet al,1990). The promoters of
human (Leet al,1994) and rabbit (Liet al.,1990) phosphofructokinase-M
genes each contain multiple binding sites for SP1. There is 95% sequence
homology between the human and rabbit proteins (Voraeta!,1986).
Faulty expression of the M-phosphofructokinase gene has been
implicated as the cause for genetic diseases including type VII muscle
glycogenosis (Tarui's disease) (Suzuki, 1997) and phosphofructokinase
deficiency(Vissingetal,1996). Themanifestationsof
phosphofructokinasedeficiencyinmuscleincludemyogenic
hyperuricemia (Mineo and Tarui, 1995), and decreased endurance during
exercise due to an inability to break down glucose (Vissinget al,1996).
Aberrant splicing of mRNA transcripts caused by mutations at 5' splice
sites (Miwaet al,1995; Nakajimaet al,1995) is the suspected cause of
phosphofructokinase deficiency (Vasconceloseta!,1995).
Rabbit (Liet al,1990) and human (Nakajimaet al,1987) M-
phosphofructokinases show high internal amino homology between their
N- and C-terminal halves. The mammalian enzyme is roughly twice the
size of phosphofructokinase found in the bacteria B. stearothermophilus,7
and its N- and C-terminal domains display 42 and 34% sequence
homology, respectively, to the sequence of the bacterial enzyme (Poorman
et al., 1984). This suggests that the evolution of the mammalian enzyme
involvedgeneduplicationofanenzymeresemblingbacterial
phosphofructokinase. The x-ray crystal structure of B. stearothermophilus
phosphofructokinase has been determined (Evans et al, 1981). From this
structure, a physical model for the muscle enzyme has been hypothesized
in which the N- and C-halves of the protein form compact globular
domains resembling the structure of bacterial enzyme, joined together by a
non-homologous linking hinge region of approximately 40 residues
(Poorman et al., 1984).
The quaternary structure of active phosphofructokinase varies by
species. E. coli (Blangy et al, 1968) and B. stearothermophilus (Evans and
Hudson, 1979) phosphofructokinases are both active as homotetramers,
while active yeast phosphofructokinase is a hetero-octamer consisting of
two different subunits in an a4134 arrangement (Tijane et al, 1979).Of
mammalian phosphofructokinases, the quaternary structure of the enzyme
from rabbit muscle has been the most extensively studied. At high protein
concentrations, the enzyme contains components of different sizes, with
sedimentation coefficients of 12.4, 18.7, and 30S (Leonard and Walker,
1972). The different oligomeric forms are able to interconvert with one
another (Hesterberg and Lee, 1981).Separation of different oligomers8
following analytical ultracentrifugation demonstrates that the larger
complexes have a higher specific activity, and shows the existence of a
non-equilibrating component comprised of denatured enzyme (Lutheret
al,1985). The smallest active form of phosphofructokinase is the 12.4S
species (Hesterberg and Lee, 1980), corresponding to a tetrameric
association of 84 kilodalton subunits (Hesterberget al.,1981).Electron
microscopy of the tetramer reveals D2 symmetry with dimensions of 9 X 9
X 14 nm (Hesterberget al,1981).
Regulation of quaternary structure is the primary route for enzyme
activation and deactivation.The allosteric inhibitor citrate binds the
dimeric form of muscle phosphofructokinase, inactivating the enzyme by
shifting the dimer-tetramer equilibrium to favor dimer formation (Caiet
al,1997; Hand and Carpenter, 1986; Hesterberg and Lee, 1982). Tetramer
formation is favored by an increase in pH from 6.5 to 8.0 (Carpenter and
Hand, 1986; Hand and Carpenter, 1986; Hesterberg and Lee, 1982), and by
the presence of allosteric activators, including fructose-1,6-bisphosphate
(Hand and Carpenter, 1986), ADP, and inorganic phosphate (Hesterberg
and Lee, 1982). Various self-association models have been hypothesized
based upon the sedimentation properties of phosphofructokinase at
changing protein concentration.Earlier models predicted the following
self-association equilibrium: 4M E-2M2 E-M4 k" 1/41\,416 (Lutheret
al.,1983), in which M4 represents the tetramer.More recent models,9
derived through comparison of sedimentation data obtained in stabilizing
and non-stabilizing buffers, minimize the contribution of the dimeric
species in the absence of inhibitors and favor the existence of octamers : 4M
E-M4 E-1/2M8 E-1/4M16 (Caieta!,1997; Cai et al, 1990).
Calmodulin is a protein found ubiquitously in eukaryotes with four
calcium binding sites facilitating intracellular calcium signaling. Several
protein kinases are activated by calmodulin (Cheung, 1983).Muscle
phosphofructokinase also binds calmodulin (Mayr and Heilmeyer, 1983).
The Stoke's radius of the phosphofructokinase-calmodulin complex, as
estimated by gelfiltration,correspondsto an interactionofthe
phosphofructokinase dimer with calmodulin (Mayr and Heilmeyer, 1983).
Theinteractionresultsindecreasesinthecatalyticactivityof
phosphofructokinase (Mayr, 1984a; Mayr, 1984b; Mayr, 1987; Zhaoet al,
1991b). Light scattering measurements revealed time-dependent decreases
in the aggregation state of the enzyme in the presence of calmodulin
(Mayr,1984a;Mayr,1984b). Thesubunitequilibriumof
phosphofructokinase is therefore shifted from higher molecular weight
aggregates to the dimeric form by association with calmodulin. Activity
losses and decreases in light scattering are suppressed in the presence of
fructose-2,6-bisphosphate or AMP (Mayr, 1984b; Mayr, 1987; Zhaoet al,
1991b),allostericeffectorsthat bind preferentiallyto the tetramer.
Following calmodulin-dependent inactivation, reactivation is achieved by10
addition of fructose-2,6-bisphosphate or ATP and is accompanied by
repolymerization of the enzyme (Mayr, 1984b; Zhao et al.,1991b).
Detailed kinetic analysis of the time-dependent inactivation of rabbit
muscle phosphofructokinase at varying calmodulin concentrationsis
consistent with an equilibrium between two conformational forms of the
inactive phosphofructokinase dimer (Mayr, 1984a; Zhao et al., 1991b). The
discovery of the alternative dimer conformation necessitated a revision of
the model for self-association equilibrium:
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where T = tetramer, D and D* = alternate conformations of dimer, I =
inhibiting protein, Keq2 ' = k27k-2,and Keg-2 = kI2/1(1-2. Rapid equilibrium
(K) exists between the dimer and tetramer states, and the interactions of
the dimer, D and D*, with the inactivating proteins (KI, KI2, KI*, and KI21
are also rapid. The equilibration between the two dimer isoforms, D and
D* (KN.') is a slow process whose rates (km and k1_2) are significantly lower11
than the rates of interconversion between DI and DI* (k12 and k12) and D12
and D *12 (k12,2 and 42,2) in the presence of inactivating protein. The
tetramer aggregates to form higher order active oligomers, Tn.Slow
aggregation of D* leads to apparently irreversible inactivation of the
enzyme (Mayr, 1984a; Zhao et al., 1991b).
Troponin C, a component of the skeletal muscle thin filament, has
effects on the self-association equilibrium of M-phosphofructokinase that
are similar to those found with calmodulin (Zhao etal., 1991b). By binding
calcium, troponin C triggers contraction in skeletal muscle by promoting
the association of myosin and actin (Cooke, 1986). The protein is highly
acidic, having strong sequence and similar structural homology to
calmodulin (Babu et al, 1985). However, troponin C does not interact with
most calmodulin-binding enzymes. Phosphorylase kinase alsoreversibly
associates with both proteins; however, the association with troponin C is
approximately two orders of magnitude lower than its interaction with
calmodulin (Cohen et al., 1979). The interaction with phosphofructokinase
is the only significant common target of the two proteins found to date
(Lan and Steiner, 1991; Zhao et al., 1991b). Several other acidic proteins,
including the liver zinc binding protein (Brand and Soling, 1986), alpha
actinin, myosin light chain, parvalbumin, soybean trypsin inhibitor,
parvalbumin (Zhao et al., 1991b), and tubulin (Lehotzky et al., 1993) also
interact with and inactivate phosphofructokinase.12
The rate enhancement of the D D* equilibrium by calmodulin
ortroponinCleadingtooverallcatalyticinactivationof
phosphofructokinase is measured by a two-step assay in which the
enzyme isfirstincubated with theinactivating protein atnear-
physiological concentrations, and is followed by removal of sample for
catalytic assay under favorable allosteric conditions (Mayr, 1984a; Zhao et
al, 1991b). The slow protein-induced inactivation of phosphofructokinase
contrasts with the quick response of enzyme activity to allosteric effectors,
which affect the rapid dimer-tetramer equilibrium.Because allosteric
regulation occurs rapidly, the effects of allosteric activators and inhibitors
on enzyme activity are measured directly through their inclusion in the
catalytic assay.Results by Zhao (Zhao et al, 1991b) demonstrated that
positive as well as negative allosteric effectors inhibit the effect of the slow
calmodulin- or troponin C-induced inactivation of phosphofructokinase.
This result suggests that the negative allosteric effectors ATP and citrate
bind preferentially to the D, and not the D* dimer conformation (Zhao et
al, 1991b).
M-phosphofructokinase contains two sites that specifically interact
with calmodulin (Buschmeier et al, 1987).One weakly-binding site of
interaction is at the C-terminus of the protein, while the other site includes
the "linking hinge" region of the model for the 3-dimensional structure of
the enzyme that was proposed by Poorman et al (Poorman et al, 1984),13
and is of high affinity (Buschmeieret al,1987). Both sites are highly basic
with a large number of hydrophobic residues, and are homologous to the
sites of myosin light chain kinase which also interact with calmodulin
(Buschmeieret al,1987).
Phosphofructokinase is found in both the insoluble and soluble
fractions of skeletal and heart muscle (Kemp, 1975; Kuoet al,1986;
Mansouret al.,1966). Phosphofructokinase localizes to the I-band of the
skeletal muscle sarcomere (Dolkenet al.,1975; Sigel and Pette, 1969). The
binding of the enzyme to insoluble elements of muscle varies under
different physiological conditions. Enzyme activity shifts from soluble to
the insoluble fraction of sheep heart during sizeable delays between the
time that the animal is killed and the time of purification (Choateet al,
1985).The enzyme can be extracted from the insoluble fraction by
incubation with ATP and magnesium (Choateet al.,1985; Mansouret al.,
1966).Phosphofructokinase binds to sheep muscle cytoskeletal proteins
during tetanic stimulation (Walshet al.,1981).The degree of binding
differs by muscle type (Walshet al.,1981).In rat tibialis muscle, low-
frequency stimulation causes a rapid binding of phosphofructokinase to
the insoluble fraction (Parra and Pette, 1995). In rainbow trout, exercise
causes a marked increase in enzyme binding inskeletal muscle, with
nearly no change in binding within cardiac muscle (Brooks and Storey,
1988).14
In vitro, phosphofructokinase interacts with several cytoskeletal
elements, including the reconstituted thin filament (Liou and Anderson,
1980), F-actin (Kuo et al., 1986; Liou and Anderson, 1980; Roberts and
Somero, 1987; Roberts and Somero, 1989), myosin (Freydina et al., 1986;
Offer eta!, 1988), and microtubules (Lehotzky et al., 1994; Lehotzky et al.,
1993; Vertessy eta!, 1997a; Vertessy eta!, 1996; Vertessy et al, 1997b). The
binding of phosphofructokinasetoF-actin decreasestheallosteric
inhibition by ATP (Liou and Anderson, 1980) and increases the activation
by fructose-2,6-bisphosphate (Kuo et al., 1986).The tetrameric form of
phosphofructokinase is stabilized upon binding to F-actin (Roberts and
Somero, 1987). The binding of phosphofructokinase is increased at lower
pH, suggesting a mechanism for the stabilization of enzyme activity
during muscle acidosis (Roberts and Somero, 1987).Polymerization of
actinfilamentsfromG-actinisstimulatedbybindingof
phosphofructokinase (Roberts and Somero, 1989).Phosphofructokinase
binds F-actin in a manner competitive with several antibodies specific to
different regions of actin, demonstrating that the enzyme binds several
different domains of the protein (Mejean et al., 1989). Optical diffraction
patterns and electron microscopy reveal that phosphofructokinase forms
regular crossbridges between actin filaments space approximately 37 nm
apart, a periodicity that corresponds to the cross-over spacing of the actin
helix (Podlubnaia et1996; Roberts and Somero, 1987).15
Microtubules are ubiquitous structures involved in many cellular
functions, including mitotic spindle formation (Bershadsky and Vasiliev,
1988). Microtubules are polymerized from the end-to-end association of
tubulin dimers in the presence of divalent cations (Weisenberg and
Timasheff, 1970) or GTP (Borisy et al, 1975; Borisy et al,1974).
Phosphofructokinase specifically interacts with tubulin (Lehotzky et al,
1994; Lehotzky et al., 1993; Vertessy et al., 1997a; Vertessy et al, 1996;
Vertessy et al., 1997b).In contrast to the interaction with F-actin, both
tubulin and assembled microtubules bind the phosphofructokinase dimer
(Lehotzkyetal.,1993).The binding causes an inactivationof
phosphofructokinase (Lehotzky et al., 1994; Lehotzky et al, 1993), the
reversibilityof which hasnot beendetermined.Theeffectof
phosphofructokinase on the aggregation of microtubules is however
similar to the effects of the enzyme on the cross-bridging of actin filaments.
Phosphofructokinase causes microtubules to form bundled aggregates
(Lehotzky et al, 1994; Lehotzky et al, 1993; Vertessy et al, 1997a).
Bundling is inhibited by the allosteric effectors ATP, ADP, fructose-1,6-
bisphosphate, and fructose-2,6-bisphosphate (Lehotzky et al, 1994).
Aldolase, the glycolytic enzyme catalyzing retro-aldol condensation
of fructose-1,6-bisphosphate to form dihydroxyacetone phosphate and
glyceraldehyde-3-phosphate, is also inactivated upon association with
microtubules (Ovadi and Orosz, 1992; Volker and Knull, 1993). Aldolase16
also binds to the phosphofructokinase dimer (Orosz et al, 1987). Aldolase-
phosphofructokinase complexes form preferentially in the presence of
microtubules, inhibiting microtubular bundling (Lehotzky et al, 1994;
Vertessy et al, 1997b) and decreasing the tubulin- and microtubule-
dependent inactivation of phosphofructokinase and aldolase (Vertessy et
al, 1997b). Aldolase also binds calmodulin, inhibiting its interaction and
inactivation of phosphofructokinase (Orosz eta!, 1988).
Phosphofructokinase-facilitated bundling of microtubules plays a
potential role in the recognition of cancerous cells by the chemotherapeutic
drugs vinblastine,vincristine, and KAR-2.The polymerization of
micro tubules is an equilibrium process with polymer growth occurring on
one end of the filament and de-polymerization on the other end. These
drugs inhibit the growth of microtubules, shifting the self-association
equilibrium toward the depolymerized state.However, in the bundled
state, the drug-catalyzed depolymerization of microtubules is inhibited
(Lehotzky et al, 1994; Orosz et al, 1997; Vertessy et al, 1997a; Weisenberg
and Timasheff, 1970). Melanoma cells (Beckner et al, 1990; Fiechter and
Gmunder, 1989) and cancerous thymocytes (Greiner et al, 1994) show
increased levels of glycolytic flux and of ATP. Taking this into account
with the observation that phosphofructokinase-facilitated bundling of
microtubules is inhibited by ATP has led to the hypothesis that the17
effectiveness of these drugs is dependent upon the high ATP levels found
in cancer cells.
Phosphorylation may also play a rolein the regulation of
phosphofructokinase.Thefirstevidenceforphosphorylationof
phosphofructokinase was demonstrated by the precipitation of 32P-
containing liver-type phosphofructokinase by antibodies after incubation
of rat liver extracts with 32P-ATP (Brand and Soling, 1975).Later,
phosphorylated phosphofructokinase was purified from mouse skeletal
muscle following injection of the animal with 32P-ATP (Hofer and Furst,
1976).The phenomenon of phosphorylation has been observed in
phosphofructokinase over a wide range of species, including bivalve
mollusks (Mytilus galloprovincialis) (Fernandez et al., 1997) earthworms
(Lumbricus terrestris) (Schaloske et al, 1996), roundworms (Ascaris suum)
(Daum et al, 1986), rainbow trout (Oncorhynchus mykiss) (Su and Storey,
1994), fungi (Aspergillus niger) (Legisa and Bencina, 1994), and liver flukes
(Fasciola hepatica) (Mahrenholz et at, 1991a). In each of these species, the
phosphorylation of phosphofructokinase is catalyzed by the catalytic
subunit of cyclic AMP dependent protein kinase (cAMP-dPK), and there is
a positive correlation between phosphorylation and enzyme activation.
The important role that carbohydrate metabolism plays in the behavior of
organisms is underscored by some of the changes that take place upon
phosphorylation of phosphofructokinase. Phosphorylation of molluskan18
phosphofructokinase coincides with a shift in the seasonal changes in
metabolism to an anaerobic state (Fernandez et al, 1998). Phosphorylation
of phosphofructokinase, along with glycogen phosphorylase, pyruvate
kinase, and pyruvate dehydrogenase, plays a major role in signaling
hibernation in a broad range of animal species (Storey, 1997).
In non-hibernating mammals such as the rabbit, phosphorylation of
phosphofructokinase has been observed throughout several tissues.L-
phosphofructokinase has been foundtobe phosphorylated upon
stimulation of liver with glucagon (Brand et al, 1983; Brand and Soling,
1982; Claus et al., 1982; Kagimoto and Uyeda, 1979; Kagimoto and Uyeda,
1980) and of adipose tissue with epinephrine (Sale and Denton, 1985).
Epinephrine stimulation of heart (Narabayashi et al, 1985) and electrical
stimulation of skeletal muscle (Sorensen-Ziganke and Hofer, 1979) lead to
phosphorylation of M-phosphofructokinase isotype.Also, an increased
level of phosphorylation of phosphofructokinase has been observed in
growing tumors (Staal et a1,1987).
Thesiteofinvivophosphorylationofliver-type
phosphofructokinase is the same as the site in vitro phosphorylated by
cAMP-dPK. The site of phosphorylation corresponds to a serine located on
theC-terminusoftheprotein containedinthesequence NH2-
AEYVSGELEHVTRRSLS-COOH (Zhaoet al,1996).As with L-
phosphofructokinase, the phosphorylation of L-6-phosphofructo-2-kinase19
is also catalyzed by cAMP-dPK (Brand et al, 1983). However, while 6-
phosphofructo-2-kinase is catalytically inactivated upon phosphorylation
by cAMP-dPK, the effects of phosphorylation of L-phosphofructokinase
are not as well defined (Uyeda et al, 1983). Sakakibara et al (Sakakibara
and Uyeda, 1983) report that phosphorylation of L-phosphofructokinase
causes a pH dependent increase in ATP and citrate inhibition, and a
decrease in the activation of the enzyme by fructose-2,6-bisphosphate and
AMP.In contrast, Pilkis et al showed that the effect of decreased
phosphofructokinase activity in glucagon-stimulated liver is abolished
upon purification of the enzyme (Pilkis et al, 1983). In all, the effect of
phosphorylationofL-phosphofructokinaseremainstobeclearly
established.
Thesiteofphosphorylationofrabbitmuscle-type
phosphofructokinase was originally mapped to a serine residue (Riquelme
et al, 1978a) within the sequence NH2-HISRKRSGEATV-COOH (Kemp et
al, 1981), located at the enzyme's C-terminus.The site of in vivo
phosphorylation is the same as the site phosphorylated in vitro by cAMP-
dPK (Sorensen-Ziganke and Hofer, 1979). The in vitro phosphorylation
reaction proceeds at approximately 2% of the rate of phosphorylation of
glycogen phosphorylase b that takes place through the combined actions of
cAMP-dPK and phosphorylase kinase (Riquelme et al., 1978b). The Km of
cAMP-dPK for phosphofructokinase is 230 1AM (Kemp et al, 1981), a value20
much larger than the 15 piM concentration of phosphofructokinase in
skeletal muscle.These unfavorable kinetic values suggest that other
factors contribute to the phosphorylation reaction in vivo (Kemp and Foe,
1983).
Early in vitro experiments with muscle phosphofructokinase and
cAMP-dPK did not give stoichiometrically complete phosphorylation.
Although the highest stoichiometry of phosphate incorporation reported
was 0.7 moles phosphate per mole phosphofructokinase protomer
(Kitajima et al, 1983), other reported levels were generally less than 0.8
moles per mole.In vitro phosphorylation of M-phosphofructokinase
causes no detectable change in the Vinax of the reaction catalyzed by
phosphofructokinase (Foe and Kemp, 1982; Kemp et al, 1981; Kitajima et
al., 1983). There is a slight decrease in the fructose-6-phosphate activation
(Ko.5 change from 1.2 to 1.5 mM), and increase in sensitivity to ATP
inhibition (Kas from 0.9 to 0.6 mM) (Kitajima etal.,1983).The most
significant effect that in vitro phosphorylation has on the enzyme's
catalytic properties is an increase in the affinity of binding ATP (Ka change
from 26 to 5011M) (Kitajima eta!, 1983).
Analytical ultracentrifugation has been used to study the effects of
invitrophosphorylationontheself-associationequilibriumof
phosphofructokinase. Earlierreportsfoundfewdifferencesin
sedimentationpropertiesbetweenthephosphorylatedandnon-21
phosphorylated forms (Cai et al., 1990; Foe and Kemp, 1982; Hussey et al.,
1977; Uyeda et al., 1978). A report by Cai (Cai et al, 1997) shows identical
averagesedimentationvs.proteinconcentrationpatternsfor
phosphorylated and nonphosphorylated M-phosphofructokinase when the
proteins were analyzed in a stabilizing buffer containing 90 mM
ammonium sulfate, which is an allosteric activator of the enzyme.
However, differences between the two patterns became apparent during
analysis in a non-activating buffer containing 65 µM glycylglycine. The
model of self-association was identical between the two forms, with the
phosphorylated form showing a higher propensity for octamer and 16-mer
formation than the unphosphorylated form: monomer E- -) tetramer-
octamer-> 16-mer (Cai et al., 1997; Cai et al., 1990). 10 mM citrate was
found to alter the model of self-association such that dimer formation was
observed (monomer E-dimer4 tetramer4 octamer E- 4 16-
mer). The phosphorylated and unphosphorylated forms of the enzyme
displayed different self-association equilibria in the presence of citrate,
with the phosphorylated form showing a 300-fold lower propensity for
dimer formation. In judging the significance of this study, it must be noted
that the phosphorylated enzyme under study contained a very low
stoichiometryofincorporatedphosphate,at0.1moles/mole
phosphofructokinase protomer (Cai et al., 1997).22
The Ka for the interaction between phosphofructokinase and F-actin
has been reported to decrease from 4 1.1M in the dephosphorylated state to
1.5 p.M in the phosphorylated state, upon cAMP-dPK-catalyzed in vitro
phosphorylation to 0.7 moles phosphate per mole of enzyme (Luther and
Lee, 1986). The effects of F-actin on the catalytic activity toward in vitro
phosphorylated phosphofructokinase were very similar to those with the
unphosphorylated form (Luther and Lee, 1986). Tetanic stimulation causes
an increase in the binding of glycolytic enzymes to the particulate fraction
of skeletal muscle (Parra and Pette, 1995).During brief periods of
stimulation,thebindingofphosphofructokinase,aldolase,and
glyceraldehyde-3-phosphate dehydrogenase along with increases in lactate
production and glycogenolysis are observed in skeletal muscle (Walsh et
al, 1981). Low-frequency stimulation of rat fast-twitch muscle induces a
rapid 30% increase in binding of phosphofructokinase (Parra and Pette,
1995).The increase in binding to F-actin by in vitro phosphorylated
phosphofructokinase takes on functional significance when considered in
light of the increased in vivo phosphorylation state of the enzyme
(Sorensen-Ziganke and Hofer, 1979) in contracting muscle.
The protein kinase that catalyzes the in vitro phosphorylation of
phosphofructokinase, cAMP-dPK, is activated in vivo by rising levels of
cAMP. In skeletal and cardiac muscle, the increase in cAMP concentration
is stimulated by the hormone epinephrine.Epinephrine stimulates the23
phosphorylation of cardiac troponin I (Wattanapermpoolet al,1995) and
slow calcium channels (Osterriederet al.,1982; Trautweinet al.,1987;
Wattanapermpooletal,1995)catalyzedby cAMP-dPK.This
phosphorylation is involved in the increased contractility that is manifest
in the increase in blood pressure and heart rate.
It's hypothesized that epinephrine signals the cascade of events
leading to phosphofructokinase phosphorylation. Treatment of rat heart
with epinephrine decreases 6-phosphofructo-1-kinase'ssensitivityto
citrate and ATP inhibition (Clarket al,1982; Narabayashiet al.,1985),
increases activation by fructose-2,6-bisphosphate and AMP (Clark and
Patten, 1981; Narabayashiet al.,1985), and causes a two-fold decrease in
the K0.5 for fructose-6-phosphate (Narabayashi eta!, 1985). The changes in
the enzyme's properties remain even after the enzyme is purified by gel
filtration (Clark and Patten, 1981), suggesting that the changes are due to a
covalentmodification.Likewise,cardiac6-phosphofructo-2-kinase
appears to be phosphorylated upon treatment with epinephrine, resulting
in its activation (Kitamuraeta!,1988; Kitamura and Uyeda, 1987).
In support of this, the enzyme from stimulated rat heart contains
approximately 1.1 moles of phosphate/84,000 g, compared to 0.6 moles
phosphate/84,000 g in control hearts (Narabayashieta!,1985). Due to the
increased extent of phosphorylation seen upon stimulation of hearts with
epinephrine, cAMP-dPK likely plays a role in catalyzing the reactionin24
vivo.Also, the reported extent of phosphorylation in epinephrine
stimulated rat heart phosphofructokinase was higher than levels that had
beenpreviouslyobtainedthroughcAMP-dPK-catalyzedhivitro
phosphorylation of the enzyme.Coupled with the large number of
protein-protein interactions that phosphofructokinase is involved with, the
discrepancy between the in vivo and in vitro phosphorylation extents
suggeststhatotherfactorsorprotein kinasesparticipateinthe
phosphorylation of the enzyme.
Thefirstobservedalterationofthepatternofinvitro
phosphorylation of phosphofructokinase came with the reaction that is
catalyzed by cAMP-dPK in the presence of either calcium-calmodulin or
calcium-troponin C (Zhao et al, 1991b), both of which are inhibitors of
phosphofructokinase.The addition of calcium-calmodulin or calcium
troponin C tothe reaction ledtoa stoichiometryof phosphate
incorporation of 1.2 or 1.6 moles phosphate/84,000 g protein, respectively
(Zhao et al, 1991b).This is a significant increase from the sub-
stoichiometric phosphorylation yields catalyzed by cAMP-dPK alone (Cai
et al, 1997; Cai et a1,1990; Kemp eta!, 1981; Zhao eta!, 1991b). Cyanogen
bromide digestion of the phosphorylated protein followed by reversed
phase HPLC mapping of the created peptides revealed phosphorylation at
both the C-terminal serine 774, and a newly identified phosphorylation
site, serine 376 (Zhao et al, 1991b). This site of phosphorylation, located25
within the sequence NH2-K-L-R-G-R-S-F-M-COOH, is part of the linking
hinge region joining the globular N- and C-terminal domains in the
hypothetical model of rabbit muscle phosphofructokinase structure first
proposed by Poorman (Poorman etal., 1984).
Studies done withelectricalstimulationofskeletalmuscle
(Sorensen-Ziganke and Hofer, 1979) and epinephrine perfusion of heart
muscle (Narabayashi et al, 1985) indirectly point to two sitesof
phosphofructokinase phosphorylation. The novel site discovered during
In vitro phosphorylation in the presence of troponin C or calmodulin,
serine 376, is the only phosphorylation site on phosphofructokinase other
than serine 774 to have been identified. cAMP-dPK, the catalyst of the
reaction, and calmodulin are both active in muscle.Troponin C is
abundant in muscle, with an estimated physiological concentration of
approximately 2 mg/ ml (Lovell and Winzor, 1977; Perry, 1974). When
consideredwiththeobservedsubcellularlocalizationof
phosphofructokinase to the insoluble fraction of contracting muscle (Parra
and Pette, 1995), a region including the thin filament, it is possible that the
troponin C-induced phosphorylation at serine 376 is physiologically
relevant.
However, direct evidence for in vivo phosphorylation at serine 376
is lacking.Proof of phosphorylation at this novel site is important for
establishing the physiological relevance of functional studies done with the26
in vitro phosphorylated enzyme. The specific aims of the experiments
presentedinthisthesiswere:thedeterminationofwhether
phosphorylation of rabbit muscle phosphofructokinase at serine 376 occurs
in vivo, and the optimization of the in vitro phosphorylation reaction.
Achievementofthesecondgoalwouldprovidesamplesof
phosphofructokinase exhibiting higher levels of phosphorylation than any
previously studied. The process of optimization might provide clues to the
conditions leading to in vivo phosphorylation at serine 376.27
Chapter 1: Determination of In Vivo Phosphorylation of
Phosphofructokinase at Serine 376
Introduction
Our laboratory was the first to discover a second serine residue of
rabbit skeletal muscle phosphofructokinase other than serine 774 that is
phosphorylated in vitro. Phosphorylation at the serine 376 occurs when
the cyclic AMP dependent protein kinase (cAMP-dPK)-catalyzed reaction
is run in the presence of either calcium-calmodulin or calcium-troponin C
(Zhao et al.,1991b), which are both inhibitors of phosphofructokinase. The
addition of calcium-calmodulin or calcium-troponin C to the reaction led
to incorporation of phosphate at two sites, with an overall stoichiometry of
1.2 or 1.6 moles phosphate/84,000 g protein, respectively (Zhao et al.,
1991b).Thisisa significant increase from the sub-stoichiometric
phosphorylation yields catalyzed by cAMP-dPK alone (Cai et al., 1997; Cai
et al., 1990; Kemp et al., 1981; Zhao et al., 1991b). This result is significant
because while calmodulin regulates the activity other protein kinases,
including myosin light chain kinase (Means et al., 1991; Means and George,
1988) and calmodulin dependent protein kinase II (Hanson and Schulman,
1992), the activity of cAMP-dPK generally isn't affected by calmodulin or
troponin C.28
Studies done with electrically stimulated skeletal muscle (Sorensen-
Ziganke and Hofer, 1979) and epinephrine perfused hearts (Narabayashi et
al,1985)indirectlysuggestthephosphorylationofmuscle
phosphofructokinase at two different sites. Serine 376 and serine 774 are
the only phosphorylation sites in muscle phosphofructokinase to have
been identified thus far. cAMP-dPK, the catalyst of the in vitro reaction,
and calmodulin are both present in muscle cytosol. Troponin is abundant
in muscle, and the troponin complex, of which troponin C is a subunit,
undergoesreversibleassociation-dissociationatphysiologicalionic
strength and pH (Lovell and Winzor, 1977). Phosphofructokinase has been
found to associate with the thin filament, a structure containing troponin,
tropomyosin, and actin which slides against thick filaments to cause
muscle contraction, during low frequency electrical stimulation of skeletal
muscle (Parra and Pette, 1995).In considering this fact with the
preponderance of troponin C in muscle (de Duve, 1972) and the high
affinity of phosphofructokinase towards troponin C and calmodulin (de
Duve, 1972; Lan and Steiner, 1991; Mayr, 1984a; Zhao et al, 1991b), it is
highly possible that phosphorylation of this novel site is physiologically
relevant.
Proof of phosphorylation at serine 376 is important for establishing
the physiological relevance of any functional studies done with the in vitro29
phosphorylated enzyme.Likewise, determination of the invivo
phosphorylation pattern may give a point of reference for optimizing the
in vitro phosphorylation reaction.
Materials and Methods
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
7-19% gradient acrylamide gels (8 X 10 cm) consisted of the proper
proportions of 40% (w/v) acrylamide and 1% (w/v) bis(acrylamide). Gel
buffers contained 0.75 M Tris pH 8.8, 0.05% (w/v) ammonium persulfate,
and 0.08% (v/v) TEMED (Malencik and Anderson, 1987). In preparation
for analysis, 25 1.1.1 protein samples were combined with 10 IA of protein
sample buffer, which contained 0.25 M Tris, 4% (w/v) sodium dodecyl
sulfate (SDS), 50% glycerol, 1 mM EDTA, 0.3 mM beta-mercaptoethanol,
and 0.03% (w/v) cresol purple, and boiled for approximately 5 seconds.
The gel reservoirs contained 50 mM Tris-phosphate, 50 mM boric acid, 1
mM EDTA, and 0.1% SDS.Under 150 V, gel electrophoresis was
conducted until the cresol purple tracking entered the bottom reservoir of
the electrophoresis apparatus. Gels were then fixed for 30 minutes in 50%
methanol, 10% acetic acid, stained for thirty minutes in 0.025% (w/v)
Coomassie Blue G-250, and destained in 5% methanol, 7.5% acetic acid.
Glycogen phosphorylase (96 kd), actin (42 kd), carbonic anhydrase (29 kd),30
and troponin C (18 kd) prepared in this laboratory were used as molecular
weight standards.
Protein Concentration Determination
The following molar absorptivitycoefficients were used in
conjunctionwith UV opticaldensitymeasurementstoquantify
concentrations of homogeneous protein solutions: El %280 nm = 10.7 for
phosphofructokinase (Hesterberg et al, 1981), 2.0 for troponin C (Malencik
et al, 1975) and calmodulin (Watterson et al., 1980), 4.0 for troponin I, 5.0
for troponin T (Malencik et al, 1975), 1.4 for cAMP-dPK, and 8.3 for S100A
(calculated from Gill and von Hippel (Gill and von Hippel, 1989)); 0%276 nm
= 4.5 for troponin (Gordon et al, 1997); El%290. = 6.3 for actin (Lehrer and
Kerwar, 1972).All other protein concentrations were determined by the
method of Bradford, using bovine serum albumin as a standard (Bradford,
1976).For calculation of molar protein concentrations, the following
molecular weights were used: phosphofructokinase = 84 kd (monomer),
troponin C =18 kd, troponin T = 32.9 kd, troponin I = 21 kd, actin = 42 kd,
tubulin = 52 kd (monomer), calmodulin = 16.7 kd, S100A = 10.4 kd
(monomer), troponin = 74 kd.
PeptideamountswerequantifiedbyintegrationofA214
chromatogram peaks appearing during HPLC separation according to the
methods of Malencik et al (Malencik et al, 1996).31
Phosphofructokinase Activity Assay
Aspectrophotometricassayofthecatalyticactivityof
phosphofructokinase was conducted by coupling the formation of
fructose-1,6-bisphosphate to the oxidation of NADH through the use of the
enzymes aldolase, triosephosphate isomerase, and a-glycerophosphate
dehydrogenase (Racker, 1947).The assay buffer contained 50 mM
glycylglycine pH 8.2,1 mM EDTA, 5 mM MgC12, 5 mM ammonium sulfate,
2.5 mM dithiothreitol, and 0.16 mM NADH. The concentration of all ATP
stock solutions were verified by absorbance at 259 nm (8259 = 15,400 L/mol
X cm), and the concentration of NADH in the assay buffer verified by
absorbance at 340 nm (c340 = 6,230 L/mol X cm). A coupling enzyme
solution containing 40 U/ml aldolase, 40 U/ ml a-glycerophosphate
dehydrogenase, and 100 U/ml triosephosphate isomerase in 50 mM
triethanolamine pH 7.5, 5 mM dithiothreitol remained stable on ice for up
to 2 hours. Samples containing phosphofructokinase were diluted when
necessary in 50 mM MOPS pH 7.0, 25% (v/v) glycerol, and 5 mM
dithiothreitol prior to assaying. To initiate the assay, 10 ill of coupling
enzyme solution was added to 990 µl assay buffer, followed by addition of
2-10 ill phosphofructokinase sample (containing approximately 0.2 vig
phosphofructokinase) in a 1 cm cuvet, and assayed at 340 nm for 432
minutes. Control values of activity were obtained by conducting the assay
using 10 [11 coupling enzymes plus assay buffer.
Surgical Epinephrine Stimulation of Rabbit Hearts
cAMP-dependentproteinkinase(cAMP-dPK)hasbeen
demonstrated to phosphorylate phosphofructokinase at serine 376 in vitro
(Zhao et al., 1991b). cAMP-dPK activity is activated in the presence of
cAMP (Taylor, 1989).cAMP concentrations in turn are regulated by
activationof betaadrenergicreceptorsinheart(Levitzki,1988).
Demonstrationofserine376phosphorylationinrabbitheart
phosphofructokinase therefore began with the injection of rabbits with
epinephrine, a known beta-adrenergic agonist.
Epinephrine stimulation of rabbit hearts was performed with live
rabbits under the supervision of Frederick Hisaw, Professor Emeritus in
the Dept. of Zoology, at Oregon St. University.A large female New
Zealand white rabbit was anaesthetized by injection into the marginal vein
with 20% (v/v) urethane in Locke's buffer, at a dosage of approximately 9
ml/kg body weight, until the pedal reflex was inhibited. Blood pressure
was measured directly by cannulation of the carotid artery.An
intravenous line containing 0.1% glucose (w/v) in Locke's solution was
established into the jugular vein at a flow rate of 15 drops per minute.
Upon establishment of stable baseline values for heart rate, respiration33
rate, and blood pressure, the I.V. solution was brought to a concentration
of 100 µg /m1 epinephrine. Rapid increases in both blood pressure and
heart rate resulted.Within one minute of attaining maximum blood
pressure, the heart was removed from the pleural cavity, frozen in liquid
nitrogen, and stored at -80 °C.
Unstimulated rabbit hearts were obtained following euthanasia by
injection into the marginal vein of a 6.5% (w/v) solution of sodium
pentobarbitol, to a final dose of 1 ml/kg body weight. Rabbits were bled,
the hearts quickly extracted and frozen under liquid nitrogen, and stored
at -80 °C.
Purification of Phosphofructokinase from Frozen Rabbit Hearts
Phosphofructokinase was purified from two frozen hearts utilizing
ATP-affinity chromatography following a combination of procedures for
purification of the enzyme from rat hearts (Narabayashi et al, 1985) and
from rabbit skeletal muscle (Ramadoss et al, 1976a).Under liquid
nitrogen, the frozen hearts were crushed between lead bricks and
subsequently ground to a coarse powder with a pre-cooled mortar and
pestle.The crushed tissue was blended in four volumes of a buffer
containing 30 mM KF (a phosphatase inhibitor), 0.2 mM EDTA, 10 mM
dithiothreitol, pH 7.5 (Buffer A). This buffer and all subsequent buffers in
the preparation were kept cold in order to safeguard enzyme activity. The34
crude homogenate was centrifuged at 5,000 X g for 15 minutes in a Sorvall
centrifuge using an SS-34 rotor.Previous studies have shown that
incubationwith0.1mM ATPand5 mM MgC12extracts
phosphofructokinase activity from the insoluble fraction of cardiac muscle
(Choate eta!, 1985; Mansour et al, 1966). However, in our preparation, no
significant activity was extracted from the 5,000 X g pellet. The enzyme
thus was assumed to reside entirely in the supernatant solution.The
supernatant solution then was centrifuged for 4.5 hours using a Type 45 Ti
rotor in a Beckman L8-70 ultracentrifuge with a speed of 40,000 RPM. The
resulting pellet, containing all of the enzyme activity, was resuspended in
30 ml of buffer B (containing 50 mM Tris-phosphate pH 8.0, 0.2 mM EDTA,
and 10 mM dithiothreitol).Suspended matter was removed through
centrifugation at 5,000 X g and discarded.
The supernatant solution from the second centrifugation then was
loaded at a flowrate of 10 ml/hour onto an ATP affinity column (0.75X 3.0
cm) comprised of N6-[6-aminohexyl-carbamoyl-methyl]-ATP-Sepharose
purchased from Sigma. After washing the column with twenty volumes of
buffer B, the column was eluted using thirty volumes of buffer B plus 300
mM fructose-6-phosphate and 300 mM ADP (Narabayashi et al., 1985;
Ramadoss et al., 1976a). The eluate was concentrated to a five milliliter
volume using an Amicon ultrafiltration concentrator with a YM-10 Diaflo
membrane, and then applied to an S-300 sizing column (2 X 100 cm)35
equilibrated in 150 mM Tris-phosphate pH 8.0, 0.2 mM EDTA, and 10 mM
dithiothreitol.The phosphofructokinase eluting in the void volume was
concentrated, then dialyzed against a buffer containing 50 mM tris-
phosphate pH 8.0, 0.2 mM EDTA, 50% glycerol (v/v), and 15 mM beta-
mercaptoethanol, and stored at -80 °C.
Cyanogen Bromide (CNBr) digestion of Phosphofructokinase
In preparing the enzyme for CNBr digestion, the buffer was
exchanged with water using the Amicon ultrafiltration apparatus. No
precipitation was observed during this transfer of buffers. In the case of
phosphofructokinase from epinephrine perfused hearts, approximately 800
[1g of protein was recovered, as determined by 0D280 nm. The protein was
then dried using a Jouan Speedvac Concentrator and resuspended in 200 1.11
of 70% formic acid, bringing the calculated protein concentration to 4
mg/ml. CNBr (2.2 mg) was added to the protein to yield a 100-fold molar
excess of CNBr over total methionine.The same protein and CNBr
concentrations were used in digestion of enzyme from unstimulated
hearts. Digestion proceeded in the dark for 36 hours. The digestion was
terminated by a ten-fold dilution of the reaction mixture with water. The
digest was dried in a speedvacuum and dissolved in a solution containing
6 M guanidine HC1, 0.1% TFA.36
Reversed Phase HPLC
Reproducibleseparationofthepeptidecontainingthe
phosphorylatable serine (the "hinge peptide") was achieved through
reversed phase HPLC. The HPLC apparatus consisted of a Dupont C18
column, a guard column packed with C18 resin, two LKB 2150 pumps, an
ISCO V4 ultraviolet absorbance detector containing a flow cell with a 5 mm
path length, a Hewlett-Packard 1046a fluorescence detector, and an LKB
2152 gradient controller.The column was eluted using a programmed
gradient (Figure 1) of buffer A (water plus 0.1% trifluoroacetic acid (TFA))
versus buffer B (100 % acetonitrile plus 0.069% TFA).
The CNBr digested sample from epinephrine-stimulated hearts was
separated into two major pools via reversed phase HPLC using gradient
#2 (table 1-1) in order to facilitate handling the 800 ptg of protein present.
Pool 1 contained peptides eluting between 2.5 and 5 minutes in the
gradient, and pool 2 contained material from between 5 and 7 minutes
(table 1-1).
Iron Chelate Chromatography
The selective separation of phosphopeptides by iron chelate
chromatography was performed following the methods of Muszynska et al37
Table 1-1
Gradient #1 was used for resolution of individual peptides
following CNBr digestion of phosphofructokinase.Buffer A = 0.1 %
trifluoracetic acid (TFA) in water; Buffer B = 0.065% TFA in acetonitrile;
flowrate = 0.75 ml/minute. Gradient #2 employed the same buffers, and
was used for bulk separation of CNBr-digested phosphofructokinase
purified from epinephrine-stimulated rabbit hearts.Flowrate = 1.0
ml/minute.Gradient #3 was used for separation of dabsyl chloride
derivatized amino acids during amino acid analysis.Buffer A = 18 mM
sodium acetate pH 6.5, plus 4% dimethyl formamide and 15% buffer B;
Buffer B = 90% acetonitrile plus 10% isopropanol; flowrate = 1.0
ml/minute. Gradient #4 was used during reversed phase HPLC isolation
of the phosphorylated hinge peptide from a subfraction of CNBr-digested
phosphofructokinase purified from epinephrine-stimulated hearts, and
also for ammonium sulfate gradient reversed phase HPLC. The buffers
used during isolation of the hinge peptide were identical to those used in
gradients #1 and #2. Ammonium sulfate reversed phase HPLC used the
same buffers as gradients #1 and #2, plus an additional 0.1 M ammonium
sulfate in buffer A. Flowrate for gradient #4 = 1.0 ml/minute.Table 1-1 Gradients used for reversed phase HPLC, amino acid analysis, and ammonium sulfate HPLC.
Gradient #1
Time (min)
o
0.1
35.1
38.1
39
%B
Gradient #2
%B
Gradient #3
%B
Gradient #4
Time (min) Time (min) Time (min) %B
10 0 0 0 10 0 10
10 7 12 5 30 5 10
70 26 29 15 40 45 35
70 41 70 20 70 50 70
10 43 70 25 70 55 70
45 0 27 10 57 1039
(Muszynska et al., 1986; Muszynska et al, 1992). In these reports, elution
ofthe unphosphorylated forms of phosvitin and histone from iron chelate
resins at low pH, and of phosphorylated forms of these proteins at pH 8.0
or higher are demonstrated.
Iminodiacetic acid substituted agarose was packed into a column
(1.5 X 5.0 cm) with distilled water and charged with five bed volumes of 50
mM FeC13. The column was then equilibrated in 100 mM acetic acid, pH
5.0. Preliminary experiments were performed on the column in which 1.0
mg samples of phosphorylated or nonphosphorylated malantide, a
synthetic peptide derived from the phosphorylatable site of phosphorylase
kinase (Zhao et al., 1991a), were loaded onto the column with a flowrate of
1 ml/minute. The peptides were washed with five column volumes of 0.1
M acetic acid pH 5.0, followed by elution with five volumes of 50 mM
ammonium bicarbonate pH 8.9.Subsequent drying of these eluted
samples followed by reversed phase HPLC corroborated published
observations, demonstrating specific binding of the phosphorylated
peptide at pH 5.0.
Approximately one half of the total material recovered in CNBr
digest pools 1 and 2, and approximately 1 mg of CNBr digested
phosphofructokinase from unstimulated rabbit hearts, underwent iron
chelate chromatography following the procedure outlined above for
malantide. The material eluting at pH 8.9 was pooled, lyophilized, and40
resuspended in 0.1% TFA. The material was then desalted by passage over
a reversed phase HPLC column, collected, dried, and resuspended in 0.1%
TFA. From the reversed phase HPLC chromatogram, it was apparent that
none of the material from unstimulated rabbit heart phosphofructokinase
bound the column, whereas a single peak appeared during desalting of the
material from epinephrine-stimulated hearts. Approximately one third of
this material binding to the iron chelate column (0.75 lig) was subjected to
molecular weight analysis using MALDI-TOF mass spectrometry, while
the remaining fraction underwent amino acid analysis.
Matrix-assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF)
Mass Spectrometry
MALDI-TOF mass spectrometry was performed by the OSU
Environmental Health Sciences Center Mass Spectrometry Laboratory
using a custom-built time-of-flight mass spectrometer. Samples analyzed
included hinge peptide that had been purified from unstimulated heart
phosphofructokinase using gradient #1 (table 1-1), and a peptide fraction
from the epinephrine perfused heart phosphofructokinase digest that had
been isolated by iron chelate chromatography. A voltage of 24 kV was
used to accelerate ablated ions from the sample stage into the instrument's
flight tube.Every mass spectrum was recorded as the sum of 30
consecutive spectra, each produced by a single pulse of 355 nm photons41
from a Nd:YAG laser (Spectra Physics). Matrix ions or ions from an added
standard were used for mass calibration. All samples were analyzed with
a saturated solution of cinnapinic acid in 33% acetonitrile/water serving as
the matrix. For each mass analysis, 0.5 pi of this mixture was mixed in a
1:4 or 1:9 ratio with the matrix solution, and 0.5 vd of this mixture was
deposited on the sample stage. At the first sign of peptide/matrix crystal
formation (generally 10-15 seconds after sample deposition when viewed
under a stereo microscope), the droplet was wiped off with a lab tissue,
leaving a seed layer of crystallites on the surface of the sample stage.
Another 0.5 vtl portion of the analyte/ matrix was then deposited on top of
the seed layer and allowed to dry. In some cases, the crystals were rinsed
by gently dipping the sample stage into water before the sample had dried.
The probe was inserted into the mass spectrometer and mass spectra were
acquired as outlined above.
Phospho-Amino Acid Analysis
Further characterization of the peptide eluting from the iron-chelate
column was accomplished through amino acid analysis and phospho-
amino acid analysis by the method of Malencik et al (Knecht and Chang,
1986; Malencik et al, 1990).Separate samples containing 0.75 tig of the
phosphopeptide, 0.75 i.tg of phosphoserine, and an amino acid standard
containing equimolar quantities of all twenty amino acids were partially42
hydrolyzed in 6 M HC1 in vacuo at 110 °C for 2 hours. Another 0.75 lig
peptide and the amino acid standards underwent gas phase hydrolysis by
heating the samples under a vacuum in a sealed dessicator to 130 °C for 24
hours in the presence of 6 M HC1.
The hydrolyzed samples were then derivatized with dabsyl
chloride. The molar ratio of dabsyl chloride to amino acid standards was
approximately 4:1, while approximately 30 nanomoles dabsyl chloride
were added to the 0.75 lig of sample present. The reagent concentration in
the derivatization buffer was 18 mM NaHCO3, pH 8.5 and 3 mM dabsyl
chloride in acetonitrile, and the samples were heated approximately 10
minutes at 60 °C. The derivatization reaction was terminated by addition
of an equal volume of a 1:1 mixture of ethanol : 50 mM sodium phosphate
pH 6.8.
The derivatized amino acids were separated and quantified using a
reversed phase HPLC system. This system was the same as that used for
reversed phase HPLC separation of peptide digest, except that absorbance
was analyzed at 460 nm, buffer A contained 18 mM sodium acetate pH 6.5,
plus 4% dimethyl formamide plus 15% buffer B, buffer B contained 90%
acetonitrile plus 10% isopropanol, and gradient #3 (Figure 1) was used.
Calibration of amino acid standard retention times and conversion of peak
areas to amino acid quantities enabled identification and quantification of
amino acid peaks.43
Ammonium sulfate gradient HPLC and gas phase sequencing
The remaining material from pools 1 and 2 were subjected to
reversed phase HPLC using a much shallower gradient (gradient #4, table
1-1) than was used in the initial pooling step (figure 1-1) in order to sub-
fractionate the hinge peptide from other peptides present for further
analysis. Repetitive HPLC separations using minute amounts of pools 1
and 2 were run in an attempt to avoid overloading the column.
A fraction with peak absorbance at 214 and 260 nm eluting from the
reversed phase column with a retention time similar to the previously
purified hinge peptide was dried down and redissolved in 0.1% TFA.
Approximately 0.3 pig of the material from the collected peak was
sequenced on an Applied Biosystems 475A gas phase protein sequencer
maintained at the Oregon St. University Center for Gene Research and
Biotechnology.
Conventional reversed phase HPLC is usually unable to separate
phospho- and dephospho- forms of peptides (Zhao et al.,1991a).
However, separation of phospho- and dephospho-malantide, while not
possible with reversed phase HPLC using conventional water-acetonitrile
gradients, can be achieved with the addition of 0.1 M ammonium sulfate in
buffer A (Zhao et al., 1991a).Reversed phase HPLC under similar
conditions was attempted using the remainder of the suspected hinge44
peptide purified by shallow-gradient HPLC in order to determine whether
multiple forms of the peptide were present within the same peak. The
buffer system included 0.1 mM ammonium sulfate, 0.1 % TFA in buffer A
and acetonitrile plus 0.069% TFA in buffer B, and was developed using
gradient #4 (table 1-1).
Results
The summary for the purification of phosphofructokinase from four
unstimulated rabbit hearts appears in table 1-1. In terms of activity yields
and quantityof phosphofructokinaseobtained,thedataforthis
preparation is typical of data obtained with enzyme preparations from
both stimulated and control hearts. This summary shows that both high
speed ultracentrifugation and the ATP affinity column chromatography
are effective tools, facilitating a five and one hundred fold reduction in
total protein, respectively. ATP affinity column chromatography reduced
the total number of proteins present to two. An elution profile of protein
from the column appears in figure 1-1.
Phosphofructokinase contains two binding sites for ATP, a catalytic
substrate site and an allosteric binding site (Colombo et al, 1975; Liou and
Anderson, 1978; Ui, 1968). In the absence of other effectors, the enzyme
specifically interacts with the ATP affinity column, which consists of ATP45
Table 1-2
Purification table for phosphofructokinase isolated from frozen
rabbit hearts. Protein concentrations were measured by Bradford analysis
(Bradford, 1976), except for the S-300 fraction, which was calculated from
OD280measurements,giventhatE194280nm=10.7forpure
phosphofructokinase (Hesterberg et al.,1981).Phosphofructokinase
catalytic activity was measured by the standard enzyme assay described in
Materials and Methods.46
Table 1-2
Fraction Volume. Protein
(m1)Conc.
(mg/ml)
Spec.
Activity
(U/ ml)
Total
Protein
(mg)
Spec. Total
Activity Activity
(U/mg) (Units)
Crude 150 17.6 2.75 2640 0.2 413
Supernatant
40 K pellet 30 14.03 8.98 420.9 0.6 269
Affinity 30 0.84 44.1 2.94 52.5 154
Column
S-300 3.25 0.409 24.6 1.33 60.0 80
Column47
covalently bound by the N6 atom of the adenine ring to a six carbon spacer
arm attached to Sepharose. Previous results in this laboratory have shown
that phosphofructokinase doesn't interact with resins in which the ATP is
linked directly to the sepharose, or with affinity resins in which the spacer
is attached to the C1 carbon of the adenine ring or attached to the gamma
phosphate.Likewise, experiments with pure rabbit skeletal muscle
phosphofructokinase showed decreased binding at flowrates greater than
10 ml/hour, or when the concentration of phosphofructokinase loaded was
higherthan0.5mg/ ml. Thissuggestsaslowinteractionof
phosphofructokinasewiththeaffinityresin. Elutionof
phosphofructokinase from the column is achieved by addition of a
combination of the substrate fructose-6-phosphate and the allosteric
activator ADP. This interaction with phosphofructokinase is thought to
cause a "dead end complex" with the enzyme (Ramadoss et al., 1976a).
Other combinationsofallostericeffectorsarelesseffectivethan
ADP/fructose-6-phosphate at dissociating phosphofructokinase from the
ATP affinity resin (Ramadoss eta!, 1976a).
Two separate pools of unbound or weakly bound protein were collected
before eluting the column with ADP and fructose-6-phosphate: the first pool
consisted of the material that passed through the column without binding at all,
and the second fraction included material that bound the column but non-48
specifically washed off with buffer.Both of these pools were present
within the broad breakthrough peak seen in the elution profile (figure 1-1).
The difference in the composition of these pools is observed with SDS-
PAGE (figure 1-2). Pool 1 (lane 7, figure 1-2) is composed mainly of the
same proteins present in the fraction loaded onto the column (lane 5), pool
2 (lane 8)is enriched in two proteins of molecular weight 85,000
(corrsponding to phosphofructokinase) and 29,000, along with several
other protein bands. 42 total units of phosphofructokinase activity washed
from the column in pool 1, while 18 units were within pool 2, accounting
for approximately 20 and 10% of the total activity recovered from the
column, respectively. The two enriched proteins of pool 2 were identical
to the two proteins eluting specifically form theaffinity column,
suggesting that the column "leaks" these proteins when washed with
buffer A. This "leakage" from the column may be the result of a shift in
the protein binding equilibrium caused by continuous dilution by buffer.
The proteinsofpool 2 may alsorepresent phosphofructokinase
comformations or oligomers which bind less tightly than the protein
specifically eluting from the column.
Gel filtration with the S-300 sizing resin was successful in separating
the 29 kD protein from phosphofructokinase (lanes 9-11, figure 1-2). It can
be inferred by the success of this separation that the 29 Kd protein and
phosphofructokinase that the two proteins do not specifically interact, or49
Figure 1-1
ElutionpatternofproteinloadedontoN646-
(aminohexyl)carbamoylmethyli-ATP Sepharose (Sigma).30 ml of a 14
mg/ml protein solution were loaded. Wash buffer: 50 mM Tris-phosphate
pH 8.0, 0.2 mM EDTA, 10 mM dithiothreitol. Arrow marks addition of 300
ADP and 300 fructose-6-phosphate [LM to the wash buffer. Flow rate =
10 ml/hour.Figure 1-1
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Figure 1-2
SDS-PAGE gel analyzing the component proteins of individual
steps in the purification of phosphofructokinase from a pool of four rabbit
hearts. Legend: Lanes 1&12, Mw Markers; 2, Crude Homogenate; 5, 40K
supernatant; 7, ATP column flow-through; 8, ATP column wash; 9, ATP
column eluate; 10, S-300 sizing column peak 1; 11, S-300 sizing column
peak 2. Protein bands stained in 0.0025% (w/v) coomassie blue G-250 in
50% methanol, 10% acetic acid.52
Figure 1-2
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that the interaction is weak. The elution position of phosphofructokinase
in the void volume, along with its high activity, suggests that the purified
protein is a higher molecular weight oligomeric form.
Specificactivitywas measured using an enzyme coupled
spectrophotometric assay using allosterically optimal conditions (Racker,
1947).The final specific activity obtained in table 1-2 is 60 U/mg. A
second purification of enzyme from control hearts yielded an activity of 53
U/mg, while the specific activity of the enzyme purified from epinephrine
perfused hearts had an activity of 45 U/mg (table 1-3).
Having purified phosphofructokinase from unstimulated and
epinephrine-stimulated rabbit hearts, attention was focussed upon analysis
of serine 376 phosphorylation.To facilitate this analysis, a peptide
fragment of phosphofructokinase containing serine 376 (referred to
throughout this text as the "hinge peptide"), was liberated from the
enzyme by CNBr digestion in a similar procedure to the one used in the
identificationofthesitesofinvitrophosphorylationof
phosphofructokinase (Zhao et al, 1991b).CNBr specifically cleaves
proteins at methionine residues, of which there are 22 in muscle type
phosphofructokinase.
From our experience, optimal peptide separation occurs when
reversed phase HPLC is run with less than 100 jig of protein.The
chromatogram of figure 1-3 depicts a high resolution separation of 50 vtg of54
Table 1-3 Activity of phosphofructokinase purified from epinephrine-
stimulated and unstimulated rabbit hearts.
Enzyme Source Specific Activity (U/mg)
Unstimulated Rabbit Hearts (4) 60
Unstimulated Rabbit Hearts (3) 53
Epinephrine-Stimulated Rabbit Hearts (2) 45
Hearts were treated and phosphofructokinase purified as described in
Materials and Methods. Final specific activity measured by the standard
enzyme assay described in Materials and Methods.55
Figure 1-3
ChromatogramofHPLCseparationofCNBrdigested
phosphofructokinase obtained from unstimulated rabbit hearts, separated
with a Zorbax C4 reverse phase column using gradient 1 (table 1-1).
Approximately 50 gg of protein was loaded onto the column.Arrow
points to hinge peptide. This fraction was isolated, dried, and analyzed by
MALDI-TOF mass spectrometry (figure 1-4) following resuspension in 10%
acetonitrile, 0.1% TFA.Figure 1-3
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a CNBr digest of phosphofructokinase from unstimulated rabbit hearts.
The peak eluting at approximately 21 minutes using gradient #1 (table 1-1)
was identified by MALDI-TOF mass spectrometry (figure 1-4) as the
unphosphorylated hinge peptide. Adjacent peaks were also analyzed by
MALDI-TOF and found to have molecular weights that did not correspond
to either the phosphorylated or unphosphorylated hinge peptide.
In order to facilitate handling of relatively large quantities of protein
present in the CNBr digestion of phosphofructokinase from epinephrine
stimulated rabbit hearts, the protein digest was separated by overloading a
C4 reversed phase HPLC column, using a steep gradient (gradient #2, table
1-1). Two peptide pools were collected in the approximate area of the
gradient where the hinge peptide was predicted to elute. Pool 1 contained
peptides eluting between 2.5 and 5 minutes, and pool 2 eluting between 5
and 7 minutes (figure 1-5). The remainder of the material was set aside,
eliminating many hydrophobic peptides from analysis, including the C-
terminal phosphorylatable peptide containing serine 774.As the hinge
peptide has been found to elute between 10-15% buffer B from reversed
phase HPLC, it was hypothesized to be included in pool 1.
Iron chelate resin specifically binds phosphorylated forms of
proteins (Muszynska et al, 1986). One half of the material collected in
pools 1 and 2 were subjected to iron chelate chromatography. Weakly
bound peptides were washed from the column with pH 5.0 buffer. Bound58
Figure 1-4
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrum of the peptide fraction (approximately 0.5 jig) which
bound totheironchelate column following CNBr digestionof
phosphofructokinase isolated from epinephrine-stimulated rabbit hearts.
Inset shows the mass spectrum of the peptide (approximately 1.0 Ilg)
isolatedbyreversedphaseHPLCfromCNBrdigested
phosphofructokinase purified from unstimulated hearts (figure 1-3).Figure 1-4
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Figure 1-5
ChromatogramofHPLCseparationofCNBrdigestof
phosphofructokinase purified from epinephrine perfused rabbit hearts
using gradient #2 (table 1-1) with a C18 reversed phase column. A total of
two separations were performed, with approximately 400 1.1g total protein
loaded each time.Fractions eluting between 2.5 and 5 minutes and
between 5 and 7 minutes were collected separately as pools 1, and 2,
respectively.The times over which the fractions were collected were
identical for each separation, and the general shapes of the chromatograms
identical. Absorbance was monitored at 215 nm. Flow rate = 1.0 ml/min.Figure 1-5
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peptide was eluted by increasing the pH to 8.9.This material was
dried,resuspended in 10% acetonitrile, and applied to reversed phase
HPLC to wash away excess iron and acetate buffer. The peptide was batch
eluted with 70% buffer B; A214 peak integration shows that a total of 2.1 lig
bound the column. MALDI-TOF mass spectrometry analysis of the bound
peptide revealed a molecular weight of 1028 (figure 1-4), 80 greater than
the molecular weight of the hinge peptide purified from control hearts and
equal to the predicted molecular weight of the phosphorylated hinge
peptide.
The amino acid composition of the peptide eluting from the iron
chelate column at pH 8.9 was determined by amino acid analysis of the
acid hydrolyzed sample. Amino acid standards, containing the twenty
naturally occurring amino acids plus phosphoserine, were subjected to
either 24 hour gas phase or two hour liquid phase acid hydrolysis,
dabsylation, and reversed phase HPLC separation using conditions
identical to those used for the peptide sample. The retention times and
peak areas of the amino acid standards were distinct and reproducible.
The amino acid analysis obtained with the peptide sample that had
undergone 24-hour hydrolysis appears in figure 1-6. Nine peaks after the
breakthrough peak are evident on this chromatogram. The large central
peak corresponds to unreacted dabsyl chloride. The largest peak eluting at
the end of the gradient corresponds to lysine, while the two peaks eluting63
Figure 1-6
Amino acid analysis of approximately 0.75 i.tg of peptide eluted
from the iron chelate colmn, following 24-hour acid hydrolysis and dabsyl
chloridederivatization.Peak identification was accomplished by
comparison to amino acid standards that were hydrolyzed, derivatized,
and separated using identical methods to those used for the sample.
Gradient #3 (table 1-1) was employed, and the amino acids were separated
with a C18 reversed phase HPLC column. Flow rate = 1.0 ml/minute.
Absorbance was monitored at 460 nm.Figure 1-6
u)
0>
K
ffealidircugh
1000
500 -
G R
\'
L
F
Hinasaire
Laztcre
L-------..-,....,
1
NEt
1
10 20
Time (min)
30 40
6465
just before it probably correspond to contaminating -NH3 (which is also
evident in the amino acid standards), and homoserine lactone, which is
created from methionine during CNBr digestion of the protein.The
remaining peaks eluted at times corresponding to those of the amino acid
standards S, G, R, L, and F.The absence of phopshoserine from this
analysis was expected due to its acid lability.
The peak areas were integrated and compared to the areas of the
amino acid standards, each present at 200 picomoles. The corresponding
amounts of each amino acid were compared and multiplied by a lowest
common denominator, yielding their molar ratios (table 1-4).The ratio
obtained may be simplified to 1:1:2:1:1:1:1 of K:L:R:G:S:F, consistent with
the primary sequence of "KLRGRSFM" of the hinge peptide.
Subjecting the peptide sample to only two hours of liquid phase
acid hydrolysis produced a pattern of derivatized amino acids similar to
the chromatogram (figure 1-7) for complete hydrolysis seen above (figure
1-6). The identities and stoichiometries of K, L, R, G, and F were the same
as seen in the 24-hour hydrolysis. However, a new peak with a retention
time corresponding to the elution position of the phosphoserine standard
appeared. A decrease in molar ratio of derivatized serine relative to the 24-
hour acid hydrolysis was also apparent (table 1-4).The calculated
stoichiometric ratio of phosphoserine to serine was approximately 1:2.66
Table 1-4 Amino acid analysis results for phosphofructokinase peptide
following 2- or 24-hour acid hydrolysis.
Amino Acid 2 Hour Hydrolysis24 Hour Hydrolysis
Serine 0.58 0.98
Phosphoserine 0.30 0
Glycine 0.95 1.12
Arginine 2.18 2.14
Leucine 0.85 0.87
Phenylalanine 1.12 0.87
Lysine 1.02 1.02
Values for each amino acid are normalized to moles of amino acid per
mole of peptide analyzed. These values were determined by integration of
peak areas in figures 1-7 and 1-8 then compared to peak areas of 200
picomole amino acid standards hydrolyzed and separated under identical
conditions.67
Figure 1-7
Amino acid analysis of approximately 0.75 lig of peptide binding an iron
chelate column. The conditions of the analysis were identical to those of
figure 1-6, except that the peptide was subjected to two, rather than 24
hours of acid hydrolysis.Phosphoserine was identified by the similar
elution position to the elution time of a phosphoserine standard analyzed
under identical conditions. All other amino acids were identified similarly,
with amino acid standards also treated to a two-hour hydrolysis prior to
dabsyl chloride derivatization.Figure 1-7
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The remaining portion of peptide pools 1 and 2 were resolved into
individual peptide aliquots through re-application to reversed phase
HPLC, using a more shallow gradient (gradient #4, table 1-1) than was
used in the initial pooling step. Figure 1-8 shows the separation of pool 1,
as monitored by absorbance at 214 and 260 nm, respectively. The hinge
peptide has been found to elute from C18 or C4 reversed phase HPLC
columns between 10-15% buffer B. In the separation of pool 2, no peaks
eluted within this range.
In the pool 1 separation, the peak eluting at 10 minutes was the
fraction most likely to contain the hinge peptide in view of its elution
position and because of its absorbance at 260 nm, a wavelength at which
the lone phenylalanine residue of the hinge peptide would absorb. The
peak was collected and the primary sequence of the peptide analyzed by
gas phase sequencing. No contaminating residues were evident at any
stage of the sequencing, indicating that this peak probably contained only
one peptide. The first five residues of the peptide were identified as K-L-
R-G-R, which matches the amino terminal five amino acids of the
phosphorylatable hinge peptide.The sequencing reaction was blocked
beyond the C-terminal arginine.70
Figure 1-8
HPLC separation of pool 1 (figure 5-1) peptides using gradient #4
(table 1-1) and a Cis reversed phase column.Approximately 10 µg of
protein was loaded onto the column for each separation, with a total of five
different separations.The marked peak (*) eluted at a position in the
gradient (13% B) corresponding to the predicted elution of the hinge
peptide. To avoid losses of the non-phosphorylated form of the peptide,
the side shoulder as well as the main peak were collected and dried in a
Savant speedvac. Absorbance was monitored at 214 and 260 nm in A and
B, respectively. Flow rate = 1.0 ml/min.Figure 1-8
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Application of the pooled peptide of figure 1-8 to a column eluted with 0.1
M ammonium sulfate in buffer A with gradient #1 (table 1-1) produced
two peaks of absorbance at 214 nm.The larger peak contained
approximately 70-80% of the total area and a second side peak had an area
approximately 20-30% of the total (figure 1-9). As overlaid in figure 1-9,
theelutionpositionofnon-phosphorylatedhingepeptideeluted
atapproximately the same time seen for the second peak when subjected to
reversed phase HPLC under identical conditions. The similarity in elution
times between these two peaks suggests that the identity of this second
peak is the non-phosphorylated hinge peptide.
Discussion
The evidence that has been presented demonstrates the in vivo
phosphorylation of rabbit muscle phosphofructokinase at serine 376 upon
stimulation of rabbit hearts with epinephrine. Phosphofructokinase from
unstimulated and epinephrine-stimulated hearts was isolated, digested
with CNBr, and separated into peptide fractions. From these fractions, the
hinge peptide, with a primary sequence of NH2-KLRGRSFM-COOH, was
purified and evidence from MALDI-TOF mass spectrometry (figure 1-4),
ammonium sulfate gradient reversed phase HPLC (figure 1-9), and amino
acid analysis (figures 1-6 and 1-7) suggest that the peptide is serine-
phosphorylated.73
Figure 1-9
Ammonium sulfate reversed phase HPLC employing gradient #4
(table 1-1). Buffer A: 0.1 M ammonium sulfate plus 0.1% TFA; Buffer B:
acetonitrile plus 0.065% TFA. C18 column employed with flow rate of 1.0
ml/minute. Absorbance monitored at 214 nm. Solid line ( ):
Separation of the 1.5 gg fraction collected in figure 9-1. Dotted line ( ):
Application of approximately 0.3 i_tg of non-phosphorylated hinge peptide
purified by reversed phase HPLC using gradient #4 (table 1-1) as in figure
1-8.Figure 1-9
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Initially, a pool of peptides eluting from a reversed phase HPLC
column within the same reproducible %B range as the elution position of
the hinge peptide was collected (figure 1-5). Reapplication of the pool to a
reversed phase HPLC column using a shallower gradient (gradient #4,
table 1-1) separated the pool into individual peptide fractions (figure 1-8).
The peptide that eluted at 10-15% buffer B was collected. This percentage
of acetonitrile is in agreement with the previously observed elution
position of the hinge peptide (Zhaoet al.,1991a), (figure 1-5). The peptide
had UV absorbance at 260 nm (figure 1-8), a property expected of the hinge
peptide that is due to its single phenylalanine residue. The identity of the
peptide was confirmed by gas phase sequencing following five rounds of
the Edman reaction. The analysis was unable to proceed past arginine 375.
Since phosphoserine decomposes in unknown reactions under the
conditions of the Edman degradation (Graveset al,1994), failure of the
sequencing reaction to proceed beyond arginine 375 is to be expected when
serine 376 is phosphorylated.
Past results have shown that reversed phase HPLC is generally
unable to separate peptides differing by only one phosphate group when
conventional water- acetonitrile gradients areemployed (Zhaoet al.,
1991a). We therefore predicted that the peak collected from reversed
phase HPLC (figure 1-8) using a shallow gradient (gradient #4, table 1-1)76
contained both forms of the hinge peptide. Application of this fraction to
reversed phase HPLC in which 0.1 M ammonium sulfate is contained in
elution buffer A yielded separation of two peaks (figure 1-9). The minor
peak rose slightly above the noise level of the UV detector and eluted at
thesamepositioninthegradientastheelutionpositionof
nonphosphorylated hinge peptide purified from skeletal muscle, under
identical gradient conditions. The major peak eluted earlier in the gradient
(figure 1-9).Using a similar procedure, the phosphorylated form of
malantide (a phosphorylatable peptide fragment from phosphorylase
kinase with a molecular weight similar to that of the hinge peptide) elutes
earlier than the non-phosphorylated form (Zhao et al, 1991a).It is
therefore likely that the earlier and later peaks of figure 1-9 represent the
phosphorylated and non-phosphorylated forms of the hinge peptide,
respectively.
A fraction of pool 1 (figure 1-5) bound to an iron chelate column. At
pH 5.0, iron chelate resin preferentially bound the phosphorylated form of
malantide in preliminary experiments (results not shown). It has also been
shown to resolve phosphorylated histone and phosvitin from their
nonphosphorylated forms (Muszynska et al, 1986). Confirmation of the
identity of the material binding the iron chelate column being the hinge
peptide was obtained by amino acid analysis following 24 hour gas phase
hydolysis (figure1-6).MALDI-TOF mass analysis determined the77
molecular weight of the peptide to be 1028 daltons (figure 1-4).This
molecular weight is 80 daltons greater than the calculated and observed
molecular weight of the nonphosphorylated hinge peptide. The difference
in molecular weight may be accounted for by phosphorylation of the
peptide, as the molecular weight of phosphate is approximately 80 daltons.
Appearance of phosphoserine during amino acid analysis of the
peptide following two-hour acid hydrolysis provides direct evidence for
the phosphorylation of the peptide (figure 1-7).The acid hydrolysis
released amino acids in ratios accurately represented the composition of
the hinge peptide, and in addition, released approximately 0.3 moles of
phosphoserine per mole of peptide. Phosphoserine is acid labile (Graves et
al., 1994); no phosphoserine was detected following the harsh conditions
employed during complete amino acid hydrolysis with 6 M HC1 at 150 °C
for 24 hours. It has been reported that only 20% of the original amounts of
phosphothreonine or phosphoserine generally remain following the gentle
acid hydrolysis employed in this study (Bylund and Huang, 1976). The
value of 0.3 moles phosphate per mole of peptide is therefore an
underestimation of the true degree of the incorporation of phosphate at
this site.
A high degree of phosphorylation is suggested from figure 1-9,
assuming that the two peaks separated by ammonium sulfate HPLC
represent the phosphorylated and nonphosphorylated forms of the hinge78
peptide. The ratio of the areas under the peaks is approximately four to
one. The preponderance of the phosphorylated peak, when taken with the
relatively high yield of phosphoserine determined during amino acid
analysis, suggests that serine 376 is significantly phosphorylated following
epinephrine perfusion of rabbit hearts.
Epinephrineperfusionofisolatedratheartsusingthe
nonrecirculating Langendorff perfusion technique (Neely et al, 1967) led
to an estimated incorporation of 1.1 moles of phosphate per mole
phosphofructokinase (Narabayashi et al., 1985). Since the phosphorylated
enzyme still underwent in vitro phosphorylation catalyzed by the catalytic
subunit of cAMP dependent protein kinase (cAMP-dPK), Narabayashi
concluded that in vivo phosphorylation had occurred at residues in
addition to serine 774, a known site of phosphorylation in skeletal muscle
(Sorensen-Ziganke and Hofer, 1979). The characterization of serine 774
phosphorylation in this study would have required a sub-digestion of the
large C-terminal peptide with V8 protease (Zhao et al, 1991b).We
thereforefocussedourattentionupon confirmationofinvivo
phosphorylation at serine 376.
Increased blood pressure upon treatment with epinephrine is
generated by an increased force of contraction within cardiac muscle. The
binding of epinephrine to beta-adrenergic receptors brings about this
increase in contraction. cAMP-dPK, stimulated by intracellular increases79
in cAMP (Taylor, 1989) caused by activation of the adrenergic receptor and
adenylate cyclase (Levitzki, 1988), plays a pivotal role in the contraction
response. cAMP-dPK phosphorylates proteins that regulate intracellular
calcium concentration, such as phospholamban inthesarcoplastic
reticulum (Colyer and Wang, 1991; Morris et al, 1991; Tada and
Kirchberger, 1975) and slow calcium channels within the sarcolemma
(Osterrieder et al, 1982; Trautwein et al., 1987).Phosphorylation of
phospholamban counteractsitsinhibitoryeffectstoward SERCA2,
allowing this protein to pump calcium from the sarcoplastic reticulum to
the cytosol. The ion pore diameter of the slow calcium channel is increased
upon phosphorylation, causing an influxofextracellularcalcium.
Increased intracellular calcium concentrations lead to muscle contraction
through activation of troponin C, which promotes the interaction of actin
andmyosin.cAMP-dPK alsoactivatesmusclecontractionby
phosphorylation of troponin I, which in turn increases the binding
constant of troponin C for calcium (Wattanapermpool et al, 1995).
cAMP-dPK plays an imporant role in the response of cardiac muscle
to epinephrine.The kinase also regulates several other intracellular
processes, including gene expression (Montminy, 1997), lipolysis (Oscai et
al, 1981; Wise and Jungas, 1978), glycogenolysis (McCullough and Walsh,
1979a; Sul et al, 1982), and inhibition of glycogen synthesis (McCullough
and Walsh, 1979b; Nakielny et al, 1991). Given the increased demand for80
ATP and the higher glucose concentrations following stimulation with
epinephrine due to increased muscle contraction and glycogenolysis,
respectively, it seems likely that phosphorylation of phosphofructokinase
would increase the enzyme's activity.However, when assasyed under
ideal allosteric conditions, the activity of phosphofructokinase purified
from epinephrine-stimulated hearts was not significantly different from
that of unstimulated hearts (table 1-3). The role of phosphorylation might
instead have an effect upon the allosteric regulation of the enzyme, or
upon one of the many interactions that this protein has been demonstrated
to undergo with the microtubules (Lehotzky et al, 1994; Lehotzky et al,
1993; Vertessy et al., 1997a; Vertessy et al, 1996), myofibrils (Kuo et al,
1986; Liou and Anderson, 1980; Luther and Lee, 1986; Offer et al, 1988;
Parra and Pette, 1995; Podlubnaia et al, 1996; Roberts and Somero, 1989),
or caveolae (Scherer and Lisanti, 1997).
In conclusion, this study confirms that the phosphorylation of rabbit
muscle phosphofructokinase at serine 376, first seen during the in vitro
phosphorylation catalyzed by cAMP-dPK in the presence of calmodulin or
troponin C, also occurs in viva The role that epinephrine stimulation of
cardiac muscle plays in phosphorylation at this site is consistent with the
hypothesized responsibility of cAMP-dPK in catalyziing the reaction in
viva These results suggest that phosphorylation at serine 376 needs to be
considered in future In vitro studies of the effects that phosphorylation has81
on both the allosteric regulation and the interactions with other proteins
that are characteristic of phosphofructokinase.82
Chapter 2
Characterization of the In Vitro Phosphorylation of Rabbit
Muscle Phosphofructokinase
Introduction
Previous work in this laboratory identified a novel site of cAMP-
dPK-catalyzed phosphorylation of rabbit muscle phosphofructokinase, at
serine 376, that occurs in vitro when the reaction is carried out in the
presence of calcium-calmodulin or calcium-troponin C (Zhao et al, 1991b).
In Chapter 1 of this thesis, phosphofructokinase that had been purified
fromepinephrine-stimulatedrabbitheartsexhibitedsignificant
phosphorylation at serine 376.
Phosphofructokinase has affinities for many different proteins
beyond calmodulin and troponin C. Allosteric regulation of the enzyme's
activity and oligomeric structure is complex. In this section, the effects of
various phosphofructokinase-binding proteins and different allosteric
conditions upon the extent of in vitro phosphorylation of the enzyme and
the stability of phosphofructokinase activity throughout the reaction are
examined. The goal of these experiments was to improve conditions for
carrying out the in vitro phosphorylation of phosphofructokinase, and to
identify effectors that may act either in conjunction with or in place of
calmodulin or troponin C in stimultating the phosphorylation reaction.83
Materials and Methods
Inactivation Assay
The protein-induced inactivationof phosphofructokinase was
measured by the method of Zhao et al (Zhao et al, 1991b), with some
minor modifications. Phosphofructokinase with a specific activity of 100-
250 Units/mg protein was initially diluted from a 10-20 mg/ml stock
solution to 0.04 mg/ml in 50 mM MOPS pH 7.0, 50% (v/v) glycerol, 2.5
mM beta-mercaptoethanol, and 2.5 mM dithiothreitol at 21 °C. Following
dilution, the specific activity of the enzyme was observed to decrease
sharply to approximately 70% of its original activity and stabilized at this
value; the enzyme was therefore diluted at least 15 minutes before addition
of inactivating protein. The assayed activity of the enzyme immediately
following dilution was taken to represent the 100% activity value for
gauging inactivation extents, and was abbreviated as "Ao". Inactivation
was initiated by mixing the phosphofructokinase with an equal volume of
water containing the inactivating protein (calmodulin or troponin C) plus 2
mM EGTA or CaC12. When tubulin- or S100-dependent inactivation was
tested, phosphofructokinase was mixed with an equal volume of 50 mM
MOPS pH 7.0, 2 mM MgC12, with either tubulin or S100, and either 2 mM
EGTA or CaC12. Control inactivation values were obtained by mixing an
equal volume of buffer in the absence of inactivating protein.In84
experiments measuring the effects of ATP or fructose-6-phosphate upon
inactivation, varying concentrations of these allosteric effectors were
included in the solutions containing the inactivating protein prior to
mixing with phosphofructokinase. At designated times following mixing,
2-30 Hi samples were withdrawn and assayed for phosphofructokinase
activity.
Reactivation of Phosphofructokinase Activity
Reactivation of phosphofructokinase activity following inactivation
was achieved by increasing the ATP concentration to 1.0 mM following
protein-inducedinactivationorcAMP-dPK-catalyzedinvitro
phosphorylation (Mayr, 1984a; Zhao et al, 1991b). The same temperatures
that inactivation was carried out at were used during reactivation; 30 °C
for reactivation following in vitro phosphorylation, and 21 °C following
protein-induced inactivation.
In vitro Phosphorylation of Phosphofructokinase
In vitro phosphorylation of phosphofructokinase was assayed
under a variety of conditions, following the general reaction protocol of
Zhao (Zhao et al, 1991b). Under standard conditions, the reaction was
performed in the presence of 50 mM MOPS pH 7.0, 0.25 mM y-32P-ATP (30
Ci/mole), 5 mM dithiothreitol, 5.0 mM MgC12, and 1.0 mM CaC12 or 1.085
mM EGTA, with or without 5 [IM troponin C or calmodulin, at 30 °C. The
reaction was initiated by the addition of cAMP-dPK followed by
phosphofructokinase at concentrations of 10 and 125 respectively.
Control reactions were run in which no cAMP-dPK was added to the
reaction solution.
For most experiments, phosphate incorporation was quantified by
liquid scintillation counting. At the indicated times, 25 [1.1 samples were
removed and spotted onto a glass filter disc on a sinterred glass funnel.
The sample was precipitated with 2-3 drops of cold 10% (w/v)
trichloroacetic acid, 2% (w/v) sodium pyrophosphate, then washed with 4
ml of the same solution. The discs were dried by washing with ethanol,
then immersed in 4 ml Aquasol. Counting was done with a Beckman LS
7000 counter. The number of counts per minute per mole of ATP was
measured for each individual reaction by spotting 4 [t1 of reaction sample
onto a glass filter disc, air-drying, then counting in Aquasol by the same
method used for the samples.
Phosphorimaging of samples separated on sodium dodecyl sufate-
polyacrilamide gel electrophoresis (SDS-PAGE) gels was employed to
quantifyphosphateincorporationaswellastodiscriminate
phosphorylated proteins from non-phosphorylated ones, for experiments
in which additional proteins were added to the in vitro phosphorylation
reaction buffer. At various points in the phosphorylation reaction, 15 11186
samples were withdrawn from the reaction buffer and incubated with 10 1.11
of SDS-PAGE sample buffer at 85 °C for 25 minutes. Following separation
of samples by SDS-PAGE, the gels were fixed, stained, and destained using
standard procedure in order to allow for visual identification of the protein
bands through comparison to molecular weight markers. The gels were
then transferred to Zip lock plastic bags and applied to a 20X25 cm
Molecular Dynamics phosphorimaging screen. In order to standardize the
number of counts per mole or ATP for each reaction, 2-6 ttl of reaction
sample were spotted on filter paper and exposed on the phosphorimaging
plates alongside the gels. Following development of the samples in the
dark for 4-8 hours, the plates were scanned with a Molecular Dynamics SI
phosphorimager. The intensities of the radioactive spots representative of
SDS-PAGE bands or spotted standards were quantified individually using
ImageQuant 5.0 (copyright 1998, Molecular Dynamics).
Variations in the constitution of the reaction buffer were tested by
substitution of the component under study. ATP (0.25 and 5.0 mM), buffer
identity (50 mM potassium phosphate pH 7.0 substituted for MOPS), and
glycerol concentration (10-40%) were each varied. In the case of high ATP
concentrations, the dilution of specific activity of the radiolabel was
compensated for by additional stock y-32P-ATP, bringing the final specific
activity to approximately 7.5 Ci/mole ATP, and the reaction was also run
in the presence of 15 mM MgC12 instead of 5 mM. The reaction was tested87
at 0.125 and 1.0 mg/ml phosphofructokinase, and the temperature at
which the reaction was run was also varied at 4, 19, 25, and 30 °C.
Phosphorylation of 1.0 mg/ml instead of 0.125 mg/ml was analyzed in the
presence of 40 p,M troponin C and 45 µg /m1 cAMP-dPK. The activity of
phosphofructokinase at various points in the in vitro phosphorylation
reactions was determined by extracting 2 ill of sample for measurement in
the coupled spectrophotometric assay.
Effects of Troponin on the Phosphorylation of Phosphofructokinase
Troponin C, troponin I, and troponin T were all purified from rabbit
skeletal muscle by the method of Potter et al (Potter, 1982). Reconstitution
and solubilization of the troponin C complex was achieved by combining
all three proteins in a 1:1:1 molar ratio in 50 mM MOPS pH 7.6, 15 mM
beta-mercaptoethanol, and 6 M urea. A total of approximately 25 mg of
protein was used. Calcium chloride was added to the sample, bringing the
calcium concentration to 2 mM. The protein was then dialyzed against 50
mM MOPS pH 7.6, 1 M NaCl, and 15 mM beta-mercaptoethanol. The
NaC1 concentration was reduced stepwise in concentration to 0.65, 0.4, and
finally 0.2 M through successive cycles of dialysis. The sample was then
concentrated with an amicon concentrator and applied to an S-300 gel
filtration column (3 X 85 cm) equilibrated in the same buffer with 0.2 M
NaCl. The flow rate was 40 ml/hour, and 1.8 ml fractions were collected.88
SDS-PAGE revealed that fractions 50-60 contained all three components of
troponin, which was assumed to be intact as a complex, while later
fractions contained unbound substituents of the complex. The protein was
concentrated to 5 mg/ml.
In vitro cAMP-dPK-catalyzed phosphorylation of
phosphofructokinase was attempted following the same general protocol
as phosphorylation in the presence of troponin C, except that 5 [tM
troponin was substituted for troponin C, and 50 mM KC1 was added to the
reaction buffer.At various times in the reaction, 25 !al samples were
removed and spotted on glass filter discs for determination of bound
phosphate by liquid scintillation counting. At 60 and 150 minutes, samples
were also removed and incubated with SDS-PAGE sample buffer for
analysis by phosphorimaging, in order to determine the total percentage of
radioactivity incorporated at phosphofructokinase versus the other
components of the reconstituted complex.
Determination of Site of Phosphorylation in the Presence of Troponin
800 jig of phosphofructokinase was phosphorylated by cAMP-dPK
in the presence of 5 µM troponin and 1 mM calcium chloride.
Phosphorimaging of phosphofructokinase phosphorylated by cAMP-dPK
in the presence of troponin and calcium in prior experiments had shown
that approximately 85% of all radioactivity incorporated is bound to89
phosphofructokinase,sothispercentage was used inquantifying
incorporation of bound phosphate by liquid scintillation counting in this
experiment. The extent of phosphorylation was approximately 0.60 +/-
0.02 (n = 3) moles phosphate per mole phosphofructokinase. The sample
was dried and resuspended in 500 µl water. TCA was added to a final
concentration of 15% (v/v). The protein was allowed to precipitate on ice
for 25 minutes, then was sedimented by centrifugation at 8,000 rpm for 5
minutes in a Beckman Microfuge 11 microcentrifuge.The supernatant
contained unbound radioactive ATP and was discarded, while the pellet
was washed with 500 ill water. The protein was then again precipitated
with TCA, separated from the supernatant by decanting it following
centrifugation, and dried with a Jouan Speedvac vacuum concentrator.
The dried protein was resuspended and digested with CNBr following the
sameprotocolaswasusedfordigestionofrabbitheart
phosphofructokinase, except that proportionately more CNBr was added
given the additional protein present.
Following digestion, the sample was resuspended in 3 M guandine
HC1, 0.1% (v/v) trifluoroacetic acid. The protein was subjected to reversed
phase HPLC separation on a C18 column using gradient #1 (table 1-1).
Fractions roughly corresponding to peaks of elution were collected in 1.6
ml microfuge tubes and dried by speedvacuum.Radioactivity was
quantified for each sample with a Bioscan-QC 2000. Radioactive fractions90
were resuspended in 50 i.11 of a buffer consisting of 90% water, 10%
acetonitrile, and 0.01% TFA, then analyzed by MALDI-TOF mass
spectrometry.
Analysis of Phosphofructokinase In Vitro Phosphorylated in the Presence
of cAMP-dPK, Troponin C, and 5 mM ATP
1 mg of phosphofructokinase underwent cAMP-dPK-dependent In
vitro phosphorylation in the presence of 5 mM ATP and 5 1.1M troponin C
plus 1 mM CaC12.0.39 +/- 0.06 (n = 5) moles phosphate/mole
phosphofructokinase were incorporated following 2.5 hours of reaction, as
determined by liquid scintillation counting.As a control, 1 mg of
phosphofructokinase was subjected to identical conditions, except that no
cAMP-dPK or radiolabeled ATP were added.
Following equilibration of a covalently linked Sephadex-melittin
affinity column (1 X 4 cm) in 50 mM MOPS pH 7.0, 0.5 mM CaC12, 2.5 mM
dithiothreitol, and 10% glycerol, each sample was passed separately
through the column at a flowrate of 10 ml/hour. The column successfully
separated troponin C from phosphofructokinase by binding troponin C, as
confirmed by SDS-PAGE and protein concentrations of the samples
passing unbound through the column.Both samples were then
concentrated using Amicon Spin Cell concentrators (Mw cutoff = 30 kd),
and applied to a P-6 sizing column (0.75X25 cm) equilibrated in the same91
buffer without calcium, at a flowrate of 20 ml/hour, to separate ATP from
the samples. The peaks of elution for both samples, as determined by
Bradford analysis, were collected and concentrated using Amicon Spin
Cell membranes. Protein concentrations were dentermined by Bradford
analysis. The final yields of purified protein were 0.73 mg phosphorylated
phosphofructokinase and 0.78 mg control.
Experiments testing ATP inhibition was conducted with both
samples.Varying amounts of ATP were included in the assay buffer,
which contained 50 mM HEPES pH 7.3, 10 mM MgC12, 2 mM ammonium
sulfate, 0.2 mM EDTA, 2.5 mM dithiothreitol, 1 mM fructose-6-phosphate,
and 0.16 mM NADH. Coupling enzymes used in this study were first
desalted by dialysis in 50 mM triethanolamine pH 7.5 and 5 mM
dithiothreitol.Inhibition of phosphofructokinase activity following 15
minutes incubation with troponin C was conducted following the standard
inactivation procedure described above.
For determining the site of phosphorylation under conditions of
high ATP concentration, 1 mg of phosphofructokinase underwent cAMP-
dPK-catalyzed in vitro phosphorylation in the presence of 5 i.tM troponin
C, 5 mM ATP and 1 mM CaC12, following the same procedure as above.
The extent of phosphorylation was confirmed by liquid scintillation
counting as0.54+/-0.25(n =5)moles phosphate per mole
phosphofructokinase. TroponinCwasseparatedfrom92
phosphofructokinase by melittin-affinity column chromatography.The
yield of phosphofructokinase following chromatography was 0.70 mg
phosphofructokinase. The sample washed of extraneous y-32P-ATP by two
rounds of TCA precipitation and microcentrifugation, dried, and digested
with CNBr following the same procedure as was used forsite
identification of phosphofructokinase phosphorylated in the presence of
troponin.
The digested enzyme was resuspended in 200 µl of 6 M guanidine -
HCI, 0.1% trifluoroacetic acid. Peptides were separated by reversed phase
HPLC using gradient #1 (table 1-1), collected, dried, and analyzed for
radioactivity. The sole peak containing radioactivity was resuspended and
analyzed by MALDI-TOF.
Mapping of sites of Phosphofructokinase Phosphorylated in the Presence
and Absence of Troponin C
1 mg of phosphofructokinase was phosphorylated in vitro by
cAMP-dPK in the presence or absence of 5 jaM troponin C following the
standard phosphorylation procedure.The phosphorylation extents
following 150 minutes of reaction were 0.71 +/- 0.04 (n = 3) mole
phosphate/mole phosphofructokinase for the reaction run in the presence
of troponin C and 0.33 +/- 0.02 (n = 3) in the absence of troponin C, as
determined by liquid scintillation counting.Melittin-affinity column93
chromatography was not performed. The protein samples were washed of
excess radioactivity and digested with CNBr, and the resulting peptides
separated by reversed phase HPLC and analyzed for radioactivity
following the same procedure employed by Zhao et al in mapping the sites
on phosphofructokinase phosphorylated by cAMP-dPK in the presence of
troponin C or calmodulin (Zhao et al., 1991b). Radioactive fractions were
resuspendedandtheirmassesanalyzedby MALDI-TOF mass
spectrometry.
Phosphorylation in the Presence of F-actin
The effect of F-actin upon the cAMP-dPK-catalyzed invitro
phosphorylation reaction was tested.F-actin was purified from rabbit
acetone muscle powder by the method of Pardee and Spudich (Pardee and
Spudich, 1982).Following centrifugation of pure F-actin, the pellet was
resuspended in 2 mM tris-HC1 pH 8.0, 0.2 mM CaC12, 0.2 mM ATP at an
approximate protein concentration of 10 mg/ml.
F-actin was added to the phosphorylation reaction buffer such that
its concentration was 1.1 mg/ ml, which would yield a 16:1 molar ratio of
F-actin:phosphofructokinaseuponadditionof0.125mg/ ml
phosphofructokinase. The phosphorylation reaction was initiated upon
the addition of cAMP-dPK and phosphofructokinase to the reaction
mixture. The reaction was tested in the presence of 5 p.M troponin C, 5 1AM94
calmodulin, or in the absence of either protein, with of 1.0 mM CaC12 or 1.0
mM EGTA included.
Phosphate incorporation was quantified by liquid scintillation
counting.Control phosphorylation of cAMP-dPK plus F-actin in the
absenceofphosphofructokinaseproducednegligiblephosphate
incorporation. Specific activity of phosphofructokinase was measured by
the coupled assay under identical conditions as those used to measure
phosphate incorporation, except that no radiolabeled ATP was used.
Effects of Tubulin on Inactivation, Reactivation, and cAMP-dPK-Catalyzed
Phosphorylation of Phosphofructokinase
Tubulin was purified from bovine brain following the methods of
Ashford et al (Ashford et al, 1998).Inactivation and reactivation of
phosphofructokinase in the presence of tubulin were studied as outlined
above. Phosphorylation of phosphofructokinase in the presence of tubulin
was studied following the above protocol for cAMP-dPK-catalyzed in vitro
phosphorylation, with tubulin substituted for troponin C or calmodulin.
Phosphate incorporation was tested in the presence of 0.025, 0.25, and 2.5
mM ATP and 0.05, 0.5, 5.0 p.M tubulin. The proteins phosphorylated were
identified by phosphorimaging of acrylamide gels of samples separated by
SDS-PAGE, and the degree of phosphorylation quantified by densitometry
using ImageQuant following phosphorimaging.95
Phosphorylation of Phosphofructokinase Catalyzed by Calmodulin
Dependent Protein Kinase II
A catalytic fragment of calmodulin dependent protein kinase II
(CamKII) truncatedatresidue 316 was testedforitsabilityto
phosphorylate phosphofructokinase. This enzyme lacks the autoinhibitory
site of the holoenzyme, but still requires calcium-calmodulin for activation,
and was a gift from Dr. Thomas Soder ling. The activity of the kinase was
first verified with myosin light chain as a substrate, compared to the
activity of myosin light chain kinase towards myosin light chain. These
reactions were initiated by addition of 10 lag/ ml of either myosin light
chain kinase or CamKII to 50 mM HEPES pH 7.5, 5 mM MgC12, 1 mM
CaCl2, and 3 mM y-32P-ATP, in the presence or absence of 5 1AM
calmodulin, at 30 °C (Edelman et al., 1990). The reaction was terminated
after 60 minutes by addition of 25 ji.1 of reaction sample to 10 H.1 SDS-PAGE
protein sample buffer, and the extent of phosphorylation quantified by
phosphorimaging following SDS-PAGE.
CamKII-catalyzed phosphorylation of phosphofructokinase was
tested under a variety of conditions. Phosphorylation of the enzyme was
attempted following an identical procedure tothe one used for
phosphorylation of myosin light chain by CamKII, with 1.511M96
phosphofructokinase substituted for myosin light chain. The reaction was
attempted in the presence of 5µM troponin C or 5 jiM calmodulin, with
both proteins, or in the absence of any additional proteins. The effect of 15
minutes prior incubation of phosphofructokinase with troponin C was
tested. The phosphorylation reaction was also attempted with 10 µg / ml
CamKII in the same conditions following 15 minutes preincubation of
CamKII at a concentration of 190 µg /ml in a buffer consisting of 50 mM
MOPS pH 7.0, 2 mM MgC12, 0.1 mM CaC12, 5 1AM dithiothreitol, and 4 [tM
calmodulin at 30 °C. Quantification of phosphate incorporation under all
conditions following a reaction time of 60 minutes was performed by
phosphorimaging of samples following SDS-PAGE.
Results
ActivityLossesOccurringDuringInVitroPhosphorylationof
Phosphofructokinase
The process of cAMP dependent protein kinase (cAMP-dPK)-
catalyzed in vitro phosphorylation of phosphofructokinase carried out in
the presence of troponin C results in a 60-80% reduction of the catalytic
activity of phosphofructokinase, as illustrated in figure 2-1 and observed
by Zhao et al (Zhao eta!, 1991b). A nearly identical rate and extent of97
Figure 2-1
Phosphate incorporation (p ) and activity loss ( a ) during cAMP-dPK-
catalyzed In vitro phosphorylation of rabbit muscle phosphofructokinase
in the presence of troponin C.Reaction initiated upon addition of 10
µg /m1 cAMP-dPK to 50 mM MOPS pH 7.0, 5 mM MgC12, 1 mM CaC12, 10%
glycerol, 2.5 mM dithiothreitol, 0.25 mM 7-32P-ATP (30 Ci/mole), 5 piM
troponin C,0.125 mg/ml phosphofructokinase.Quantification of
phosphate incorporation was measured by liquid scintillation counting.
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phosphofructokinase activity loss occurs when the enzyme is subjected to
the same in vitro conditiions without the addition of cAMP-dPK (Zhao et
al, 1991b). This result demonstrated that activity losses observed during
In vitro phosphorylation were not necessarily due to phosphorylation, but
were rather a result of troponin C-induced inactivation.
Following troponin C- or calmodulin-induced inactivation of
phosphofructokinase, the activity of the enzyme may be partially restored
by the addition of the allostericeffectors fructose-1,6-bisphosphate,
fructose-2,6-bisphosphate, or ATP (Mayr, 1984a; Zhao et al.,1991b).
Association of phosphofructokinase with troponin C or calmodulin is
necessary for the reactivation to occur (Mayr, 1984a). Because of the slow
irreversible shift to non-reactivatable aggregates taking place during
prolonged incubation with calmodulin or troponin C, more complete
reactivation is achieved when itisinitiated at earlier times in the
inactivation reaction (Zhao et al., 1991b).However, early reactivation
diminishes the extent of phosphorylation.
During the cAMP-dPK-catalyzed in vitro phosphorylation reaction,
the specific activity decreased from 180 to 50 U/mg, carried out in the
presence of 50 mM MOPS pH 7.0, 5 mM MgC12, 1 mM CaC12, 2.5 mM100
dithiothreitol, 10% glycerol, 5 1.1M troponin C, and 0.25 mM ATP.
Approximately 100 minutes after initiation of the reaction, reactivation was
attempted by addition of 5 mM ATP, 5 mM fructose-1,6-bisphosphate, and
0.1 mM AMP. A 30 minute incubation in the presence of these allosteric
effectors resulted in a 12% increase in activity, to 70 U/mg. Zhao et al
reported an extent of 15% reactivation upon addition of 0.2 mM fructose-
2,6-bisphosphate following invitro phosphorylation under identical
conditions (Zhao et al., 1991b).Following additional incubation of 30
minutes, the specific activity then returned to 50 U/mg. These results and
those of Zhao et al (Zhao et al., 1991b) therefore show that addition of
allosteric effectors at the conclusion of the cAMP-dPK-catalyzed in vitro
phosphorylation reactionincompletelyrestoresphosphofructokinase
catalytic activity.
Thereducedactivityoftheenzymefollowinginvitro
phosphorylation contrasts with the relatively unaffected activity of enzyme
phosphorylated in vivo through stimulation of rabbit hearts with
epinephrine. The specific activity of phosphofructokinase obtained from
epinephrine-stimulated rabbit hearts was not significantly different from
the activity of the enzyme of unstimulated hearts (table 1-3), while serine
376 was phosphorylated in phosphofructokinase from stimulated hearts,
but not found to be phosphorylated in the unstimulated heart enzyme. A
study with epinephrine perfused rat hearts also shows no change in the101
phosphofructokinase activity compared to enzyme activity of control
hearts (Narabayashi et al., 1985) when the enzymes were assayed under
activating allosteric conditions. This discrepancy in activity data suggests
that the conditions of the in vitro phosphorylation do not represent
completely the conditions for the in vivo phosphorylation.
Significant and apparently irreversible losses in enzyme activity
occur as a result of the harsh conditions under which cAMP-dPK catalyzes
phosphorylation of serine 376 in vitro.Experiments characterizing the
effectsof phosphorylation at serine 376 upon phosphofructokinase
function or structure would be difficult to interpret with denatured
enzyme, soit was important to determine conditions of invitro
phosphorylation of the enzyme yielding native, phosphorylated enzyme.
Large-scale preparation of in vivo phosphorylated phosphofructokinase
following epinephrine stimulation of rabbit hearts was impractical because
of the low yields of enzyme per heart, the difficulty of surgery, and the
relative instability of the enzyme to storage. It was therefore necessary to
attempt obtaining phosphorylated, native enzyme through optimization of
in vitro phosphorylation of the more readily available skeletal muscle
phosphofructokinase.
With the goal of obtaining both maximum phosphorylation and
maximum reactivation,severalalterationsof the invitro reaction
conditions have been tested. These include variations in the conditions of102
the cAMP-dPK-catalyzed in vitro reaction; for example, variation of the
temperature; variation of the concentrations of phosphofructokinase, ATP,
glycerol, and phosphate; and the addition of other proteins known to
interact with phosphofructokinase, including reconstituted troponin,
tubulin, and F-actin.Also, calmodulin dependent protein kinase II
(CamKII), a general protein kinase stimulated by calcium/calmodulin and
active in heart (Lindemann and Watanabe, 1985; Vittone et al., 1993), was
tested for its ability to catalyze phosphorylation of the enzyme in addition
to cAMP-dPK.
TemperatureDependenceofInVitroPhosphorylationof
Phosphofructokinase
The slow, time-dependent inactivation of phosphofructokinase is
responsible for an observed intrinsic loss of phosphofructokinase activity
when the concentration of the enzyme is lowered. This intrinsic loss in
activity increases at higher temperatures, as is illustrated by figure 2-2.
The phosphofructokinase and ATP concentrations used in this experiment,
0.125 mg/ ml and 0.25 mM, respectively, are equal to those in the in vitro
phosphorylation reaction.This enzyme concentration is close to the
concentration of phosphofructokinase in skeletal muscle (approximately
0.2 mg/ ml (de Duve, 1972)), while the physiological concentrations of ATP
oscillate (Smolen, 1995), with values reported between 6-12 mM in rat hind103
Figure 2-2
Time course of phosphofructokinase activity loss at different
temperatures. 0.125 mg/ml phosphofructokinase was incubated in 50 mM
MOPS pH 7.0, 5.0 mM MgC12, 1 mM CaC12, 0.25 mM ATP, 5 mM
dithiothreitol, 10% glycerol at the indicated temperatures: (v ) 20 °C, )
24 °C, (* ) 27 °C,(a ) 30 °C.
Insettable:Extentofphosphateincorporationonto
phosphofructokinase following 4 hours of cAMP-dPK-catalyzed in vitro
phosphorylation in the presence of troponin C. The reaction was initiated
by addition of 10 µg /ml cAMP-dPK to 50 mM MOPS pH 7.0, 5 mM MgC12,
1 mM CaCl2, 10% glycerol, 2.5 mM dithiothreitol, 0.25 mM y-32P-ATP (30
Ci/mole), 5µM troponin C, 0.125 mg/ml phosphofructokinase. Extent of
phosphate incorporation extents were measured by liquid scintillation
counting.Figure 2-2
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legskeletal muscle (Goodman et al,1974; Tornheim, 1988) and
approximately 6 mM in rat heart (Narabayashi etal., 1985).
In vitro phosphorylation of phosphofructokinase was attempted at
different temperatures. The inset table within figure 2-2 charts the effect of
temperatureontheextentofphosphateincorporationof
phosphofructokinase.At 4 °C, a temperature that nearly completely
stabilizes enzyme activity, no detectable phosphorylation took place. At
room temperature, 19 °C, the activity was somewhat stabilized, but the
extent of phosphorylation was limited to 0.3 +/- 0.15 moles/mole
phosphofructokinase. The minimal temperature studied which allowed
phosphorylation to take place was 30 °C, a temperature at which A/ Ao
approaches 0.50 in the absence of troponin C and 0.25 in its presence. This
experiment demonstrates that temperature elevated to 30 °C is partly
responsible for the activity loss seen during the phosphorylation reaction.
Effects of Phosphate, Glycerol, and ATP on the In Vitro Phosphorylation
Reaction
The presence of either inorganic phosphate or glycerol stabilizes
phosphofructokinase from time-dependent inactivation. Phosphate is an
allosteric activator of phosphofructokinase (Kuhn et al., 1974). Complete
stabilization of enzyme activity occurs over 24 hours at room temperature
when 0.125 mg/ ml phosphofructokinase is incubated in pH 7.0 50 mM106
phosphate. Glycerol has been used to stabilize the enzyme following its
purification from rabbit skeletal muscle (Kuo et al., 1986). Addition of 25%
glycerol was necessary to slow the intrinsic and calmodulin- and troponin
C-dependent inactivation of phosphofructokinase rates to a measurable
time scale (Zhao et al., 1991a).The stabilizing properties of these two
agents were each examined in the phosphorylation reaction. Substitution
of 50 mM phosphate for 50 mM MOPS in the reaction buffer led to
complete stabilization of the enzyme from activity loss throughout the two
hour reaction.However, only 0.25 +/- 0.02 moles of phosphate were
incorporated per mole phosphofructokinase under these conditions.
Increases in glycerol percent led to incomplete incorporation of phosphate.
At 20% glycerol, 0.36 +/- 0.02 moles of phosphate were incorporated, and
at 30% and 40% glycerol, phosphorylation dropped to 0.18 +/- 0.09 and
0.18 +/- 0.14 moles/mole phosphofructokinase, respectively (table 2-1).
Between periods of contraction, rest, and energy deprivation, the
concentration of ATP in muscle may vary. ATP is the substrate for the in
vitro phosphorylation reaction, and both a substrate and allosteric effector
of phosphofructokinase catalytic activity.Troponin C-induced loss of
phosphofructokinase activity was nearly completely inhibited in the
presence of 5 mM Mg-ATP (figure2-3).The loss in activity of
phosphofructokinase in the presence of 5 mM Mg-ATP plus troponin C107
Table 2-1 Extent of cAMP-dPK-catalyzed in vitro phosphorylation of
phosphofructokinase in the presence of glycerol or inorganic phosphate.
Addition Concentration Moles phosphate/mole PKF
phosphate2 50 mM 0.25+/-0.02(n=4)
glycerol1 10% 1.17+/-0.15(n=2)
glycerol3 20% 0.36+/-0.02(n=2)
glycerol3 30% 0.18+/-0.09(n=2)
glycerol3 40% 0.18+/-0.14(n=2)
Phosphofructokinase was phosphorylated in vitro following standard
reaction conditions (1), with the exceptions of (2) substitution of potassium
phosphate for MOPS buffer or (3) at higher concentrations of glycerol.
Extent of phosphate incorporation following 2 hours of reaction at 30 °C
was quantified by liquid scintillation counting.108
Figure 2-3
Effects of elevated ATP concentration upon phosphofructokinase activity
during the cAMP-dPK-catalyzed in vitro phosphorylation reaction in the
presence or absence of troponin C. The reaction was initiated upon
addition of cAMP-dPK to 10 µg /ml cAMP-dPK to 50 mM MOPS pH 7.0,
Mg Clz 1 mM CaC12, 10% glycerol, 2.5 mM dithiothreitol, 0.125 mg/m1
phosphofructokinase with: () 0.25 mM y-32P-ATP (30 Ci/mole), 5 mM
MgC12, and no additional troponin C. Ao = 290 U/mg;) 0.25 mM y-32P-
ATP (30 Ci/mole), 5 mM MgC12, 51.1.M troponin C. Ao = 70 U/mg;) 5.0
mM y-32P-ATP (7.5 Ci/mole), 15 mM MgC12, no additional troponin C. Ao
= 83 U/mg; (0 ) 5.0 mM y-32P-ATP (7.5 Ci/mole), 15 mM MgC12, 5 1.1.M
troponin C. Ao = 121 U/mg.
"Ao" refers to the specific activity of phosphofructokinase assayed
immediately following the addition of inactivating protein.1.0
0.8
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<
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(20%) over two hours was also less than the intrinsic activity loss seen in
the absence of troponin C when the enzyme is incubated with 0.25 mM
Mg-ATP.
Phosphorylation data under conditions of high and low ATP
concentrations appear in the table 2-2.As a control for the effects of
elevated ATP levels on the in vitro phosphorylation reaction, the cAMP-
dPK-catalyzed phosphorylation reaction was performed in the presence of
5 1.1M troponin C and 0.25 mM Mg-ATP, resulting in 1.79 +/- 0.37 moles of
phosphate incorporated per mole phosphofructokinase protomer.This
value dropped to 0.71 +/- 0.28 moles phosphate when the reaction was run
in the presence of 5 mM Mg-ATP. In the absence of troponin C, the
phosphorylation extents were similar for the reactions run with 0.25 or 5
mM ATP, at 0.17 +/- 0.01 and 0.31 +/- 0.09 moles phosphate/mole
phosphofructokinase, respectively.
The allosteric properties of phosphofructokinase phosphorylated to
the extent of 0.39 +/- 0.06 (n = 5) moles phosphate in the presence of 5 11M
troponin C and 5 mM ATP were then examined. The specific activity of
the phosphorylated enzyme decreased from 140 U/mg to 124 U/mg, while
the activity of a control sample treated under the same conditions, with the
exception of added cAMP-dPK decreased from 145 U/mg to 124 U/ mg
following the reaction. Both samples were then passed separately over a111
Table 2-2 Extent of phosphorylation at an elevated ATP concentration.
[ATP] (mM) [Troponin C] (1M) Moles P/Mole PFK
0.25 0 0.17+/-0.01(4)
5.0 0 0.31+/-0.09(3)
0.25 5.0 1.79+/-0.37(7)
5.0 5.0 0.71+/-0.28(7)
PhosphofructokinaseunderwentcAMP-dPK-catalyzedinvitro
phosphorylation following standard conditions, except thatspecific
activities of 30 and 7.5 Ci/mole were present for 0.25 and 5.0 mM 7-32P-
ATP.Phosphorylation extents were measured with liquid scintillation
counting at the conclusion of 2 hours of reaction.112
melittin-Sepharose affinity column. Troponin C interacts specifically with
melittin (lio, 1993; Steiner and Norris, 1987), which bound and separated
troponin C from phosphofructokinase, while free phosphofructokinase
passed through unbound.The phosphofructokinase buffers of both
samples were then adjusted by dialysis to 50 mM Tris-phosphate pH 8.0,
0.2 mM EDTA, 5 mM dithiothreitol, in order to remove excess ATP
present.The final specific activities of the phosphorylated and control
enzyme samples following this treatment were 75 and 64 U/ mg,
respectively.
The sensitivities of the two enzyme samples to inhibition by ATP or
troponin C appear in figures 2-4 and 2-5. ATP inhibition was measured by
direct adjustment of its concentration in the assay buffer, while the two-
step inactivation assay outlined in Methods was used to measure troponin
C inhibition in which phosphofructokinase was assayed following 15
minutes preincubation with the varying concentrations of troponin C in 50
mM MOPS pH 7.0, 25% (w/v) glycerol, and 5 mM dithiothreitol. Both
phosphorylated and unphosphorylated forms of the enzyme were
relatively insensitive to inhibition by troponin C. This lack of sensitivity,
compared to strong sensitivity seen with newly thawed enzyme (table 2-5),
is most probably due to time spent in the manipulations of enzyme
samples.The process of phosphorylating the enzyme, separating the
components by melittin affinity chromatography, and concentrating the113
Figure 2-4
Effects of ATP inhibition on phosphofructokinase phosphorylated
in vitro in the presence of 5 mM ATP. (p) Phosphofructokinase
phosphorylated to 0.39 +/- 0.06 (n=6) moles phosphate/mole in the
standard in vitro phosphorylation reaction catalyzed by cAMP-dPK in the
presence of 5 tiM troponin C. (0) Control phosphofructokinase treated to
the same conditions as phosphorylated phosphofructokinase, but without
addition of cAMP-dPK. Assay buffer used for measuring catalytic activity
contained 50 mM HEPES pH 7.3,10 mM MgC12, 2 mM ammonium sulfate,
0.2 mM EDTA, 2.5 mM dithiothreitol, 1 mM fructose-6-phosphate, and 0.16
mM NADH, and coupling enzymes, with varying amounts of ATP.
Phosphorylated phosphofructokinase Ao = 54 U/mg; control Ao = 63
U/mg.
Figure 2-5
Effects of troponin C inhibition on phosphofructokinase
phosphorylated in vitro in the presence of 5 mM ATP. Phosphorylated
and control enzyme samples were the same as those studied in figure 2-4.
0.02 mg/ml phosphorylated () and control ( 0) phosphofructokinase
was incubated in 25 mM MOPS pH 7.0, 0.1 mM CaC12, 2.5 mM
dithiothreitol, and 25% glycerol, with varying concentrations of troponin
C. Following 15 minutes incubation at room temperature, the enzyme was
assayed in a buffer containing contained 50 mM glycylglycine pH 8.2, 1
mM EDTA, 5 mM MgC12, 5 mM ammonium sulfate, 2.5 mM dithiothreitol,
0.16 mM NADH, and coupling enzymes. Phosphorylated
phosphofructokinase Ao = 64 U/mg; control Ao = 60 U/mg.114
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protein samples required over 24 hours to complete.Nonetheless, the
phosphorylated enzyme behaved identically to the control sample in both
experiments. ThedifferencesinATPsensitivitybetween
phosphofructokinase phosphorylated solely at the C-terminus and non-
phosphorylated enzyme have been reported to be small (Kitajima et al,
1983). This identical behavior between control and phosphorylated
samples suggested further that phosphorylation occurred exclusively at
serine 774 when the phosphorylation reaction was run in the presence of 5
mM ATP.
Allosteric effectors of phosphofructokinase have been previously
reported to decrease the extent of troponin C- or calmodulin-induced in
vitro phosphorylation of the enzyme (Zhao et al, 1991b). However, the
precise site of phosphofructokinase phosphorylated under these conditions
had yet to be mapped. We therefore examined the site of phosphate
incorporation following CNBr digestion by separation and analysis of
peptide fractions by reversed phase HPLC.The shape of the A214
chromatogram suggests that the digestion was complete (figure 2-6). Peak
fractions were pooled, dried, and their radioactivity analyzed using a
Bioscan QC 2000 counter.The only significantly radioactive fraction
(figure 2-7) eluted within a broad peak at approximately 52 minutes, a
position characteristic of the elution position of the C-terminal peptide.
The molecular weight of the major substituent within this peak was116
Figure 2-6
Reversed phase HPLC mapping of the site of phosphofructokinase
phosphorylated in vitro by cAMP-dPK in the presence of 5.0 mM ATP and
5 111\4 troponin C. Phosphofructokinase was phosphorylated to 0.54 +/-
0.25 (n=5) moles phosphate/mole enzyme, as determined by liquid
scintillation counting, then digested with CNBr.Panel A shows the
chromatogram with absorbance monitored at 214 nm; Panel B shows
absorbance monitored at 280 nm. The sample was separated with a Cis
revered phase column using gradient #1 (table 1-1) with a 0.75 ml/minute
flowrate.1.0
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Figure 2-7
Radioactive monitoring of fractions collected from reversed phase HPLC.
Phosphofructokinase was phosphorylated by cAMP-dPK in vitro in the
presence of 5 mM ATP and 5 1.1M troponin C, digested with CNBr, and
separated by reversed phase HPLC as detailed in figure 2-6.Fractions
were dried in a Jouan speedvac and radioactivity quantified for each
sample with a Bioscan-QC 2000.200
0
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determined by MALDI-TOF mass spectrometry to be 8125 daltons,
calculated from a weighted average of the peak intensities within a
molecular weight range of approximately 8000-8200 (figure 2-8).This
molecular weight is approximately 80 daltons greater than the calculated
molecular weight of the nonphosphorylated C-peptide, 8045 daltons.
Because the peptide eluted from the reversed phase column at a high
acetonitrile concentration, it is hydrophobic.This hydrophobicity may
have interfered with its interaction with the MALDI matrix, explaining the
observed reduced signal to noise ratio.It can be concluded that while a 5
mM concentration of ATP inhibits the activity loss occurring upon
phosphorylation of phosphofructokinase by cAMP-dPK in the presence of
troponin C, there also is little phosphorylation at serine 376. This result is
further evidence that the high concentration of ATP inhibits the interaction
of phosphofructokinase with troponin C.
Phosphorylation at Elevated Phosphofructokinase Concentrations
Inactivation of phosphofructokinase occurs through a shift in the dimer-
tetramer equilibrium, favoring dimer formation.Phosphofructokinase
concentrationgovernsthisself-associationequilibrium. High
concentrations favor the formation of active tetramers121
Figure 2-8
MALDI-TOF mass spectrum of the radioactive phosphofructokinase
peptide phosphorylated 1.17 vitro by cAMP-dPK in the presence of 5 mM
ATP and 5 11M troponin C.The peptide eluted at approximately 52
minutes during isolation by reversed phase HPLC (in figure 2-6), was
dried, and resuspended in 250 of a buffer containing 10% acetonitrile plus
0.1% trifluoroacetic acid prior to mass analysis.Figure 2-8
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and higherorderaggregates, while lowering phosphofructokinase
concentration shifts the equilibrium to dimer formation (Hesterberg and
Lee, 1981).
The effect of elevated phosphofructokinase concentration upon the
extent of phosphorylation and activity loss was tested. Figure 2-9 shows
that in the cAMP-dPK-catalyzed in vitro phosphorylation reaction run in
the absence of troponin C, loss of catalytic activity is virtually undetectable
at 1 mg/ml (1211M protomers) phosphofructokinase. This loss increases to
approximately 30% with 0.125 mg/ml (1.5 p,M) phosphofructokinase, the
concentration of the enzyme regularly used in the in vitro phosphorylation
reaction.Addition of 5 W\/1 troponin C leads to a dramatic drop in the
activityof0.125 mg/ml phosphofructokinase, but additionofa
proportional concentration of troponin C, 40 p,M, to 1.0 mg/ ml leads to
onlyapproximately 40%activityloss.High concentrationsof
phosphofructokinase therefore appear to be more resistant to troponin C-
induced inactivation.
Addition of 5µM troponin C to the phosphorylation reaction
containing 0.125 mg/ml phosphofructokinase led to a maximum extent of
1.0 moles phosphate per mole enzyme after 2.5 hours (figure 2-10). A
proportional increase in the concentration of troponin C (40 .tN4) and an
increased concentration of cAMP-dPK (45 µg /ml) were included in the
phosphorylation reaction containing 1.0 mg/ml phosphofructokinase.124
Figure 2-9
Time course of phosphofructokinase activity loss during cAMP-
dPK-catalyzed hi vitro phosphorylation of phosphofructokinase at 0.125
and 1.0 mg/ml phosphofructokinase concentrations. The in vitro
phosphorylation reaction was conducted under standard conditions with:
(o) 0.125 mg/m1 phosphofructokinase, in the absence of troponin C. Ao =
104 U/mg; (0 ) 0.125 mg/ml phosphofructokinase, in the presence of 5 i.tM
troponin C. Ao = 119 U/mg; () 1.0 mg/ml phosphofructokinase, in the
absence of troponin C. Ao = 124 U/mg; (7) 1.0 mg/ml
phosphofructokinase in the presence of 40 µM troponin C. Ao = 107
U/ mg.Figure 2-9
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Figure 2-10
Time course of cAMP-dPK-catalyzed in vitro phosphorylation of
phosphofructokinase at a concentration of 0.125 or 1.0 mg/ml in the
presence of troponin C.() Phosphorylation catalyzed by cAMP-dPK
following the standard reaction protocol, with 10 µg /ml cAMP-dPK, 0.125
mg/ml phosphofructokinase, and 5 1.IM troponin C; () Phosphorylation
of 1.0 mg/ml phosphofructokinase catalyzed by 45 1.1g/m1 cAMP-dPK in
the presence of 40 i_tM troponin C. Phosphorylation extent was quantified
by liquid scintillation counting.1.5
127
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Following 2.5 hours of reaction, only 0.1 moles of phosphate were
incorporated onto the enzyme, demonstrating a lowered degree of
phosphateincorporationundertheconditionsofhigh
phosphofructokinase concentration.
Phosphorylation in the Presence of F-actin
Filamentous actin (F-actin) has been demonstrated to both enhance
theallostericactivationofphosphofructokinasebyfructose-2,6-
bisphosphate (Kuo et al., 1986) and decrease its sensitivity to ATP
inhibition (Liou and Anderson, 1980).The effect of F-actin upon the
cAMP-dPK-catalyzed in vitro phosphorylation of phosphofructokinase
was tested in the presence and absence of troponin C or calmodulin. A
concentration of 1.1 mg/ml F-actin was selected for these studies, yielding
a 16:1 molar ratio of monomeric F-actin to phosphofructokinase. This ratio
issignificantly lower than the ratio of 150 moles actin per mole
phosphofructokinase, based upon reported concentrations in skeletal
muscle of 25 mg/ ml (595 1AM) actin (Hasselbach and Schneider, 1951) and
0.33 mg/ml (4 1.1M) phosphofructokinase (de Duve, 1972). Given the high
binding affinity of phosphofructokinase for actin (Kd of approximately 10
nM (Kuo et al.,1986)), and the observation that the binding of
phosphofructokinase by 1 mg/ ml F-actin remains linear at enzyme
concentrations higher than 0.6 mg/ml (Roberts and Somero, 1987), this129
ratio was appropriate for maximizing potential effects of F-actin upon the
in vitro phosphorylation of phosphofructokinase under these conditions.
It was not convenient to increase the concentration of actin filaments due
to limits in protein solubility in the stock solution. Pilot studies with 6:1
and 16:1 molar ratios of F-actin to phosphofructokinase showed no
difference in phosphate incorporation during the cAMP-dPK-catalyzed in
vitro phosphorylation reaction in the presence of troponin C, so all
phosphorylation time course data was collected at the 16:1 molar ratio in
the hope of maximizing any stabilizing effects F-actin might have upon
phosphofructokinase. Figure 2-11 shows the effects of F-actin upon the
phosphorylation of phosphofructokinase with the addition of troponin C
(A) or calmodulin (B).
The extent and rate of cAMP-dPK-dependent phosphorylation of
phosphofructokinase with calcium-troponin C is unchanged by the
addition ofF-actin.In the presenceof calcium-calmodulin, the
phosphorylationisslightlyretarded compared totheextentsof
phosphorylation in the control reactions without F-actin (figure 2-11 B, and
table2-3).Approximately1.4and1.1molesphosphate/mole
phosphofructokinase were incorporated in the presence of F-actin plus
calcium-troponinCorcalcium-calmodulin,respectively. The
phosphorylation reaction was run in the absence of phosphofructokinase130
Figure 2-11
Time courses of cAMP-dPK-catalyzed in vitro phosphorylation of
phosphofructokinase in the presence of F-actin in addition to either
troponin C (TnC) or calmodulin (Cam). A) In vitro phosphorylation
conducted under standard condtitions including: () 5 1.1M troponin C
plus 1.0 mM CaC12; (l7 ) 5 1.11\4 troponin C, 1.0 mM CaC12, and 1.1 mg/ ml F-
actin; (4 ) 5 1.i.M troponin C, 1.1 mg/ ml F-actin, and 1.0 mM EGTA
substituted for CaC12. B) In vitro phosphorylation conducted under
standard conditions including: () 5 tiM calmodulin plus 1.0 mM CaC12;
Off) 5 p.M calmodulin, 1.0 mM CaC12, and 1.1 mg/ ml F-actin; (&) 5 1.1M
calmodulin, 1.1 mg/ml F-actin, and 1.0 mM EGTA substituted for CaC12.
Extents of phosphorylation were quantified by liquid scintillation
counting.A)
B)
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Control phosphorylation in the absence of F-actin and in the presence of
either troponin C (A) or calmodulin (B) achieved incorporation of 1.45 and
1.79 moles phosphate, respectively(table2-3).todetect non-specific
binding of labeled ATP or phosphorylation of F-actin by cAMP-dPK
/ troponin C. The degree of radioactivity incorporated by F-actin alone
wasminimal. c AMP-dPK-c atalyzedphosphorylationof
phosphofructokinase in the absence of troponin C or calmodulin was
minimally affected by the presence of F-actin (table 2-3).
In vitro phosphorylation of serine 376 carried out in the presence of
calmodulin or troponin C is dependent upon the presence of calcium. In
the presence of EGTA, phosphorylation of serine 376 is inhibited, while the
overall extent of phosphorylation returns to values expected in the absence
of troponin C (table 2-3) or calmodulin (Zhao et al., 1991b).With the
addition of F-actin, however, the calcium dependence of the reaction was
generally lowered (figure 2-11, and table 2-3).The extent of phosphate
incorporation was slightly lower for phosphorylation in the presence of
EGTA with troponin C, at 1.26 moles phosphate, and equivalent for
calmodulin,at1.16molesphosphate, when comparingtothe
phosphorylation in the presence of calcium, which yielded values of 1.41
and 1.10 moles phosphate with troponin C and calmodulin, respectively.
The effect of F-actin upon the troponin C-dependent activity loss
also was examined. As seen in the other experiments,133
Table 2-3Extent of cAMP-dPK-catalyzed in vitro Phosphorylation of
Phosphofructokinase in the presence of F-actin.
Additional Protein Ca2+/ EGTA Moles P/ Mole PFK
0.35
0.49
0.47
1.45
0.36
1.41
1.26
1.79
1.10
1.16
None
7:1 F-actin
16:1 F-actin
TnC
TnC
16:1 F-actin, Tnc
16:1 F-actin, TnC
Cam
16:1 F-actin, Cam
16:1 F-actin, Cam
Ca2+
Ca2+
Ca2+
Ca2+
EGTA
Ca2+
EGTA
Ca2+
Ca2+
EGTA
Phosphofructokinase was phosphorylatedinvitro by cAMP-dPK
following the standard conditions, in the presence of the indicated
additionalproteins. Fora"7:1"molarratioofF-actinto
phosphofructokinase, 0.5 mg/ ml F-actin were present; for "16:1", 1.1
mg/ml F-actin were added; calmodulin or troponin C were added to final
concentrations of 5 [IM where indicated. The concentrations of CaC12 or
EGTA were 1 mM. The extent of phosphorylation was determined by
liquid scintillation counting following 2.5 hours of reaction.134
phosphofructokinase's intrinsic activiy loss at pH 7.0, 0.25 mM ATP, 30 °C
for 1.5 hours was approximately 30% (figure 2-12).The loss in activity
during the phosphorylation reaction in the presence of 5µM troponin C
and cAMP-dPK is approximately 60%. Addition of F-actin to this reaction
marginally stabilized enzyme activity at the outset of the reaction.
However, the final overall loss of activity at the reaction's conclusion
approached A/Ao = 0.40, the same value as is obtained without F-actin.
Phosphorylation in the Presence of Reconstituted Troponin
Troponin C is a component of the thin filament responsible for
calcium signal transduction in muscle contraction. The protein associates
with troponin T and troponin I in a high affinity heterotrimeric complex
associated with F-actin. Past results in this laboratory have shown that the
troponin complex also catalyzes phosphofructokinase inactivation, to an
extent similar to that seen with troponin C (Zhao et al, 1991b).
Reconstitution of troponin was achieved through combination of the three
purified component proteins under high salt, followed by stepwise transfer
of buffers to a low salt (50 mM KC1) environment.Any unbound
component proteins were separated from the reconstituted protein by S-
300 size exclusion chromatography (figure 2-13).135
Figure 2-12
Effects of F-actin on the activity of phosphofructokinase occurring
during cAMP-dPK-catalyzed in vitro phosphorylation of the enzyme in the
presence and absence of troponin C. Activity measurements were taken
during the phosphorylation reaction performed following the standard
conditions with 10 µg /ml cAMP-dPK, 1.0 mM CaC12, and non-radioactive
ATP. (e) Activity of phosphofructokinase in the absence of troponin C or
F-actin. Ao = 77 U/mg;() Activity in the presence of 5 1.1M troponin
C. Ao = 98 U/mg; (A ) Activity in the presence of both 5 [1,1\4 troponin C
and 1.1 mg/ml F-actin. Ao = 170 U/ mg.1.0
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Figure 2-13
Elution profile for S-300 gel filtration (3 X 85 cm) separation of
reconstituted troponin from unincorporated troponin C, troponin T, or
troponin I.The column was equilibrated and washed with a buffer
containing 50 mM MOPS pH 7.6, 0.2 mM NaC1, and 15 mM beta-
mercaptoethanol, at a flowrate of 40 ml/hour. A total of 25 mg protein
was loaded onto the column.0.2
0.1
0.0
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Concentrations of KC1 greater than 50 mM are necessary to maintain the
solubility of the troponin complex.Before testing the effects of the
troponin complex on the extent of phosphorylation or specific activity of
phosphofructokinase, the activity of the enzyme in various concentrations
of KC1 was probed. At 50 mM KC1, a sharp reduction in the activity of
0.125 mg/ml phosphofructokinase was observed after 15 minutes (table 2-
4). This activity loss was alleviated however upon addition of 1 mM ATP.
A reduced level of cAMP-dPK-catalyzed phosphorylation in the presence
of troponin C was observed with 100 mM KC1, while the phosphorylation
reaction was completely inhibited at 200 mM (table 2-5).Fortunately,
complete phosphorylation was observedat50 mM KC1,asalt
concentration at which troponin remained soluble.
The phosphorylation reaction was conducted in the presence of
cAMP-dPK plus 50 mM KC1 and either 5 [LM reconstituted troponin or
troponin C, in the presence of either EGTA or calcium. Because troponin T
and troponin I are also substrates of cAMP-dPK (Rapundalo, 1998), the
phosphorylation pattern was analyzed by phosphorimaging of SDS-PAGE
gels used to separate the reaction components.The results of the
phosphorylation time course appear in figure 2-14. Phosphorylation to the
level of 1.22 moles phosphate occurred in140
Table 2-4 Time-dependent activity loss of phosphofructokinase in the
presence of KC1.
[KC1] (mM) [ATP] (mM) A/ Ao, 30 minutes
1 0 0 0.83
2 50 0 0.24
3 50 1.0 0.78
0.02 mg/ml phosphofructokinase was incubated in a buffer containing 50
mM MOPS pH 7.0, 5 mM MgC12, 1 mM CaC12, 5 mM dithiothreitol, and
10% glycerol at 30 °C.Indicated concentrations of ATP or KC1 were
included in the incubation buffer. The specific activity was measured at
the initiation and following 30 minutes incubation, using the standard
catalytic assay outlined in Materials and Methods. Measured Ao values
were: 1 = 115 U/mg, 2 = 85 U/mg, 3 = 115 U/mg.141
Table 2-5 Effect of KC1 on cAMP-dPK-catalyzed in vitro phosphorylation of
phosphofructokinase.
[KC1] (mM) Moles P/Mole PFK
0 1.18+/-0.01 (n =2)
50 1.16+/-0.23 (n =6)
100 0.46+/-0.01 (n =2)
200 0.02(n = 2)
PhosphofructokinaseunderwentcAMP-dPK-catalyzedinvitro
phosphorylation for 2 hours in the presence of 5 1.IM troponin C following
standard conditions, in addition to the indicated KC1 concentrations. The
extent of phosphate incorporation was determined by liquid scintillation
counting.142
Figure 2-14
TimecourseforcAMP-dPK-catalyzedinvitro
phosphorylation of phosphofructokinase in the presence of reconstituted
troponin. Measurementofphosphateincorporationat
phosphofructokinase in the standard in vitro phosphorylation conditions,
including: (0 ) 5 1AM troponin C with 1 mM CaC12; ( 0 ) 5µM troponin C
with 1 mM EGTA substituted for 1 mM CaC12; (p ) 5 [IM reconstituted
troponin with 1 mM CaC12; () 5µM reconstituted troponin with 1 mM
EGTA substituted for 1 mM CaC12.The incorporation of phosphate at
troponin T within the reconstituted troponin complex was also measured
in the standard in vitro phosphorylation conditions, including: (6, ) 5 1..tM
troponin and 1 mM CaC12; ( ) 5 [tM troponin and 1 mM EGTA
substituted for 1 mM CaC12. The percentage of phosphate incorporated at
each protein was first determined using phosphorimaging of reaction
samples separated by SDS-PAGE, then quantified by liquid scintillation
counting.Hgue 2-14
20
1.5
0 FFK + Tn + Ca2+
a FR +Tn + EGTA
-A-TnT (in Tn), + FFK+ Ca2+
p TnT (in Tn), + FFK+ E-GTA
0 FFK + TnC+ Ca2+
0 FFK + TnC+ EGTA
0 2J 40 83 83 100
Time (rrinties)
123 140
143144
the presence of troponin C and calcium. Addition of 1 mM EGTA to
the reaction brought about a sharp drop in phosphorylation extent, to 0.11
moles phosphate/mole phosphofructokinase. In the presence of calcium,
the only significant target of phosphorylation by cAMP-dPK/troponin was
phosphofructokinase.Approximately 0.28 moles of phosphate were
incorporated in these conditions, a significant drop-off from the troponin
C-induced phosphorylation of the enzyme. In the absence of calcium (1
mM EGTA), both phosphofructokinase and troponin T were significantly
phosphorylated by cAMP-dPK. Approximately 0.57 and 0.48 moles of
phosphate were incorporated onto phosphofructokinase and troponin T,
respectively, under these conditions. No phosphorylation of troponin I
was observed in the presence of calcium plus phosphofructokinase,while
less than 0.1 moles of phosphate were incorporated in the presence of
EGTA.
Identification of the sites of cAMP-dPK-catalyzed phosphorylation
of phosphofructokinase in the presence of troponin was attempted using
reversed phase HPLC following CNBr digestion of the components.
MALDI-TOF mass analysis of several of the isolated peptides yielded
molecular weights which did not match the predicted molecular weights of
any of the peptides that would be produced by CNBr digestion oftroponin
I, troponin C, troponin T, cAMP-dPK, or phosphofructokinase. A majority
of peaks present at the end of the reversed phase HPLC gradient suggested145
that there are a large number of highly hydrophobic or very large peptides
present. A combination of the inability to identify the isolated peptides
with the propensity of large peptides suggests that the CNBr digestion was
incomplete, and the analysis therefore unable to identify the site of
phosphofructokinase phosphorylation.
Interaction, Reactivation, and Phosphorylation in the Presence of Tubulin
Both the dimer and microtubular forms of tubulin interact
specificallywiththephosphofructokinasedimer,catalyzingthe
inactivation of the enzyme (Hesterberg and Lee, 1981; Lehotzkyet a1,1994;
Lehotzkyet al.,1993; Vertessyet al.,1997a; Vertessyet al.,1996;Vertessyet
1997b).Since past inactivation studies were done at high tubulin
concentrations(10p.M)(Lehotzkyet al,1993),thesensitivityof
phosphofructokinase to tubulin inactivation in this study is hard to gauge
in comparison to the inactivation of phosphofructokinase induced by other
proteins.
Table 2-6 plots the loss of phosphofructokinase activity when 0.02
mg/ ml of the enzyme is incubated with varying concentrations of troponin
C or tubulin at pH 7.0 for 15 minutes. Strong inhibition by both troponin C
and tubulin is apparent. Greater than 50% inactivation was achieved with
0.10 µM tubulin dimer, or 0.20 [tM troponin C. These results suggest that146
Table 2-6 Inactivation of Phosphofructokinase by Tubulin or Troponin C.
[TnC] (IM) A/ Ao, 15 min [Tubulin] (IAM) A/ Ao, 15 min
0 0.91 0 0.85
0.025 0.79
0.050 0.64
0.20 0.47 0.100 0.45
0.250 0.23
0.40 0.25 0.500 0.08
1.000 0.05
Inactivation of 0.02 mg/ml phosphofructokinase by troponin C was
measured by incubation of the two proteins in a buffer containing 25 mM
MOPS pH 7.0, 25% glycerol, 1.25 mM beta-mercaptoethanol, 1 mM CaC12,
and 1.25 mM dithiothreitol, as indicated in Materials in Methods. Tubulin-
dependentinactivationof0.02mg/m.1phosphofructokinasewas
conducted in 50 mM MOPS pH 7.0, 25% glycerol, 1 mM MgC12, 1 mM
CaC12, 1.25 mM beta-mercaptoethanol, and 1.25 mM dithiothreitol.
Activitywasmeasuredimmediatelyfollowingmixingof
phosphofructokinase with the inactivating protein (Ao), and after fifteen
minutes incubation.Ao for troponin C-induced inactivation equaled
81+/- 8 U/mg (n=3) and for tubulin-induced inactivation equaled 91 +/- 9
U/mg (n=3).147
equivalent concentrations of tubulin monomer and troponin C achieve the
same level of inactivation of phosphofructokinase.
The effects of the phosphofructokinase substrates ATP or fructose -6-
phosphateon tubulin-dependentinactivationweretested.The
inactivation was carried out using 0.25 µM tubulin, a concentration caused
A/ Ao of 0.02 mg/ml phosphofructokinase to decrease to 0.20 over the
course of 15 minutes. Table 2-7 shows that a 10 p,M concentration of ATP
adequately cancels this inactivation, while millimolar concentration of
fructose-6-phosphate have little effect on enzyme inactivation.
Reactivation was tested for the enzyme in the presence of troponin
C.Phosphofructokinase (0.02 mg/ml) was incubated with varying
concentrations of troponin C. Reactivation was initiated by addition of 1
mM ATP following 15 minutesinactivation.Followingintrinsic
inactivation in which no troponin C was added, addition of 1 mM ATP
produced no change in phosphofructokinase specific activity (table 2-8).
However, approximately 20% reactivation was seen in the presence of
troponin C, throughout the range of troponin C concentrarions studied.
The reactivation reaction appeared to reach completion 20 minutes
following addition of ATP.
Reactivation also occurred over a range of tubulin concentrations
using an identical reactivation procedure as used in testing troponin C-
dependent reactivation. The extent of reactivation was approximately148
Table 2-7 Effects of fructose-6-phosphate or ATP on tubulin-induced
inactivation of phosphofructokinase.
[ATP] (.1M) A/ Ao, 15 min [F-6-P] (1.1M) A/ Ao, 15 min
0 - control 0.87 0 - control 0.87
0.01 0.59 0.01 0.22
0.10 0.69 0.10 0.27
1.00 0.87 1.00 0.42
0.02 mg/ml phosphofructokinase was incubated with 0.25 1.1.M tubulin in a
buffer containing 50 mM MOPS pH 7.0, 25% glycerol, 1 mM MgC12, 1 mM
CaC12, 1.25 mM beta-mercaptoethanol, 1.25 mM dithiothreitol, and the
indicated concentrations of ATP or fructose-6-phosphate. Samples were
assayed directly following dilution, and after 15 minutes inactivation.
"Control" refers incubation of phosphofructokinase in the absence of
tubulin. Ao =108 +/- 2 U/mg (n=3).149
Table 2-8 Reactivation of phosphofructokinase following troponin C-
induced inactivation.
[TnC] p.MA/ A0,15 minA/ AO, 35 minChangeA/ AO, 55 minChange
0 0.73 0.75 +0.02 0.73 0.00
0.1 0.34 0.53 +0.19 0.55 +0.21
0.2 0.27 0.45 +0.18 0.48 +0.21
0.4 0.13 0.39 +0.26 0.42 +0.29
0.02mg/ mlphosphofructokinasewasinactivatedwithvarying
concentrations of troponin C following the inactivation protocol outlined
in Materials and Methods. Following 15 minutes inactivation, the ATP
concentration was adjusted to 1 mM to initiate the reactivation reaction.
The enzyme was assayed at 15, 35, and 55 minutes following the onset of
inactivation. Ao = 96 +/- 7 U/mg (n=3).150
20%, a result similar to the one observed for reactivation with troponin C.
The reactivation appeared to proceed more slowly, however, with activity
increasing between 15-35 minutes, and continuing between 35-55 minutes
following the initiation of inactivation (table 2-9).
The cAMP-dPK -catalyzed in vitro phosphorylation reaction was
tested in the presence of tubulin, with in vitro phosphorylation in the
presence of calcium-troponin C as a control. Phosphate incorporation was
monitored with phosphorimaging following separation of the reaction
components by SDS-PAGE.The average amount of phosphate
incorporation under standard conditions in the presence of troponin C was
1.5 +/- 0.3 (n = 3) moles phosphate per mole phosphofructokinase.
Phosphate incorporation in the presence of tubulin was 0.40 +/- 0.18 (n =
7) moles per mole enzyme. No correlations between ATP or tubulin
concentration and phosphorylation extent were observed when the
concentrations of these components were varied.
Effects of S100 on Phosphorylation and Activity of Phosphofructokinase
Members of the S100 family of EF-hand calcium-binding proteins
share structural homology with calmodulin and troponin C.Over 17
members of this protein family have thus far been identified. Some S100
protein family members bind and confer calcium sensitivity to several151
Table 2-9 Reactivation of Phosphofructokinase Following Tubulin-induced
Inactivation.
[Tubulin]
(-1.1\n)
A/ Ao, 15 minA/ Ao, 35 minChangeA/ Ao, 55 minChange
0 0.74 0.75 +0.01 0.82 +0.08
0.1 0.32 0.46 +0.14 0.56 +0.24
0.2 0.31 0.40 +0.09 0.49 +0.18
0.4 0.09 0.29 +0.20 0.33 +0.24
0.02mg/ mlphosphofructokinasewasinactivatedwithvarying
concentrations of tubulin following the inactivation protocol outlined in
Materials and Methods.Following 15 minutes inactivation, the ATP
concentration was adjusted to 1 mM to initiate the reactivation reaction.
The enzyme was assayed at 15, 35, and 55 minutes following the onset of
inactivation. Ao = 94 +/- 6 U/mg (n=3).152
proteins that are also targets of calmodulin.While calmodulin is
ubiquitously expressed, different members of the S100 protein class are
limited in expression to distinct cell types (Schafer and Heizmann, 1996).
At a concentration of 1 1.1,M, an undetermined member of the S100
protein family purified from bovine brain was found to inhibit the activity
of phosphofructokinase to 33% of its zero-time activity following 20
minutes incubation in vitro (Zhao et al, 1991b).S100A1, one of two
members of this protein family expressed in brain (Schafer and Heizmann,
1996), was purified from beef heart totestitsability to catalyze
phosphofructokinase inactivation and modulate cAMP-dPK-catalyzed
phosphorylation.At 5 [tM S100A1, no effect on phosphofructokinase
activity was seen following 15 minutes incubation of 0.02 mg/ml PFK in
the presence and absence of calcium (table 2-10).This result contrasts
sharply with the published inactivation of phosphofructokinase by S100,
and with inactivation by troponin C, in which 50% inactivation is achieved
following 15 minutes incubation with 0.2 1.iM of this protein (table 2-6 and
(Zhao et al., 1991b)). S100A1 also showed no enhancement of cAMP-dPK-
catalyzed in vitro phosphorylation of the enzyme, with approximately 0.3
moles phosphate incorporated in the presence or absence of this protein
(table 2-11).Table 2-10 Effect of S100 on inactivation of phosphofructokinase.
[S100] (uM) A/ Ao, 15 minutes
0 0.74
0.2 0.67
0.5 0.69
1.0 0.75
5.0 0.61
5.0 + 1 mM EGTA 0.67
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0.02 mg/ml phosphofructokinase was inactivated in the presence of
varying concentrations of S100 in a buffer containing 25 mM MOPS pH 7.0,
25% glycerol, 1.25 mM beta-mercaptoethanol, 1 mM CaC12, and 1.25 mM
dithiothreitol, as indicated in Materials in Methods. Ao = 124 +/- 13
U/mg (n=2).154
Table 2-11 Effect of S100 on cAMP-dPK-catalyzed in vitro phosphorylation
of phosphofructokinase.
Added Protein Ca2±/EGTA Moles P/ Mole PFK
None Ca2+ 0.31
TnC Ca2+ 1.0
S100 Ca2+ 0.36
S100 EGTA 0.22
PhosphofructokinaseunderwentcAMP-dPK-catalyzedinvitro
phosphorylation under standard conditions. As indicated, 5 I.A.M additional
protein (troponin C or S100), and 1 mM EGTA or CaC12 were included in
thereaction.Phosphate incorporation was quantified by liquid
scintillation counting following 2 hours of reaction.155
Phosphorylation of phosphofructokinase by Calmodulin Dependent
Protein Kinase II
Calmodulin dependent protein kinaseII(CamKII) has been
reported to catalyze phosphorylation of phosphofructokinase (Mahrenholz
et al, 1991b). The extent of phosphorylation reported was 0.15 moles of
phosphate per mole of phosphofructokinase, a low value which calls into
question the specificity of this reaction. This protein kinase is, however,
present and active in heart. We therefore tested the ability of an active
truncated form of CamKII to phosphorylate phosphofructokinase.
The experimental results appear in table 2-12. Before assessing the
suitability of phosphofructokinase as a substrate of CamKII, the activity of
the enzyme towards the substrate myosin light chain (MLC) was tested,
comparing the activity of myosin light chain kinase (MLCK) towards this
substrate as a control.Quantification of phosphate incorporation was
performed by phosphorimaging following separation of the reaction
components by SDS-PAGE. Both CamKII and MLCK were active towards
MLC, phosphorylating the light chain at 0.90 and 0.82 moles phosphate,
respectively (table 2-12, (1) and (2)).Exclusion of calmodulin from the
reaction lowers the extent of phosphorylation to 0.12 moles phosphate (3),
demonstrating the calmodulin dependence of the catalytic fragment of
CamKII.156
Table 2-12
Extent of phosphorylation of calmodulin dependent protein kinase
II (camKII)-catalyzed in vitro phosphorylation of phosphofructokinase.
The phosphorylation of myosin light chain was initiated by addition of 10
µg /ml of either myosin light chain kinase or camKII catalytic peptide to 50
mM HEPES pH 7.5, 5 mM MgCl2, 1 mM CaCl2, and 3 mM y-32P-ATP, in the
presence or absence of 5 p.M calmodulin, at 30 °C.Phosphorylation of
phosphofructokinase was attempted following a similar procedure to the
one used for phosphorylation of myosin light chain, with 1.5 1AM
phosphofructokinase as a substrate in an identical reaction buffer, in the
presence or absence of 5 pM troponin C or calmodulin, as indicated in the
table. The effect of 15 minutes pre-incubation of phosphofructokinase with
troponin C was tested. The phosphorylation reaction was also attempted
following 15 minutes preincubation of 190 pg/m1 camKII in 50 mM MOPS
pH 7.0, 2 mM MgCl2, 0.1 mM CaC12, 5 p,M dithiothreitol, and 4 p,M
calmodulin at 30 °C.All phosphorylation reactions were allowed to
proceed for 60 minutes at which time phosphorylation extent was
determined by phosphorimaging of the sample separated by SDS-PAGE.Table 2-12 In vitro phosphorylation of phosphofructokinase catalyzed by CamKII
Protein KinaseSubstrateMoles
Pi/ Mole
substrate
Conditions
1) CamKII
2) MLCK
3) CamKII
4) CamKII
5) cAMP-dPK
MLC 0.90 2 µg /ml CamKII, 5 !AM Calmodulin, 1.0 }AM MLC, 3 mM ATP,
5 mM MgC12, 1 mM CaC12, 2.5 mM DTT, 50 mM HEPES pH
7.0. Temperature = 30 °C Time of reaction = 120 minutes
MLC
MLC
PFK
PFK
6) CamKII PFK
0.82 Same as (1), but with 10 µg /ml MLCK
0.12 Same as (1), but without calmodulin
0.02 Same as (1), but with 1.5 p,M (125 µg /ml) PFK
1.2 Same as (4), but with troponin C instead of calmodulin, 15
1.1.g/m1 cAMP-dPK instead of CamKII, 10% glycerol, and 50
mM MOPS pH 7.0 instead of HEPES.
0.02 Same as (4), but with prior separate preincubations of camKII
with 5 JAM calmodulin plus 3 mM ATP and PFK with 5 1.LM
troponin C
7) CamKII PFK 0 Same as (4), but without calmodulin.158
Invitro phosphorylationof phosphofructokinase by CamKII was
attempted under a variety of conditions. Under conditions identical to
those yielding complete phosphorylation of MLC by CamKII, the
phosphorylation of phosphofructokinase was negligible (4). The reaction
was re-attempted following preincubations of CamKII with calmodulin
and ATP, and phosphofructokinase with troponin C (6), in an attempt to
pre-activate the kinase. There was no change in phosphate incorporation
undertheseconditions. Thedegreeofphosphofructokinase
phosphorylation catalyzed by CamKII was small compared to the control
cAMP-dPK-catalyzed phosphorylation of the enzyme (5).It is therefore
unlikely that phosphofructokinase is a specific substrate of CamKII.
In Vitro Phosphorylation of Phosphofructokinase Catalyzed by cAMP-dPK
In vitro phosphorylation of phosphofructokinase by cAMP-dPK in the
absenceoftroponinCyielded0.3molesphosphate/mole
phosphofructokinase, as determined by liquid scintillation counting. Two
radioactive peptides eluted at positions characteristic of the hinge and C-
terminal peptides upon HPLC separation of peptides created by CNBr.
Approximately 10% of the overall radioactivity eluted at 20 minutes, while
the remaining 90% eluted at 52 minutes. The gradient used for separation
of these peptides was the same gradient used for separation of peptides
generated by CNBr digestion following phosphorylation in the presence of159
troponin C (Zhao et al, 1991b). The elution position of the minor fraction
of radioactivity was identical to the elution position of the radiolabeled
hinge peptide (figure 2-13).These results reconfirm (Zhao et al, 1991b)
that a small, but detectable, amount of phosphorylation occurs at serine
376 in the absence of troponin C.160
Figure 2-15
Reversed phase HPLC mapping of sites on phosphofructokinase in
vitro phosphorylated by cAMP-dPK in the absence of troponin C. The
extent of phosphorylation was 0.33 +/- 0.02 (n=3) moles phosphate per
mole phosphofructokinase, as determined by liquid scintillation counting.
Peak fractions were collected, dried, and analyzed for radioactivity.
Chromatogram absorbance measured at 214 nm.Figure 2-15
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Discussion
Reducedactivityofphosphofructokinase followinginvitro
phosphorylation catalyzed by the catalytic subunit of cAMP dependent
protein kinase in the presence of troponin C (figure 2-1) contrasts with the
specific activity of enzyme phosphorylated in vivo through stimulation of
rabbit hearts with epinephrine (table 1-3).When assayed under ideal
allosteric conditions, the specific activity of phosphofructokinase obtained
from epinephrine perfused rabbit hearts was not significantly different
from the activity of enzyme obtained from unstimulated hearts, even
though the two enzyme samples had different levels of phosphorylation at
serine 376.The insensitivity of the activity when assayed under ideal
allosteric conditions of rat heart phosphofructokinase toward epinephrine
treatment has also been documented (Narabayashi et al, 1985).
The concentration of phosphofructokinase in resting muscle is
approximately 0.33 mg/ml (de Duve, 1972). However, the activity of the
protein in muscle is several-hundred-fold lower than would be expected of
this concentration of phosphofructokinase (Passonneau and Lowry, 1962).
Since the rate of spontaneous dimer formation occurring for 0.33 mg/ml
phosphofructokinase alone would be too low to account forthe
discrepancy between actual and potential activity of the enzyme in muscle,163
the interaction of enzyme with inactivating factors such as troponin C or
calmodulin in vivo is probable (Mayr, 1984a).
Phosphofructokinase activity is regulated by the enzyme's self-
association equilibrium.Self-association is in turn controlled by the
concentration of enzyme, binding of allosteric effectors, and its interactions
with other proteins.
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In this model, positive allosteric effectors bind to and stabilize the
tetramer while negative effectors bind and stabilize the dimer, resulting in
shifts in the rapid dimer-tetramer equilibrium (Mayr, 1984a; Zhao et al.,
1991b). As demonstrated by simultaneous decreases in light scattering and
enzyme activity in the presence of calmodulin (Mayr, 1984a), or troponin C
(Lan and Steiner, 1991), these proteins specifically interact with dimeric
phosphofructokinase.Calmodulin and troponin C interact with both164
distinct conformational forms of the dimer, D and D*, and increase the rate
of D D* equilibrium (Zhao et al., 1991b).
Bothpositiveandnegativeallostericeffectorsof
phosphofructokinase inhibit protein-induced inactivation of the enzyme,
and several common effectors, with the exception of ATP, had been
demonstrated to minimize the effects of troponin C or calmodulin upon
the extent of cAMP-dPK-catalyzed in vitro phosphorylation (Zhao et al.,
1991b). The effect of a 5 mM concentration of ATP upon the extent of in
vitro phosphorylation in the presence of troponin C and its effects on
enzyme activity were tested in this thesis. ATP has previously been shown
to stabilize the dimeric form of the enzyme (Mayr, 1984a). As expected
(Zhao eta!, 1991b), 5 mM ATP completely protected phosphofructokinase
from troponin C-induced inactivation (figure 2-3).This effect of ATP in
inhibiting inactivation is most likely due to stabilization of the D
conformation of the dimer (Zhao et al, 1991b), which counteracts the
D .3D* conversion caused by interaction with troponin C.
This high concentration of ATP also limited the extent of cAMP-
dPK-catalyzed in vitro phosphorylation in the presence of troponin C to
less than one mole phosphate per mole phosphofructokinase (table 2-2).
Phosphopeptide mapping by reversed phase HPLC following CNBr
digestion confirmed that the lone site of phosphorylation was at serine 774
(figures 2-6, 2-7, and 2-8).Assuming that ATP specifically binds the D165
conformation, this result suggests that this conformation of the dimer is
either a poor substrate for cAMP-dPK-catalyzed in vitro phosphorylation,
or that binding of ATP makes it a poor substrate.
A high concentration (1 mg/ml) of phosphofructokinase stabilizes
the enzyme from intrinsic and troponin C-dependent inactivation (figure
2-9).In consideringthatthe enzyme tetramerisstabilizedat
concentrations greater than 0.2 mg/ml (Mayr, 1984a), this result is
consistent with the interaction of troponin C with the dimeric form of
phosphofructokinase. Complete phosphorylation of phosphofructokinase
was also markedly minimized at elevated concentrations of the enzyme
(figure 2-10).This result, when considered with the lowered degree of
cAMP-dPK-catalyzed phosphorylation observedinthe presenceof
troponin C or calmodulin plus tetramer-stabilizing allosteric activators of
the enzyme (Zhao et a!, 1991b), suggests that the tetrameric form of
phosphofructokinase is not a substrate for serine 376 phosphorylation
catalyzed by cAMP-dPK.
Dimerization of the enzyme appears to be a necessary step in the
phosphorylation of serine 376 by cAMP-dPK. This result agrees with the
three-dimensional model of rabbit M-phosphofructokinase based upon the
crystal structures of E. coli and B. stearothermophilus phosphofructokinase
(Poorman et al, 1984). In this model, the linking hinge regions containing
the phosphorylatable serine 376 lies at the dimer-dimer interface of the166
tetramer. Steric hindrance would therefore inhibit phosphorylation at this
site when the enzyme is a tetramer, but would be alleviated upon enzyme
dimerization.
The requirement of dimerization prior to in vitro serine 376
phosphorylationissupportedbythehypothesizedlatencyof
phosphofructokinase as a dimer in vivo (Mayr, 1984a), and the finding that
thissite was phosphorylated soon afterthe onset of epinephrine
stimulation in vivo (Results, chapter 1).If dimerization is required, then
conversion of the dimeric phosphorylated enzyme to the tetrameric form
would be a necessary step preceding enzyme activation. Zhao et al (Zhao
et al, 1991b) and Mayr (Mayr, 1984a) have demonstrated reactivation of
enzyme activity following brief periods of troponin C- or calmodulin-
induced inactivation upon addition of various allosteric effectors of the
enzyme, including ATP, AMP, ADP, citrate, and fructose-2,6-bisphosphate.
In both Mayr's and Zhao's studies, long delays prior to introduction of
additional allosteric effectors limited the degree of reactivation obtained.
In this study, reactivation of enzyme activity following cAMP-dPK-
catalyzed in vitro phosphorylation in the presence of 5 [tM troponin C was
attempted, yielding approximately 12% reactivation of activity (Results).
A similar degree of reactivation was obtained following 160 minutes
inactivation of unphosphorylated phosphofructokinase under conditions
resembling those used in the in vitro phosphorylation reaction (Mayr,167
1984a). This inability of allosteric effectors to completely restore enzyme
activity following in vitro phosphorylation of the enzyme may well be a
result of a significant degree of irreversible dimer aggregation, D-) (Din,
having taken place.
Phosphofructokinase has been proven to interact with several
different proteins.It is possible that some of these interactions inhibit
irreversible inactivation in vivo, while allowing for enhancement of
phosphorylation at serine 376. The limits of reactivation achieved with
allosteric ligands and the observation that phosphofructokinase is active
following in vivo phosphorylation is perhaps reconciled by a recent report
showing that the bacterial proteins, GroEL and GroES specifically
reactivated heat-denatured rabbit skeletal muscle phosphofructokinase
(Melegh and Minami, 1997).It is possible that a eukaryotic heat shock
protein catalyzes refolding of phosphofructokinase in vivo. Experiments
with heat shock cognate 70 (Burdon, 1987; Kabakov and Gabai, 1993), or
other molecular chaperones found in muscle, may demonstrate a route
whereby phosphofructokinase is stabilized from undergoing "irreversible"
dimer aggregation, or even stimulate refolding of theinactivated
aggregates, (D*r,)>nD* during in vitro phosphorylation of the enzyme,
thus providing better yields of active enzyme.
Priorworkshows73%inactivationof20p.g /ml
phosphofructokinase following 20 minutes incubation with 1 1AM troponin168
and 0.1 mM calcium, and 54% inactivation in the presence of troponin plus
0.1 mM EGTA (Zhao et al, 1991b).The enzyme is therefore strongly
inactivated by troponin, in a slightly calcium-dependent manner. We
hypothesizedthattroponinmightdirectcAMP-dPK-catalyzed
phosphorylation to serine 376 in a manner similar to calmodulin or
troponin C because troponin has an acidic isoelectric point, catalyzes
phosphofructokinase inactivation, and contains troponin C as a subunit.
However, our results showed that in the presence of calcium, the extent of
phosphorylation by cAMP-dPK plus troponin was only 0.28 moles/mole
phosphofructokinase, compared to 1.22 moles phosphate incorporated in
the presence of troponin C.Substitution of EGTA for calcium during
cAMP-dPK-catalyzed in vitro phosphorylation of phosphofructokinase
appears to have opposite effects when the reaction occurs in the presence
of troponin C versus reconstituted troponin. With troponin C, the extent of
phosphorylation decreased to 0.11 moles/ mole enzyme, while with
troponin, the extent of phosphofructokinase phosphorylation doubled to
0.57 moles phosphate (figure 2-14).The significance of this result is
difficult to interpret.However, itis clear from these results that
reconstituted troponin is unable to significantly enhance cAMP-dPK-
catalyzed in vitro phosphorylation of phosphofructokinase.
The most abundant skeletal muscle protein is actin. Under certain
physiological conditions, including prolonged muscle contraction (Parra169
and Pette, 1995), phosphofructokinase localizes to the insoluble fraction of
muscle cells, of which actin is a major substituent. Phosphofructokinase
specifically interacts with both reconstituted filamentous actin (F-actin)
and thin filaments in vitro (Kuo et al, 1986; Liou and Anderson, 1980;
Roberts and Somero, 1987; Roberts and Somero, 1989).This interaction
causes decreased sensitivity to ATP inhibition and an increased sensitivity
to fructose-2,6-bisphosphate activation.G-actin has no effect on the
allosteric properties of phosphofructokinase (Kuo eta!, 1986).
F-actin stabilizes phosphofructokinase from inactivation by ATP,
throughpreferentialbindingtothetetramericformof
phosphofructokinase (Roberts and Somero, 1987).Despite the reported
stabilization of tetrameric phosphofructokinase upon binding F-actin, a
high yield of phosphate incorporation was obtained during cAMP-dPK-
catalyzed in vitro phosphorylation carried out in the presence of a 16:1
molar ratio of F-actin to phosphofructokinase and 5 1.1M calmodulin or
troponin C (figure2-11, A andB).Unfortunately, whilefull
phosphorylation of phosphofructokinase was achieved in the presence of
F-actin, large losses in enzyme activity still occurred (figure 2-12). These
results alone suggest minimal interaction between phosphofructokinase
and F-actin under the conditions studied. However, F-actin did alter the
calcium dependence of the phosphorylation reaction as troponin C- or
calmodulin-induced enhancement of phosphorylation still occurred even170
in the presence of 1 mM EGTA (figure 2-11).Phosphofructokinase was
also inactivated under these conditions (results not shown), so the
proposed phenomenon of F-actin-induced stabilization of the enzyme
during phosphorylation was discounted.
Like troponin C and calmodulin, tubulin is an acidic protein that
interacts specifically with phosphofructokinase (Lehotzky et al., 1993;
Orosz et al., 1997; Vertessy et al., 1997a; Vertessy et al., 1996).It strongly
inactivates the enzyme, achieving extents of inhibition equivalent to those
of troponin C at comparable concentrations (table 2-6).Tubulin also
catalyzeslimitedreactivationofphosphofructokinasefollowing
inactivation of the enzyme (tables 2-8 and 2-9).It has been demonstrated
by fluorescence anisotropy that tubulin specifically interacts with dimeric
phosphofructokinase (Lehotzky et al., 1993). However, unlike cAMP-dPK-
catalyzed phosphorylation of both serine 376 and 774 in the presence of
troponin C or calmodulin, phosphorylation in the presence of tubulin leads
to incomplete phosphate incorporation.The degree of phosphate
incorporatedinthepresenceof51.1Mtubulin was0.4moles
phosphate/mole phosphofructokinase, compared to 1.5 moles phosphate
incorporated in the presence of troponin C in a parallel experiment
(Results). From the phosphorylation, fluorescence anisotropy, and activity
data, it can be concluded that dimerization of phosphofructokinase is not
the sole requirement for full in vitro phosphorylation of the enzyme.171
One possible explanation for the different levels in cAMP-dPK-
catalyzed phosphorylation in the presence of tubulin or reconstituted
troponin as opposed to those in the presence of troponin C or calmodulin
may be different sites of interaction betweenphosphofructokinase and
these proteins. The hinge and C-terminal peptides of phosphofructokinase
created by CNBr digestion have been demonstrated as the two major sites
of phosphofructokinase which directly interact with calmodulin (Mayr,
1987). The sites of phosphofructokinase that interacting with tubulin are
not as clear. Phosphofructokinase is cleaved by subtilisin at one site near
its N-terminus (Gottschalk et al, 1983).Subtilisin cleavage is inhibited
when the enzyme is incubated in a 1:1 molar ratio with tubulin (Vertessy et
al.,1996).This result suggests that a site near the N-terminus of
phosphofructokinase interacts with microtubules; however, additional
sites of interaction (at the hinge or C-terminus) can not be ruled out from
this data alone.
It is also possible that cAMP-dPK-catalyzed phosphorylation at
serine 376 only occurs with a conformational form of the dimer that
interacts with troponin C or calmodulin, but not with tubulin. Troponin C
and calmodulin interact with both D and D* forms of phosphofructokinase
(Zhao et al., 1991b). The precise conformational form of the dimer that
tubulin interacts with has yet to be demonstrated, and it is possible that
only one of the dimer conformations makes a suitable substrate for cAMP-172
dPK-catalyzed phosphorylation at serine 376.If the dimer conformation
that is a substrate for phosphorylation at serine 376 by cAMP-dPK and the
conformationinteractingwithtubulinaredifferent,variationin
phosphorylation could occur in the two cases.It is also possible that
tubulin sterically inhibits the approach of cAMP-dPK to the hinge region of
the phosphofructokinase dimer.
Phosphofructokinase fulfills a structural role within the cell as well
as a catalytic one. The enzyme acts as a "crossbridge", bundling together
microtubule filaments (Lehotzkyet al.,1994; Lehotzkyet al.,1993; Vertessy
et al.,1997a; Vertessyet al.,1996), or actin filaments (Roberts and Somero,
1987; Roberts and Somero, 1989).This crossbridging rearranges the
structural properties of these filaments into bundled networks, adding
another dimension of complexity to the shapes that these networks can
adopt.
Bundle formation plays a role in microtubule-directed cellular
mobility and intracellular transport (Porter and Johnson, 1989), and in
structural organization within the cell (Aamodt and Culotti, 1986; Balaban
et al.,1989).Microtubule associated proteins (MAPS) other than
phosphofructokinase, including MAP2, tau, and MAP4, have been
implicatedtoplayrolesinbundleformation(MacRae,1992).
Phosphorylation of MAP4 inhibits bundle formation (Moriet al.,1991),
signaling arrest of the G2 phase of the cell cycle of mouse oocytes (Aizawa173
et al, 1991).The involvement of phosphofructokinase in microtubule
bundle formation has been demonstrated through increased microtubular
turbidity (Lehotzky et al, 1993) and electron microscopy (Lehotzky et al,
1994).Additional MAPS do not appear to affect phosphofructokinase-
dependent bundling (Lehotzky et al, 1993).Phosphofructokinase forms
crossbridges between microtubules at regular intervals of 20 nm (Lehotzky
et al, 1994). The dimensions of the crossbridges are approximately 12X13
nm; previous electron microscopy has approximated the dimensions of the
tetramer to be close to these values, at 9X14 nm (Hesterberg et al, 1981).
The similarity of crossbridge and tetramer dimensions, coupled with the
observed dimerization and inactivation of phosphofructokinase upon
association with microtubules (Lehotzky et al, 1993), supports the
hypothesis that following initial binding of phosphofructokinase dimers,
inactivetetramers form atthe crossbridges between microtubules
(Vertessy eta1,1997a).
The crossbridging of microtubules by phosphofructokinase is
inhibited by fructose-2,6-bisphosphate, fructose-1,6-bisphosphate, and Mg-
ATP (Lehotzky et al, 1994).The abilities of the anti-tumor drugs
vinblastine and KAR-2 toinhibitmicrotubule polymerization are
attenuated by the presence of phosphofructokinase in vitro (Vertessy et
1997a). The balance of cytosolic allosteric effectors and the availability of174
phosphofructokinase to bind microtubules therefore are hypothesized to
factor into resistance to these drugs.
Phosphofructokinase forms periodic crossbridges between F-actin
filaments spaced approximately 37 nm apart (Roberts and Somero, 1987).
In the presence of troponin and tropomyosin, this crossbridging becomes
more dispersed (Roberts and Somero, 1989). Thisweakened crossbridging
reflects the lower amount of overall binding of phosphofructokinase under
these conditions, which has also been demonstrated by the decreased
allosteric activation of the enzyme seen with reconstituted thin filaments,
ascomparedtoF-actin(LiouandAnderson,1980). The
phosphofructokinase-catalyzed bundling reactionisindependentof
fructose-2,6-bisphosphate and fructose-6-phosphate, while ATP seems to
inhibit the reaction.The exact roles which bundling play upon the
regulation of the function of actin have not been as well characterized as
they have been for microtubules.It is possible that the formation of
crossbridges stabilize the overall structure of myofibrils.
When analyzing the effects of phosphorylation upon regulation of
thisenzyme,itisimportanttoconsiderthedifferentrolesof
phosphofructokinase within the cell. While dimeric phosphofructokinase
is unable to catalyze phosphorylation of fructose-6-phosphate, it still can
interact with microtubules to catalyze bundling (Lehotzky et al., 1994;
Lehotzky et al., 1993; Vertessy et al., 1997a; Vertessy et al., 1996).This175
phenomenon of disparate functions existing for a given polypeptide is not
unique to phosphofructokinase (Campbell and Scanes, 1995; Weaver,
1998). For example, glyceraldehyde-3-phosphate dehydrogenase functions
cytosolically as a tetramer to catalyze phosphorylation of glyceraldehyde-
3-phosphate, while it functions as a monomer within the nucleus as uracil
DNA glycosylase to excise misincorporated uracil from the cellular DNA
(Meyer-Siegler et al, 1991).The observation that F-actin abolishes the
calcium-dependence of serine 376 phosphorylation, and the hypothesis
within this discussion that tubulin interacts with a form of the
phosphofructokinase dimer that is conformationally distinct from the form
that is a substrate for serine 376 phosphorylation may become more
significant when considering alternative functions of phosphofructokinase.
Experiments analyzing the effects of phosphorylation at serine 376, serine
774, or both sites on the ability of the enzyme to catalyze bundling of F-
actin or microtubules could also further elucidate the significance of
phosphorylation of this enzyme.
Calmodulin and troponin C are the only two proteins found to date
which enhance cAMP-dPK-catalyzed phosphorylation of serine 376 and
serine 774 of phosphofructokinase.Both proteins are members of the
evolutionarily related EF-hand family (Schafer and Heizmann, 1996).
These proteins contain two distinct calcium binding EF-hand motifs,
flanked by hydrophobic regions at either terminus and separated by a176
central hinge region. S100A1, a member of this family expressed in brain,
skeletalmuscle,cardiacmuscle,andkidney,inhibitsglycogen
phosphorylase (Zimmer and Dubuisson, 1993) and stimulates adenylate
cyclase (Fano et al., 1989), two proteins which are also regulated by
calmodulin (Schafer and Heizmann, 1996).Following isolation of this
protein from cow heart, we found that it conferred neither inactivation nor
modulationofinvitrocAMP-dPK-catalyzedphosphorylationof
phosphofructokinase (tables 2-10 and 2-11).
These results contrasted with prior results in which an unknown
subtype of S100 purified from beef brain displayed strong inhibition of
phosphofructokinase catalytic activity (Zhao et al, 1991b).S100A1 and
S100B are the two subtypes expressed in brain (Schafer and Heizmann,
1996), so it is likely that S100B was the subtype responsible for earlier
observed inactivation.This subtype promotes autophosphorylation and
activation of Ndr, a general serine/threonine kinase critical for regulation
of cell division which is evolutionarily related to the cAMP and cGMP
dependent protein kinases (Millward et al., 1998).Future experiments
with the S100B subtype, or other subtypes of the 5100 family, for example
S100C, a subtype expressed solely in smooth and heart muscle (Naka eta!,
1994), may reveal a role for S100 proteins in modulating phosphorylation
of phosphofructokinase at serine 376.177
Caveolins are a protein family with an affinity for cholesterol which
recruit signal transducing kinases and phosphatases to the plasma
membrane through protein-protein interactions (Okamoto et al, 1998).
Caveolin-3 is a member of this protein class, and is expressed in skeletal,
cardiac, and diaphragm muscle (Tang et al, 1996; Way and Parton, 1995).
Immunoprecipitation,chemicalcrosslinking,andsizeexclusion
chromatography have demonstrated that caveiolin-3 interacts with the
tetrameric form of phosphofructokinase in vitro (Scherer and Lisanti,
1997). This interaction is enhanced by fructose-2,6-bisphosphate, fructose-
6-phosphate, fructose-1,6-bisphosphate, and AMP, and is inhibited by ATP
and citrate. The ability of caveolins for nucleating the formation of signal
transduction complexes (Okamoto et al., 1998), and the specific interaction
of caveolin-3 with the phosphofructokinase tetramers under favorable
allosteric conditions warrants examination of the role that caveolin-3 might
play in the phosphorylation and reactivation of phosphofructokinase.
cAMP-dPK has been only protein kinase found to catalyze in vitro
phosphorylation of phosphofructokinase.CamKII (table 2-12), cGMP
dependent protein kinase (PKG) (Zhao et al., 1991b), and protein kinase C
(PKC)(Zhaoetal,1991b)donotappeartophosphorylate
phosphofructokinase to a significant extent. The in vivo significance of
phosphorylation of the enzyme by cAMP-dPK is supported by the
observationthatphosphofructokinasepurifiedfromepinephrine-178
stimulated rabbit hearts is phosphorylated at serine 376. The mechanism
for stimulation of cAMP-dPK by increasing cAMP levels as a result of beta-
adrenergic receptor binding of epinephrine is well established (Taylor,
1989). These results do not rule out the possibility that CamKII, PKG, PKC
or other protein kinases might phosphorylate the enzyme under different
in vitro conditions than those tested, particularlyifthey work in
conjunction with yet-to-be-determined protein factor(s).179
General Conclusion
Stimulation of hearts with epinephrine causes increased contraction,
which is mediated by intracellular increases in cAMP concentration and
activation of cAMP-dPK (Levitzki, 1988; Taylor, 1989).Variable reports
have shown that following electrical stimulation of skeletal muscle
(Sorensen-Ziganke and Hofer, 1979), or hormonal stimulation in isolated
heart (Narabayashi et al, 1985), two or more moles of phosphate are
incorporated per phosphofructokinase protomer.It was established later
that one of these sites of phosphorylation corresponds to serine 774 (Kemp
et al, 1981; Riquelme et al, 1978b). A second site of phosphorylation, at
serine 376, was discovered as a result of in vitro incubation of skeletal
muscle phosphofructokinase with cAMP-dPK and either calmodulin or
troponin C (Zhao eta!, 1991b). Results from this thesis have demonstrated
that serine 376 phosphorylation occurs in vivo as well.The site is
phosphorylated in enzyme purified from rabbit hearts following surgical
stimulation with epinephrine, while phosphofructokinase purified from
rabbit hearts that had not undergone the surgical procedure did not
display serine 376 phosphorylation.Given the known effects that
epinephrine has upon activation of cAMP-dPK, the demonstrated in vitro
phosphorylation at serine 376 catalyzed by cAMP-dPK (Zhao et al, 1991b),
and the extent of in vivo phosphorylation at this site in enzyme purified180
from epinephrine-stimulated hearts, the second in vivo phosphorylation
site of phosphofructokinase previously in contracting skeletal muscle is
most likely serine 376.
There is a sharp decline in the catalytic activity of rabbit muscle
phosphofructokinasethatoccursduringtheprocessofinvitro
phosphorylation catalyzed by cAMP-dPK in the presence of calmodulin or
troponin C (figure 2-1, and (Zhao et al, 1991b)).Both calmodulin and
troponin C are inactivators of phosphofructokinase (table 2-5, and (Lan
and Steiner, 1991; Mayr, 1984a; Zhao et al, 1991b)). When assayed under
optimal assay conditions, the catalytic activity of phosphofructokinase
phosphorylated at serine 376 as purified from epinephrine-treated rabbits,
and the activity of the unphosphorylated rabbit heart enzyme, were not
significantlydifferent(table1-3).This observation, and also the
observation of similar catalytic activity losses in the presence and absence
of cAMP-dPK during incubation of phosphofructokinase under conditions
necessary to catalyze phosphorylation of serine 376 (Zhao et al, 1991b),
suggests that activity losses observed during in vitro phosphorylation of
serine 376 can be attributed to the secondary irreversible aggregation
reactions that take place during prolonged incubation of the enzyme with
calmodulin or troponin C.Simple removal of the inactivating proteins
does not restore the activity of phosphofructokinase.181
The conditions for in vitro phosphorylation at serine 376 described
by Zhao et al (Zhao et al., 1991b) are different than those in which in vivo
phosphorylation of the enzyme occurs, as judged by differences in catalytic
activities of enzymes phosphorylated in vivo and in vitro. A second aspect
of this thesis dealt with a search for in vitro conditions that would allow
phosphorylation to take place with minimal irreversible loss of activity.
Examination of the self-association model suggested that enhancement of
the rate of phosphorylation, possibly facilitated by a different protein
kinase, reduction of the rate of aggregation, and reversal of the aggregation
process are possible ways to achieve the desired results. A successful
outcome should provide the samples needed for a complete functional and
physical characterization of phosphorylated phosphofructokinase.In
addition, the conditions thus identified might give clues regarding the
process of in vivo phosphorylation.
Additional allosteric effectors of phosphofructokinase (ATP and
inorganic phosphate), alteration of conditions to better stabilize the
enzyme's catalytic activity (lower temperatures and higher glycerol
content),andadditionalphosphofructokinase-bindingproteins
(reconstituted troponin, F-actin, and tubulin) were tested for their abilities
to protect the enzyme's activity and for their effects upon cAMP-dPK-
catalyzed invitro phosphorylation.Throughout thisstudy, only
conditions that destabilized enzyme activity resulted in phosphorylation at182
more than one site of the enzyme. In the case of the cAMP-dPK-catalyzed
in vitro phosphorylation of the enzyme in the presence of 5 mM ATP, the
site of phosphate incorporation was mapped to serine 774, with no
detectable levels of phosphorylation occurring at serine 376.This
necessary requirement of inactivation, when considered with results
showing that catalytic inactivation leads to dimerization (Hand and
Carpenter, 1986; Hesterberg and Lee, 1982; Hill and Hammes, 1975;
Lehotzky et al, 1993; Mayr, 1984a; Zhao et al, 1991b), supports the
hypothesis that dissociation to the dimer is necessary for cAMP-dPK-
catalyzed phosphorylation at serine 376. This hypothesis conforms to the
model of enzyme structure proposed by Poorman et al (Poorman et al,
1984) in which the linking hinge regions containing serine 376 are situated
at the dimer-dimer interface, making the site sterically inaccessible to
cAMP-dPK-catalyzed phosphorylation when the enzyme exists as a
tetramer.
Given the high concentration of phosphofructokinase in muscle (de
Duve, 1972) and its proportionately low in vivo activity (Passonneau and
Lowry, 1962), the enzyme is likely to be maintained as a dimer in vivo,
possibly through interaction with other proteins, such as calmodulin
(Mayr, 1984a) or troponin C.According to self-association models
describingcalmodulin-andtroponinC-inducedinactivationof
phosphofructokinase,dimerizationpredisposesthe enzyme tothe183
irreversible formation of dimer aggregates (Mayr, 1984a; Zhao et al.,
1991b). Addition of the allosteric effectors ATP, fructose-1,6-bisphosphate,
and AMP, a proven means for reactivation of phosphofructokinase activity
following brief periods of troponin C- or calmodulin-induced inactivation
(Mayr, 1984a; Zhao et al., 1991b), failed in this study to reactivate enzyme
activity following in vitro phosphorylation (Results). The inability of ATP
to reactivate phosphofructokinase following the relatively long time period
necessary for complete in vitro phosphorylation may be due to significant
dimer aggregation. As dimerization appears to precede phosphorylation
at serine 376, and the enzyme is not reactivatable following in vitro
phosphorylation, it is likely that stabilizing factors are present in vivo
which prevent aggregation, or there are factors present such as molecular
chaperones (Melegh and Minami, 1997) or heat shock proteins which
catalyze the renaturation of protein from the aggregated state.
When additional proteins known to bind phosphofructokinase were
included in the cAMP-dPK-catalyzed in vitro phosphorylation reaction,
none were able to substitute for troponin C- or calmodulin-enhancement
phosphorylation extent, nor did they stabilize the activity of the enzyme
during phosphorylation. Addition of a 16:1 molar ratio of F-actin to the in
vitro phosphorylation reaction did not preventactivitylossesof
phosphofructokinase (figure 2-12), or alter the rate or extent of phosphate
incorporation (figure 2-11).F-actin did however appear to reverse the184
requirement of calcium necessary for full phosphorylation to take place.
Though F-actin binds phosphofructokinase with high affininty (Kuo et al,
1986), more experimental evidence is needed to establish its role in the in
vitro phosphorylation reaction and determine whether binding of
phosphofructokinase to F-actin takes place. In vivo, troponin C associates
with the thin filament as a component of the troponin complex (Potter,
1982). While reconstituted troponin has been shown to induce catalytic
inactivation of phosphofructokinase (Zhao et 8Z, 1991b) it did not appear
to have the same phosphorylation-enhancing properties as isolated
troponin C (figure 2-14).S100A, a member of the EF-hand family of
proteins, was found to neither affect inactivation (table 2-10) nor enhance
cAMP-dPK-catalyzed in vitro phosphorylation of phosphofructokinase
(table 2-10).
Published results (Lehotzky et al, 1994; Lehotzky et al, 1993) have
shown thattubulininactivatesphosphofructokinaseina manner
promoting dimer formation. Results in this thesis illustrate the potency of
this inactivation as comparable to troponin C-induced inactivation (table 2-
5). Also similar to the phosphofructokinase-troponin C interaction was the
partial reactivation of phosphofructokinase that occurs upon addition of
ATP following tubulin-induced inactivation.The phosphofructokinase-
tubulin interaction differed from that of phosphofructokinase-troponin C
in that cAMP-dPK-catalyzed in vitro phosphorylation was not enhanced in185
the presence of tubulin (Results).These results demonstrate that dual
phosphorylation of phosphofructokinase has requirements in addition to
dissociation of the tetramer to the dimer. Perhaps the dimer assumes a
different conformation upon association with troponin C and calmodulin
than it does with tubulin. Alternatively, access to the phosphorylation site
may be blocked in the phosphofructokinase-tubulin complex.
Inconclusion,resultsfromthisthesisdemonstratethat
phosphorylationatserine376ofphosphofructokinaseoccurs
physiologically.The effects of several allosteric effectors and of other
proteins known to interact with phosphofructokinase were tested for their
abilities to alter the cAMP-dPK-catalyzed in vitro phosphorylation reaction
with the goal of producing a more active form of the enzyme
phosphorylated at serine 376. While this study did not yield more ideal
conditions for phosphorylation, a strong correlation between dimerization
of the protein and dual phosphorylation of the enzyme was observed.
As dimerization appears to precede phosphorylation at serine 376,
and the enzyme is not reactivatable following in vitro phosphorylation, it
is likely that stabilizing factors with functions resembling those of the
bacterial GroEL or GroES (Melegh and Minami, 1997) are present in vivo
which prevent aggregation. A recommended future direction for this
research would examine theeffectsof known chaperones on the
phosphorylation of phosphofructokinase.The protein chaperones and186
chaperonins, which facilitate protein folding in vivo in part through the
prevention ofaggregation, may play arolein the physiological
phosphorylation of phosphofructokinase.Chaperones, such as HSC 70
(Beckmann et al, 1990; Schlesinger, 1990) or HSP 90 (Jakob et al, 1995;
Wiech et al, 1992), could be tested independently or in conjunction for
their abilities to promote reversible dissociation and the phosphorylation
of phosphofructokinase.Conversely, their presence may stabilize
phosphofructokinase from aggregationduring phosphorylation,or
promote refolding of aggregated phosphofructokinase to its native
structure following phosphorylation.187
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Appendix211
Purification of Tubulin from Bovine Brain
The tubulin purification protocol described roughly followed the
method of purification through successive polymerization/depolymerization
of microtubules as outlined by Ashford et al (Ashford et al., 1998). Within
60 minutes of slaughter, 390 g of bovine brainwas homogenized in 400 ml
of cold buffer A, containing 100 mM MOPS pH 6.8, 0.5 mM MgC12, 1 mM
ATP, and 0.2 mM EDTA. The solutionwas centrifuged 15 minutes at 9,000
RPM with a GSA rotor at 5 °C.
The pellet was discarded, and to the pink supernatant (volume---- 250
ml) glycerol at 37 °C was added to bring the final glycerol concentration to
33%.The concentrations of ATP, GTP, and MgC12were then quickly
adjusted to 2.5 mM, 0.5 mM, and 3.5 mM, respectively, to initiate
microtubule polymerization.The solution was brought to 37 °C with a
water bath and incubated at this temperature for one hour. A Beckman type
45 Ti rotor was also brought to 37 °C,as was the vacuum chamber of the
ultracentrifuge,in preparation forcentrifugationatthistemperature.
Following incubation, the solutionwas centrifuged at 23,000 RPM for two
hours at 37 °C.212
The pellet was resuspended ina minimal volume of cold buffer B
(approximately 20 ml), which contained 100 mM MOPS pH 6.8,0.5 mM
MgC12, 2 mM EGTA, 0.5 mM EDTA, and 1 mMbeta-mercaptoethanol.
The protein concentrationwas determined by Bradford analysis, then diluted
to 25 mg/ml with buffer B. The solution was centrifuged at 36,000 RPM for
30 minutes at 5 °C. The pelletwas discarded.1/2 volume of 37 °C glycerol
was added tothesupernatant, which brought thetotal volume to
approximately 60 ml.The concentration of ATP, GTP, and MgC12were
adjusted to1 mM, 0.5 mM, and 4 mM, respectively,and the solution
incubated 60 minutesat37°C,forsecond round of microtubule
polymerization. The solutionwas then centrifuged at 36,000 RPM for 60
minutes at 37 °C. The resultingsupernatant was discarded, and the pellet
stored at 80 °C following freezing under liquid nitrogen.
The pellet was resuspended in approximately 20 ml buffer B, after
thawing, resulting in a total volume of 30 ml anda protein concentration of
approximately 11 mg/ml. Inactive tubulinwas removed by centrifugation at
23,000 RPM for 30 minutes at 5 °C.
AL
The supernatant was applied toa phosphocellulose column (3 X 10
cm), which was pre-equilibrated in buffer C, containing50 mM MOPS pH
6.8,1 mM EDTA, and 0.2 mM MgC12.The sample was applied at a
flowrate of 100 ml/hour, then washed with buffer C. Pure tubulin,as judged213
by a single band of approximately 52-57 kilodaltonson an SDS-PAGE gel,
washed through the column unbound. The tubulin sample (approximately
45 ml, at 3.0 mg/m1) was stable to freezing under liquid nitrogen and storage
at -80 °C.
Thawed tubulin was concentrated to approximately 11 mg/ml using
an Amicon concentrator with a YM-30 membrane. 37 °C glycerol was then
added to bring its concentration to 33%.The MOPS, GTP, and MgC12
concentrations were adjusted to 80 mM, 1 mM, and 2 mM, respectively, and
the solution allowed to polymerize at 37 °C for 30 minutes. The proteinwas
then layered onto a glycerol cushion and centrifugedat 30,000 RPM and 37
°C in a Beckman type 75 Ti rotor for 90 minutes.The resulting pellet
contained only active tubulin, andwas resuspended in a minimal volume of
a buffer containing 80 mM MOPS pH 6.8, 1 mM MgCl2, and 1 mM EGTA,
and was stored at -80 °C. From 400g of brain processed, approximately 20
mg of pure tubulin was obtained.
Purification of Phosphofructokinase from Rabbit Skeletal MuscM
Phosphofructokinase was purified from rabbitskeletal muscle
following the same general procedure outlined by Kuoet al (Kuo el al..
1986). A female New Zealand White rabbit, weighing approximately2 kg,
was euthanized by injection of approximately 4 ml of sodium pentobarbitol214
into the marginal vein of the rightear.Following injection, the rabbit was
skinned, and the fast-twitch muscle from the back legs and lower backwas
excised and placed on ice. Approximately 450g of muscle were obtained.
All steps in the preparation were performed in the cold, unless
otherwise noted. The muscle was ground witha Butcher Boy meat grinder.
It was then homogenized with a Waring blendor, ata ratio of three liters
buffer A, which contained 30 mM KF, 4 mM EDTA, and 15 mM beta-
mercaptoethanol, to one kilogram of muscle.The inactive, insoluble
fraction was separated from the active, soluble fraction by spinning the
solution at 4,200 RPM on a.1 -6 preparative centrifuge. The supernatantwas
filtered through glass wool toremove lipid particulates, and the pellet
discarded.
The supernatant pH was adjusted to 6.8 using 2.0 M Trizma base. A
low pH at this point is usually indicative of too much time having elapsed
between euthanasia and the initial protein extraction. Low yields of activity
are generally obtained when this happens.
The solution was transferred toa stainless steel container and cooled
to approximately 2 °C in a 80 °C freezer. The formation of iceon the sides
of the container was avoided by occasional stirring of the solution. When
the solution reached 2 °C, -20 °C isopropanolwas added dropwise to bring
the final isopropanol concentration to between 15 and 20%, while allowing
the temperature of the solution to drop to below 2 °C. Upon addition of215
isopropanol, the solution's red color became noticeablylighter, signifying
protein precipitation. The protein solutionwas transferred to a 20 °C walk-
in freezer and stirredon a stirplate for an additional 20 minutes.
This solution was thenspun at 4,200 RPM in a J-6 centrifuge for 15
minutes.The red supernatantwas discarded, and the white precipitate
resuspended using a dounce homogenizer ina minimal volume of buffer B,
which contained 100 mM Tris-phosphate,0.2 mM EDTA, 5 mM sodium
pyrophosphate, 7.5 mM beta-mercaptoethanol.The protein solution was
then dialyzed against one liter of buffer B for 2 hours.Excessive volumes at
the point of pellet resuspension anda long dialysis time have been observed
to lower enzyme activity.
Following dialysis, buffer Bwas added to the protein solution such
that the total volume was approximately 1/20 of the volumeof the original
crude supernatant. The solutionwas then heated to between 57-59 °C and
maintained at this temperature for 3 minutes ina hot water bath. Following
heat treatment, the proteinwas rapidly cooled to 5 °C on ice. The solution
was then centrifuged on an SS-34 rotor at 9,000 RPM for 10 minutes. The
yellow supernatantwas set aside, and the thick pellets washed with a
minimal volume of buffer B (approximately 20 mltotal).The washed
pellets were again centrifuged, and the resulting clearsupernatant combined
with the yellow supernatant from the precedingstep.216
The supernatant fraction was brought to 38% ammonium sulfate
saturation (213 g/liter solution), then incubated at 5 °C for one hour. The
solution was centrifuged at 9,000 RPM with an SS-34 rotor for 15 minutes.
The resulting supernatant was then adjusted to 55% ammonium sulfate
saturation (101 g/liter), and incubated in the cold overnight.
A 20 ml solution containing a 1:1 mixture of human saliva and buffer
C (35 mM sodium phosphate pH 8.0, 0.2 mM EDTA, 7.5 mM beta-
mercaptoethanol) was mixed, then clarified by centrifugation.The 55%
ammonium sulfate precipitate was collected following centrifugation with
an SS-34 rotor at 9,000 RPM for 25 minutes. The pellet was resuspended
with the saliva-buffer C solution and dialyzed for at least 24 hours against
buffer C, in order to remove ammonium sulfate and digestany glycogen
present tofacilitateseparation of phosphofructokinase from glycogen
phosphoiylase.
Following dialysis, the solution was centrifuged 10 minutes on SS-34
at 9,000 RPM, and the supernatant applied to a DEAE-52 column (3 X 20
cm) which had been equilibrated in buffer D (50 mM Tris-pbosphate pH
8.0, 0.2 mM EDTA, 5 mM sodium pyrophosphate, and 15 mM beta-
mercaptoethanol). The flow rate through the columnwas 135 ml/hour, with
10 ml fractions collected.The column was washed with buffer D, then
eluted with a linear gradient of buffer D between 0.1-0.5 mM Tris-
phosphate. Thesinglepeakof columnelutioncontainedpure217
phosphofructokinase, as determined by SDS-PAGE. Fractionsat the center
of this peak contained phosphofructokinase witha higher specific activity
than the shoulder fractions, andso were pooled together and concentrated
using an Amicon concentrator witha YM-10 membrane. The concentrated
protein was then dialyzed against 50 mM Tris-phosphate pH 8.0, 0.2 mM
EDTA, 5 mM dithiothreitol, and 80% glycerol for 24 hours.Following
dialysis, the protein was stored at 80 °C.
Purification of the Catalytic Subunit of cAMP-dependent Protein Kinase
The catalytic subunit of cAMP-dependent protein kinase (cAMP-
dPK) was purified from beef heart. Following slaughter, approximately 10
kg of fresh beef heart was separated from its connective tissue, then ground
with a Butcher Boy meat grinder.The protein was extracted with 2.5
volumes of 4 mM EDTA pH 7.0, and 15 mM beta-mercaptoethanol ina
Waring blendor for one minute at full speed.The homogenate was
centrifuged at 4,200 RPM for 10 minutes ina J-6 centrifuge. The resulting
supernatant was filtered through glass wool to remove lipid particulates, and
air
the pellet discarded.
The pH of the supernatantwas then adjusted to 7.6 with 6 M
ammonium hydroxide. This solutionwas hand-stirred for one hour with 5
liters of DEAE-52 that had been equilibrated in buffer A, containing 30 mM
Tris -HCI pH 7.6,10 mM NaC1, 4 mM EDTA, and15 mM beta-0
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Elution profile for protein purified with DEAE-52 anion exchange
column chromatography.The DEAE-52 column (3 X 20 cm) was
equilibrated and washed after application of sample with a buffer containing
50 mM Tris-phosphate pH 8.0,0.2 mM EDTA,5 mM sodium
pyrophosphate, and 15 mM beta-mercaptoethanol.The column flowrate
was 135 ml/hour, and 10 ml fractions collected.Following application of
approximately 270 mg of sample and washing with the above buffer, the
column was eluted with a linear gradient of the buffer containing 0.1-0.5
inM Tris-phosphate.219
Table A-1
Profile of purification of phosphofructokinase from rabbit skeletal
muscle.Purification was performed according to methods outlined in
Appendix.Protein concentrations were determined by the method of
Bradford et al (Bradford, 1976) for all fractions except for the Concentrated
DEAE Eluate and 80% Glycerol Stock fractions, which were determined
from 0D280 measurementsgiventhatEl %280nm =10.7forpure
phosphofructokinase (Hesterbergetal.,1981).Phosphofructokinase
catalytic activity was measured by the standard enzyme assay described in
Materials and Methods.Table A-1 Profile for purification of phosphofructokinase from rabbit skeletal muscle.
Fraction Volume (ml) Protein Conc.
(mg/ml)
Total Protein
(mg)
Specific Activity
(Units/mg)
Total Activity
(Units)
Crude 780 30 23,400 1.7 39,700
Supernatant
Isopropanol 66 65 4,290 5.0 21,450
Pellet
Heat Step 76 8.5 646 48 31,000
Supernatant
Ammonium 5 28.6 430 88.6 38,000
Sulfate Pellet
Sample loaded
onto DEAE-52
22.5 12 270 77.5 20,900
Concentrated 4.5 6.7 30.2 65.8 1,980
DEAE Eluate
80% Glycerol 1.2 20.3 24.4 110 2,680
Stock221
mercaptoethanol, and allowed to settle for two hours. The mixture was then
centrifuged at a low speed (1,000 RPM in a J6 centrifuge), and the
supernatants discarded.The remaining DEAE was then poured into a
column, and washed with buffer A until the optical density of the solution
eluting fell below 0.4. At that point, the column was eluted with buffer A
plus 0.5 M NaC1, and the resulting protein peak pooled.
Solid ammonium sulfate was added until 70% saturation was
reached.During ammonium sulfate addition, the pH of the solution was
monitored and adjusted to 7.6 with 6 M ammonium hydroxide, in order to
insure maximal protein precipitation. The solution was centrifuged at 4,200
RPM for 15 minutes in a J-6 centrifuge, and the resulting pellet resuspended
in a minimal volume of buffer B (30 mM potassium phosphate pH 6.7, 4
mM EDTA, and 15 mM beta-mercaptoethanol).The solution was then
dialyzed against several changes of thisbuffer, with the last round of
dialysis being performed against buffer B adjusted to pH 6.1.
The dialyzed solution was passed through three successive CM-52
Sephadex columns (5 X 15 cm) equilibrated in pH 6.1 buffer B.The
concentration of cAMP in the unbound material washing from the column
was adjusted to 10 and incubated with stirring for 15 minutes in order
to specifically reverse the interaction between the catalytic and regulatory
subunits of cAMP-dPK.222
The pH of this solution was then adjusted to 6.7 with dilute
ammonium hydroxide, and applied to a CM-52 column (4 X 30 cm)
equilibrated in pH 6.7 buffer B. Following washing with the same buffer,
the column was eluted with pH 6.7 buffer B plus 1 M KC1.
Following CM-52 chromatography, the solution was diluted two-fold
with water plus 15 mM beta-mercaptoethanol and applied to a hydroxy-
apatite column (2 X 20 cm, from LKB) equlibrated in buffer C, which
contained 10 mM potassium phosphate pH 6.7, 0.2 M KC1, and 15 mM
beta-mercaptoethanol. The column was washed with buffer C, then eluted
withthesamebuffer,containing200 mM potassiumphosphate
concentration.
The eluted protein was pooled and concentrated with an Amicon
concentrator and YM-30 membrane. The concentrated protein was applied
to an S200 sizing column (2.5 X 90 cm) equilibrated and washed with 30
mM potassium phosphate pH 6.7, 0.1 mM EDTA,. 1 mM dithiothreitol, and
0.15 M KC1.Two peaks emerged from the column, one peak of high
molecular weight components and a large second peak containing the pure
C-subunit of cAMP-dPK, with an approximate molecular weight of 39
kilodaltons as judged by SDS-PAGE.
The pure cAMP-dPK was pooled, concentrated to between 1-2
mg/ml, and dialyzed against 60% glycerol, 1 mM dithiothreitol. The yield
of the purification was approximately 20% with approximately 4 mg of223
cAMP-dPK purfied per kilogram of heart tissue.The final Vmax of the
purified cAMP-dPK was 1.24 moles phosphate incorporated/minute/mg,
using mixed histone as a substrate.
Purification of S100A from Bovine Heart
Approximately 10 kg of fresh beef hearts were cleared of connective
tissue and ground in an identical manner to the one used for purification of
cAMP-dPK from beef heart. The protein was extracted with 2.5 volumes of
100 mM NaC1 pH 8.0 and 5 mM beta-mercaptoethanol by blending at high
speed for one minute in a Waring blendor.The protein was applied to a
DEAE-52 column (9 X 30 cm) pre-equilibrated in and then washed with
buffer A (20 mM Tris-HC1 pH 8.0,0.1 mM EDTA, 5 mM beta-
mercaptoethanol).The column was then further washed with the same
buffer containing 0.18 M NaC1, and the protein of interest eluted using the
same buffer at 0.5 M NaCl.
The concentrations of MgC12 and CaC12 in the 0.5 M NaC1 eluate
were adjusted to 2 mM and 1 mM, respectively. This protein solution was
then loaded onto an Isco Phenyl Cellulose column (5 X 10) equilibrated in
buffer B, containing 20 mM Tris-phosphate pH 8.0, 2 mM MgC12, 1 mM
CaCl2, 0.5 mM NaC1, and 15 mM beta-mercaptoethanol.
The column was step eluted.The initial wash was performed with
buffer B.This was followed with successively washing the column with224
buffer B in the absence of NaCI, followed by washing with buffer A, and
was finally washed with 10 mM sodium citrate pH 7.5.Elution of pure
S100A was achieved with 50 mM sodium citrate pH 7.5.Pure calmodulin
eluted from the column in the presence of 3 mM EDTA pH 7.0.
The results of amino acid analysis of the S100A fraction (table A-2)
following the protocol of Malencik et al (Malencik et al., 1990), shared
nearly identical amino acid composition with a published amino acid
sequence of S100A from bovine brain (Kuwano et al., 1986). The purity of
calmodulin and S100A were each verified by SDS-PAGE.Table A-2 Amino acid analysis of S100A1 purified from beef heart
Amino Acid Peak Area
(standards)
PicomolesPeak Area
(protein)
Picomoles # Residues Corrected #
Residues/91
AA Protein
Actual #
Residues*
Aspartate 17,451 200 24.106 276 3.31 13.1 13
Glutamate 20,718 200 32,252 311 3.73 14.8 15
Serine 33,786 200 21,257 126 1.51 6.0 5
Threonine 46,071 200 22,789 99 1.19 4.7 4
Glycine 68,891 200 50,241 146 1.75 6.9 6
Alanine 45,757 200 36,456 159 1.91 7.6 8
Pro line 41,906 200 1,229 6 0.07 0.3 0
Valine 49,906 200 36,921 148 1.77 7.0 8
Arginine 35,903 200 1,008 6 0,07 0.3 0
Methionine 48,952 200 9,637 39 0.47 1.9 2
Isoleucine 67,922 200 5,616 17 0.20 0.8 1
Leucine 61,306 200 73,228 239 2.86 11.4 11
Phenylalanine 54,383 200 26,120 96 1.15 4.6 5
Lysine 114,278 200 99,200 174 2.08 8.3 9
Histidine 38,888 200 7,680 39 0.47 1.9 2
Tyrosine 118,204 200 19,030 32 0.39 1.5 2
SINAI was purified from beef heart according to the methods outlined in the Appendix. The materialwas subjected to
amino acid analysis following 24-gas phase acid hydrolysis according to Materials and Methods Chapter 1.